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We shall not cease from exploration 
And the end of all our exploring 
Will be to arrive where we started 
And know the place for the first time... 
 
What we call the beginning is often the end 
And to make an end is to make a beginning. 
 
Four Quartets – T.S. Eliot 
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Preface 
Cancer is one of the major causes of death in the western world. Current treatment of cancer 
is limited to surgery, radiotherapy, and the use of cytotoxic agents, despite their well-known 
side effects and problems associated with the development of resistance. For most forms of 
disseminated cancer, however, no curative therapy is available and the discovery and 
development of novel, active chemotherapeutic agents is desperately needed.  
An active drug substance is very rarely administered as the pure chemical compound itself. It 
is almost always transformed or formulated into a well-defined pharmaceutical product, 
which is suitable for the intended use in humans [1,2]. Thus, pharmaceutical formulation links 
the preclinical and clinical development phases of an investigational cytotoxic agent by 
enabling administration and thus evaluation of the drug in humans. Anticancer agents for 
experimental use are generally intended for intravenous administration to ensure absolute 
bioavailability, to circumvent possible presystemic metabolism or degradation in the 
gastrointestinal tract, and to be able to stop administration in case of acute toxicity [1]. 
Consequently, the development of a pharmaceutical formulation of a novel anticancer agent is 
associated with the design of sterile and stable injectable products. The pharmaceutical 
development of a novel compound for human use comprises a range of activities, as is 
depicted in Figure 1 (adapted from [1]). In order to successfully formulate a novel compound, 
a broad knowledge of analytical techniques, pharmaceutical sciences, regulatory guidelines, 
and clinical practice is required [1,2]. 
 
 
 
 
 
 
 
Figure 1.  Development route of an investigational anticancer agent and pharmaceutical 
formulation aspects. 
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Cisplatin, or cis-diamminedichloroplatinum(II) (Figure 2) is an anticancer agent that has been 
in use for over 30 years. Its use is widespread and few other anticancer agents have been 
proven as effective as cisplatin. However, serious side effects, the most prominent of which 
are nefro-, oto- and neurotoxicity and severe nausea and vomiting, limit its clinical use. 
Another major clinical problem is tumor resistance, which can be either intrinsic or acquired 
[3-6].  
H3N
H3N Cl
Pt
Cl
 
Figure 2. Structure of cisplatin. 
 
The limitations of cisplatin as an anticancer agent have stimulated the search for alternative 
metal-based anticancer agents and alternative pharmaceutical formulations of platinum, with 
more acceptable toxicity profiles, but retention, and if possible expansion, of efficacy. 
Common characteristics of metal complexes, which can prove important in formulation 
development, are the generally low aqueous solubility and high susceptibility to ligand 
exchange, resulting in low stability, especially in solution. Different aspects related to the 
pharmaceutical development of metal-based compounds (depicted in Figure 1) are 
summarized in this preface.    
Analytical aspects 
For each investigational drug a set of analytical methods has to be developed and validated to 
enable characterization and quality control of the chemical substance and pharmaceutical 
product [1,2]. Requirements and specifications for analytical methods, analysis of drug 
substances and final products have been recorded in regulatory guidelines [7-10]. After 
definition of a reference standard to which all other batches can be compared, specifications 
can be defined for both drug substance and final product [2,11].  
Structural and analytical characterization and purity determinations are performed by various 
techniques, such as nuclear magnetic resonance (NMR), infrared (IR), and mass spectroscopy 
(MS), ultraviolet/visible light (UV/VIS) spectrophotometry, and high performance liquid or 
gas chromatography (HPLC, GC). The development of a stability-indicating assay, which can 
discriminate between the parent compound and degradation products is crucial. The method 
should also be capable of separating the parent compound from contaminants (intermediate 
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products, solvents used in the synthesis, related products, etc.) and excipients [1,2].  
Metals can be analyzed by atomic absorption spectrometry (AAS). This type of analysis, 
however, only determines the presence of the element and not the form in which it is present 
or which ligands are attached to it. Therefore, other methods are required to obtain more 
specific structural information about the compound. A wide variety of HPLC methods has 
been developed for the marketed anticancer platinum compounds (cisplatin, carboplatin, and 
oxaliplatin) and their degradation, biotransformation and reaction (with e.g. thiol compounds) 
products (comprehensively reviewed in [12]). However, development of analytical techniques 
that provide sufficient insight into the structure and stability of novel metal compounds 
remains a challenge. This is illustrated by the fact that it was necessary to develop a broad 
range of analytical techniques to structurally and analytically characterize AP 5280, a novel 
polymer-conjugated platinum agent [13]. No single method provided a total picture of the 
structure and integrity of this molecule, but a combination of analytical techniques led to 
insight into all aspects considered important for its quality control.  
NAMI-A, a novel antimetastatic ruthenium agent, is a typical example of a labile metal 
compound in which ligands are readily exchanged. Many different substitution reactions lead 
to a plethora of possible degradation products, including products resulting from the oxidation 
or reduction of the central ruthenium atom. A stability-indicating HPLC method was 
developed that was capable of detecting the major degradation products [14].  
 
Solubility aspects 
A drug intended for intravenous administration has to show aqueous solubility in order to 
prevent precipitation in the blood stream, resulting in pain, phlebitis, and altered 
bioavailability [1]. A number of solubilization approaches is available for the development of 
a parenteral dosage form of a drug [2,15]. In summary, these consist of pH adjustment in case 
of an ionizable functional group, use of co-solvents, surfactants, complexing agents (e.g. 
cyclodextrins), and/or production of dispersed systems (e.g. emulsions, liposomes, 
nanoparticles). However, most of these approaches do not improve the solubility of (heavy) 
metal complexes, although microsomes and liposomes have been successfully developed for 
cisplatin [3-6]. In fact, many promising novel metal-containing compounds have not even 
reached the animal toxicology studies, because they could not be dissolved or 
pharmaceutically formulated. For example, many ruthenium agents containing solely amine 
and chloride or carboxylate ligands, as well as some of their rhodium counterparts, such as 
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fac-[RuCl3(NH3)3] and mer-[RhCl3(NH3)3], showed antitumor activity, but proved to be 
insoluble in aqueous solutions. As a result, they could not be formulated and were abandoned 
for further development [16]. 
Very few metals are soluble in water in their elemental state [17]. However, different ligands 
can provide varying degrees of solubility. Furthermore, conjugation to a variety of compounds 
such as polymers can increase aqueous solubility of metal complexes, as is the case for AP 
5280. 
Stability aspects 
Metals are prone to oxidation and reduction and show facile substitution of ligands, especially 
in solution. Metal complexes are often more sensitive towards solvents, humidity, light, or air 
than organic pharmaceuticals. Hydrolytic instability and a wide variety of decomposition 
products hamper clinical application [5]. At the same time, the reactivity of metal complexes 
determines their interaction with biological targets (DNA and proteins). These processes are 
closely related to their mechanisms of action in terms of anti-tumor activity, toxicity and 
biotransformation [18]. A very reactive compound can decompose before it is applied to the 
patient and reaches its target, while very stable compounds might be excreted, without any 
interaction in the biological medium, as is known, for example, of gadolinium complexes 
[16]. The ligands of metal complexes will determine to a large extent the stability, and thereby 
the activity, toxicity, and pharmacokinetics of the compounds. 
From a pharmaceutical point of view, stability refers to the storage life or utility time, i.e. the 
period of time a drug substance, excipient, final product, reconstituted product, or infusion 
solution conforms to its specifications under certain conditions (temperature, humidity, light) 
[1]. The aim of the pharmaceutical development of a drug candidate is to manufacture a 
product that has a sufficient shelf-life (>1 year) at a practically convenient storage condition 
(room temperature (+20-25°C) or refrigerated condition (+2-8°C)). Insight into the stability of 
a new drug substance, both in the solid state and in solution, is obtained in the preformulation 
stage, and based on these data along with results obtained in solubility experiments, a decision 
is made on the formulation of the final product. Accelerated stability studies performed at 
elevated temperatures will generate data on the stability of drug substance and final product, 
necessary to designate long-term storage conditions. Real-time stability studies of the 
pharmaceutical product at the long-term storage condition (set temperature and level of 
humidity) are then required. Furthermore, to anticipate fluctuations in conditions that could  
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occur during e.g. shipment, stability testing of the final product needs to be performed at 
defined intermediate and/or accelerated conditions [19]. Additionally, photostabillity testing 
of the drug substance and final product is required by separate testing [20].  
Once a drug substance and final product have been assessed for their stability, it is also 
necessary to evaluate the clinical product. In general, a (lyophilized) pharmaceutical product 
will be reconstituted and/or further diluted using a suitable (isotonic) infusion fluid to the 
desired infusion concentration. Drug stability in infusion solutions can vary widely with the 
dilution solution and concentration. For example, the stability of cisplatin in solution is 
dependent on the chloride ion concentration, with a higher chloride ion concentration 
producing more stable cisplatin solutions [21]. To assure the quality of the product that is 
administered to the patient, stability should be assessed for commonly applied infusion 
solutions (normal saline, 5% (w/v) dextrose) over the concentration range and under the 
conditions (temperature, light) intended in the clinical setting.  
Manufacturing aspects 
Manufacturing of investigational anticancer agents to be used in clinical trials, although 
generally performed on a small scale, has to comply with the principles of current Good 
Manufacturing Practices (cGMP) [22]. This implies selection, definition, and validation of the 
manufacturing process and its subsequent steps. For example, in case of the production of a 
sterile dosage form for intravenous use, the stability of the active substance dictates whether 
the product can be terminally sterilized by moist heat, or needs aseptic processing and sterile 
filtration [23,24]. An aseptic manufacturing process requires well-trained personnel and high 
standard environmental conditions of the production facilities, especially with respect to 
particles and micro-organisms. Equipment and production materials, such as filters, have to be 
validated for their suitability in the manufacture of the specific pharmaceutical product. 
Definition of the critical steps in the production process (e.g. stability of the formulation 
solution, freeze-drying parameters) at the development stage is of crucial importance in view 
of future upscaling of the production.  
Compatibility aspects 
During the formulation studies, compatibility of the drug product with the primary packaging 
material (container, closure) must be assessed. Furthermore, compatibility testing is important 
to determine the optimal administration parameters and devices (container and tubing). These 
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tests will determine whether e.g. adsorption or absorption to the infusion container, tubing, 
and/or in-line filter, leaching of plasticizers, or physical reactions such as precipitation take 
place [25]. The platinum compounds cisplatin and carboplatin are known to interact with 
aluminum, resulting in a black precipitate upon contact, and should not come into contact with 
aluminum-containing devices [21]. Additionally, in vitro biocompatibility testing may provide 
information about the potential to cause pain, phlebitis, and/or hemolysis of a pharmaceutical 
formulation. Such reactions can be expected upon intravenous administration of solutions 
containing drugs with deviant tonicity and pH values from blood [25-27]. Formulation- and 
administration-related adverse effects can thus, to some extent, be anticipated preclinically 
and patient discomfort can be minimized by adjustment of administration parameters. 
Scope of the thesis 
In this thesis, the pharmaceutical development of two novel metal-based antitumor agents is 
presented. Chapter 1 covers the pharmaceutical development of NAMI-A, a ruthenium-based 
antimetastatic agent. The pharmaceutical development of AP 5280, a polymer-conjugated 
platinum agent, is described in Chapter 2. The aim of the studies was to develop a stable, 
intravenous dosage form for both novel agents that would allow clinical evaluation of the 
products. This comprised development of analytical methods for the quality control of drug 
substance and final product, the formulation and manufacturing processes, and stability and 
(bio-)compatibility studies of the final product. 
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Chapter 1: NAMI-A. 
Introduction 
The success of cisplatin [cis-diamminedichloroplatinum (II)] as an anticancer agent has 
stimulated the search for cytotoxic compounds with more acceptable toxicity profiles, but 
retention, and if possible expansion, of activity. This has generated interest in molecules 
containing other heavy metals of Groups 8, 9, and 10 (formerly known as Group VIII) of the 
periodic table, which have similar properties to platinum. These metals may differ in 
oxidation state, ligand affinity, and substitution kinetics. Because of their variation in 
chemical characteristics, the mode of action and spectrum of activity of these compounds can 
differ significantly from cisplatin [1-3]. 
Although some elements have proven to be very useful as drugs to cure or diagnose diseases 
(reviewed in [4]), in general heavy metals and their complexes are well renowned for their 
toxic effects. They bind to sulfur and nitrogen sites on proteins and thereby interfere with 
many biochemical pathways [3]. Acute heavy metal poisoning results in severe 
gastrointestinal symptoms, particularly nausea, vomiting, diarrhea and abdominal pain. The 
kidney is frequently affected by heavy metals, as they accumulate in renal tubular fluid and 
are capable of disturbing renal metabolic processes. Chronic low level exposure to heavy 
metals causes neuromuscular injury, particularly peripheral neurotoxicity, cerebellar 
disturbance, myalgia, and lassitude [2]. This type of toxicity is observed with the use of 
platinum anticancer agents and, most likely, other heavy metals investigated for their 
antitumor properties will not differ in this respect.  
Group 8, 9 and 10 heavy metals 
The transition elements, to which the Group 8, 9 and 10 metals belong, show typical chemical 
behavior that is not shared by the main-group elements. All are metals with partly filled d or f 
subshells that conduct heat and electricity well, with very few exceptions they exhibit variable 
valence, and their ions and compounds are colored in most oxidation states. Because of their 
partly filled subshells, they form complexes easily, and bonding is usually of a more ionic 
than covalent nature [5].  
Groups 8, 9 and 10 are composed of iron, cobalt and nickel in the first transition series, in 
which the 3d subshell is partly filled. Ruthenium, rhodium and palladium make up the second 
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transition series, in which the 4d subshell is partly filled, and osmium, iridium and platinum 
form the third transition series, with a partly filled 5d subshell (Figure 1). Especially the 
extended 4d and 5d orbitals give rise to good complex-forming abilities, often strengthened 
by π-bond formation (back-donation). Therefore, Groups 8, 9 and 10 are subdivided into the 
iron group (first transition series) and the platinum group (second and third transition series) 
[5].   
As the metals of Groups 8, 9 and 10 have many different valences and form complexes easily, 
a multitude of compounds can be synthesized with a wide variety of ligands. Thus far, several 
new compounds have been proven active in vitro against different types of tumor cell lines 
and can thus be marked as potential new anticancer agents. Among them, ruthenium 
complexes seem very promising. 
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Figure 1. Groups 8, 9 and 10 of the periodic table of elements. 
 
Ruthenium 
A wide range of ruthenium agents has been synthesized and tested for their antitumor 
properties in the past 30 years. Most of these agents, independent of the ligands attached to 
the ruthenium ion, have shown relatively low cytotoxicity and are less toxic than cisplatin, 
correspondingly requiring a higher therapeutic dose [6,7]. Extensive binding to many cellular 
and extracellular components may account for this fact [7]. Despite their low cytotoxic 
potential, many ruthenium complexes increase the lifetime expectancy in tumor-bearing hosts 
[7].  
Ruthenium(III) complexes likely remain in their (relatively inactive and unreactive) Ru(III) 
oxidation state until they reach the tumor site. In this environment, with its lower oxygen 
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content and pH than healthy tissue, reduction to the more reactive Ru(II) oxidation state takes 
place. In this manner (termed “activation by reduction”), ruthenium(III) compounds may 
provide selective toxicity [3,6,7]. However, to be active in vivo, the complexes must have a 
biologically accessible reduction potential, which can vary considerably with the ligands 
present [6]. 
A second mechanism that could explain the observed antitumor activity is the high affinity of  
ruthenium(III) for the transferrin iron-binding sites. This binding capacity provides a 
possibility to target ruthenium(III) complexes to tumors with high transferrin receptor 
densities [3,6,7]. 
A large number of ruthenium complexes (both in the II and III oxidation states) with in vitro 
antitumor activity have been synthesized. The interested reader is referred to references 1, 3, 
7, and 8 for reviews on the different cytotoxic ruthenium compounds. The only ruthenium 
anticancer agent that has entered clinical trials thus far is imidazolium trans-tetrachloro 
(dimethylsulfoxide)imidazoleruthenium(III), or NAMI-A. This chapter describes its 
pharmaceutical development.  
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Abstract 
NAMI-A is a novel ruthenium complex with selective activity against metastases currently in 
Phase I clinical trials in the Netherlands. Pharmaceutical quality control of NAMI-A drug 
substance and lyophilized product warranted the development of an assay for determination 
and quantification of NAMI-A and degradation products. A High Performance Liquid 
Chromatography (HPLC) method was developed, consisting of a C18 column with 0.50 mM 
sodium dodecylsulphate in 3% methanol at pH 2.5 (acidified using trifluoromethanesulfonic 
acid) as the mobile phase and UV-detection at 358 nm. The HPLC method was proven to be 
linear, accurate and precise. Stress testing showed that degradation products were separated 
from the parent compound. By combining results of nuclear magnetic resonance (NMR) and 
HPLC experiments, one degradation product was identified as the mono-hydroxy species of 
NAMI-A. HPLC analysis with off-line detection of the eluate with flameless Atomic 
Absorption Spectrometry (AAS) showed that under most conditions, all ruthenium-containing 
compounds show a peak in the HPLC chromatogram and that all ruthenium applied to the 
column is recovered quantitatively. For completely degraded solutions of NAMI-A some 
ruthenium is retained on the column. Suitability of the HPLC method for the pharmaceutical 
quality control of NAMI-A lyophilized product was demonstrated.  
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Introduction 
NAMI-A, imidazolium trans-tetrachloro(dimethylsulfoxide)imidazoleruthenium(III),  H2im 
[trans-RuCl4(DMSO)Him], Figure 1 [1] is a novel ruthenium anticancer agent. Preclinical 
pharmacological studies with NAMI-A showed selective activity against lung metastases of 
murine tumors [1-3] and low toxicity in mice and dogs [4-6]. Its action seems to be 
independent of the origin (type of primary tumor) and stage of growth of the metastases [2, 7]. 
The precise mechanism of action, however, has yet to be proven, although recent evidence 
suggests an interaction with cell cycle regulation, inhibition of matrix metalloproteinases, and 
induction of antiangiogenesis [7-10]. 
Figure 1.  Chemical structure of NAMI-A. Molecular weight = 458.18 g/mol. Molecular formula: 
C8H15Cl4N4ORu(III)S. 
 
Based on its promising activity and toxicity profile, NAMI-A is developed as a potential 
anticancer agent and has currently entered Phase I clinical trials. NAMI-A is pharmaceutically 
formulated as a lyophilized product for intravenous administration. The quality control of both 
drug substance and lyophilized product necessitated development of an assay for 
determination and quantification of NAMI-A and its potential degradation products.  
This paper describes the development and validation of a stability-indicating reversed-phase 
high performance liquid chromatography (RP-HPLC) method with ultraviolet (UV) detection 
for pharmaceutical quality control of NAMI-A drug substance and lyophilized product. 
Furthermore, profiling of degradation products using deuterium nuclear magnetic resonance 
(2H NMR) and ultraviolet/visible light (UV/VIS) spectrophotometry is reported. To test the 
quantitative recovery of ruthenium from the column and the ability of the HPLC system to 
detect all ruthenium-containing compounds, experiments are described where column eluates 
are analyzed for ruthenium with flameless Atomic Absorption Spectrometry (AAS). 
Ru
ClCl
ClCl
N
NH
SCH3
O
CH3 NH
NH
+
-
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Materials and methods 
Chemicals 
NAMI-A was supplied by SIGEA Srl (Trieste, Italy). NAMI-A DMSO-d6 (NAMI-A with a 
deuterated DMSO ligand) was kindly provided by Professor G. Mestroni (Department of 
Chemistry, University of Trieste, Italy). NAMI-A lyophilized product and distilled water were 
manufactured in-house (Department of Pharmacy & Pharmacology, Slotervaart Hospital, 
Amsterdam, The Netherlands). 
Methanol (HPLC grade) was obtained from Biosolve Ltd. (Amsterdam, The Netherlands). 
Trifluoromethanesulfonic acid, sodium acetate trihydrate, acetic acid 96% (v/v), sodium 
dihydrogen phosphate dihydrate and hydrogen peroxide 30% (v/v) were purchased from 
Merck (Darmstadt, Germany) and sodium dodecylsulphate from Fluka Chimica GmbH (Buch, 
Switzerland). All reagents were of analytical grade and used without further purification. 
UV/VIS spectrophotometry 
UV/VIS spectra were recorded with a Model UV/VIS 918 spectrophotometer (GBC Scientific 
Equipment, Victoria, Australia). Spectra were recorded from 800 to 260 nm. Samples were 
prepared by dissolving NAMI-A in distilled water to a final concentration of 100 µg/ml.  
High Performance Liquid Chromatography 
HPLC instrumentation and conditions 
The HPLC system consisted of a model SP8800 ternary pump (Thermo Separation Products 
(TSP), Fremont, CA, USA), a model 996 photo diode array (PDA) detector (Waters, Milford, 
MA, USA) and a model SP8880 autosampler (TSP). Chromatograms were processed using 
Millenium® software (Waters). Separation was achieved using a µBondapak C18 column 
(Waters), protected with a C8 guard column (Security Guard, Phenomenex, Torrance, CA, 
USA). The mobile phase consisted of 0.50 mM sodium dodecylsulphate in 3% methanol, 
acidified to pH 2.5 using trifluoromethanesulfonic acid (triflic acid). The flow rate was 0.5 
ml/min and the system was operated at ambient temperature. The detection wavelength was 
358 nm and on-line spectral analysis was carried out with the PDA system. The injection 
volume was 20 µl. A run time of 10 minutes was employed for the standard samples 
HPLC-UV method development for NAMI-A 
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(calibration curve and quality control), and a run time of 30 minutes for stress testing samples 
to detect degradation products. 
Sample preparation  
NAMI-A drug substance: 500 µg/ml samples of NAMI-A drug substance were prepared by 
diluting 500 µl of a 1 mg/ml stock solution in distilled water with 500 µl mobile phase.  
NAMI-A lyophilized product: NAMI-A 50 mg/vial lyophilized powder for intravenous use 
was dissolved and diluted to 50.0 ml using distilled water. Of this solution 500 µl was diluted 
with 500 µl mobile phase, resulting in a theoretical sample concentration of 500 µg/ml 
NAMI-A.  
Validation procedure 
The HPLC method was validated with respect to the following parameters: linearity, 
accuracy, precision and stability-indicating capability. Validation was carried out in 
compliance with ICH guidelines [11]. 
Linearity 
A 1 mg/ml stock solution of NAMI-A in mobile phase was diluted with mobile phase to six 
concentration levels (100, 200, 300, 400, 500 and 600 µg/ml). Three separate runs were 
analyzed in duplicate. Least squares regression analysis of concentration, weighted by the 
reciprocal of the concentration squared [1/(concentration)2] versus the NAMI-A peak area was 
applied. Linearity of each calibration curve was evaluated both by visual examination and the 
F-test for lack of fit. 
Accuracy and precision 
Accuracy, between-day and within-day precision were determined by analyzing samples at 
four concentration levels (100, 300, 500 and 600 µg/ml in mobile phase) in triplicate in three 
separate analytical runs. Samples were prepared from a separate stock solution of 1 mg/ml 
NAMI-A in mobile phase. Accuracy was measured as the percentage deviation from the 
nominal concentration. Between-day and within-day precision were determined by 
performing one-way analysis of variance (ANOVA) for each test concentration using the 
analytical run as the grouping variable. From ANOVA analysis, the day mean square 
(DayMS), error mean square (ErrMS) and grand mean (GM) were obtained. Between-day and  
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within-day precisions were calculated using equation 1 and 2, where n is the number of 
replicates. 
Between-day precision (%) = 100 × √ErrMS / GM (1) 
Within-day precision (%) =  100 × √ ((DayMS-ErrMS)/n) / GM (2) 
Stability-indicating capability 
The capacity of the HPLC method to determine the presence of degradation products was 
tested by subjecting NAMI-A to stress conditions (acid, alkaline, neutral, heat, oxidation, and 
high intensity light). In all cases, 1 mg/ml solutions of NAMI-A were prepared and stored at 
room temperature in the dark (except for the solutions exposed to heat and high intensity 
light). For the acidic conditions, 0.1M acetate buffer at pH 3 was prepared. Neutral and 
alkaline conditions were created by adjusting the pH of a 0.1M phosphate buffer to pH 7 and 
10, respectively. Throughout the experiments, the pH of the solutions was monitored and 
adjusted as necessary. A solution in distilled water was exposed to heat in a stove at 50°C 
(Heraeus, Hanau, Germany) and to UV/VIS light in the range of 320-800 nm at an intensity of 
765 W/m2. To this purpose, a Suntest CPS+ instrument with xenon lamp and glass filters with 
a cut-off at 320 nm (Atlas Materials Testing Technology LLC, Chicago, IL, USA) was used. 
Oxidation of NAMI-A took place in 15% hydrogen peroxide. Each solution prepared for 
stress testing was sampled at different time points, depending on the rate of degradation. At 
selected time points, 500 µl samples were taken, diluted with 500 µl mobile phase and 20 µl 
of the resulting solution was injected into the HPLC system. 
Profiling of degradation products 
NMR spectroscopy  
2H NMR spectra were recorded using a Bruker AC 200 spectrometer at 30.7 MHz. NAMI-A 
DMSO-d6 samples were dissolved in 0.15 M aqueous phosphate buffer (pH 3.5 and pH 7.4) at 
a concentration of 25 mM (11.45 mg/ml) and immediately analyzed.  Spectra were stored at 
regular time intervals and each spectrum was measured with 128 scans. 
The NMR experiments were duplicated using HPLC under identical storage conditions. 
Samples (45 µl) were taken every 30 minutes for 6 hours, diluted with 955 µl mobile phase 
and injected into the HPLC system for the solutions at pH 7.4. For the solutions at pH 3.5, 
samples were taken immediately and every two hours until 24 hours after preparation.  
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AAS 
Ruthenium concentrations were measured using a SpectrA-A 30/40 Zeeman Graphite Furnace 
Atomic Absorption Spectrometer (Varian, Techtron Pty Ltd, Victoria, Australia), using a 
procedure described earlier [12]. 
Solutions containing 25 mM NAMI-A in 0.15 M phosphate buffer at pH 3.5 and 7.4 were 
prepared. For both solutions, 85 µl samples were taken immediately after preparation, diluted 
with 915 µl mobile phase and injected into the HPLC system. Subsequently, the solutions 
were stored at room temperature, protected from light, and the next sample was taken after 24 
hours for the solution at pH 7.4 and after 72 hours for the solution at pH 3.5. The 
chromatograms were recorded and fractions from the outlet of the PDA detector were 
collected every 30 seconds, resulting in 250 µl fractions. The ruthenium concentration in each 
fraction was measured using AAS. Furthermore, the total ruthenium concentration in each test 
solution was measured at the same time points as the fractions were collected. 
 
Results and discussion 
UV/VIS spectrophotometry 
NAMI-A has a UV/VIS spectrum showing one major absorption band with a maximum at 
390 nm. During storage of a 100 µg/ml solution of NAMI-A in distilled water at room 
temperature (+20-25ºC) and protected from light, its UV/VIS spectrum changes due to 
degradation as depicted in Figure 2. An isosbestic point is observed at 358 nm. Similar 
changes in the UV/VIS spectrum take place when NAMI-A is dissolved in mobile phase.   
High Performance Liquid Chromatography development 
Like cisplatin, NAMI-A consists of a metal with several ligands, including more than one 
chloride ion. Even though cisplatin forms a square planar structure and NAMI-A an 
octahedron and different types of ligands are present, NAMI-A has been shown to show 
similar substitution reactions of chloride by water as cisplatin [13,14]. Cisplatin is known to 
form mono- and di-aqua products, especially when stored in chloride-free solutions. 
With respect to this degradation pathway, it was necessary to develop an HPLC method 
capable of discerning the different hydration stages of NAMI-A. 
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Figure 2.  Change in UV/VIS spectrum of a solution of 100 µg/ml NAMI-A in distilled water in time 
from t=0 to 96 hours (stored at 20-25°C in the dark). The directions of the small arrows 
indicate an increase or decrease in absorption upon degradation; the large arrow 
indicates the isosbestic point at 358 nm. 
 
El-Khateeb et al. [15] investigated several HPLC-UV methods for the analysis of cisplatin. It 
was found that some commonly used components of mobile phases such as acetonitrile and 
several carboxylic acids used for pH adjustment interact with the aqua complexes of cisplatin, 
making it impossible to properly analyze the degradation products. They developed an HPLC 
method utilizing a mobile phase consisting of 0.50 mM sodium dodecylsulphate (added as 
anionic hydrophobic ion-pairing agent) in 3% methanol, its pH adjusted to pH 2.5 using 
trifluoromethanesulfonic acid. In combination with this mobile phase, a µBondapak C18 
column at 37°C, flow of 0.5 ml/min and UV-detection at 305 nm provided the optimal system 
for separation of cisplatin from its aqua-complexes. This HPLC method was used as a starting 
point for the development of a method for the analysis of NAMI-A. Influence of column 
temperature (20-37ºC) on the separation of NAMI-A and its degradation products was 
negligible. UV-detection at 358 nm was selected, as this was the isosbestic point of NAMI-A 
degradation in distilled water and mobile phase (Figure 2). The total peak area at 358 nm 
should remain unchanged during the course of degradation if all products show UV-
absorption and elute from the column. 
Injection of reference NAMI-A into this HPLC system resulted in a single peak in the 
chromatogram at a retention time of approximately 4 minutes, the identity being confirmed as 
NAMI-A by its UV/VIS spectrum. The absence of secondary peaks indicates negligible 
decomposition of NAMI-A during the chromatographic process. 
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Validation of the HPLC-UV method 
Linearity 
All calibration curves proved linear in the concentration range of 100-600 µg/ml, as 
confirmed by the F-test for lack of fit (α=0.05). For all three calibration curves correlation 
coefficients >0.998 were calculated using least squares regression analysis. Table 1 shows the 
nominal and observed concentrations for the different concentration levels for the six 
analytical runs. The deviation from the nominal concentration was less than 2% for all 
concentration levels. 
Accuracy and precision 
The between- and within-day precisions were less than 5% and the accuracy within 3.1% 
(Table 2). The limit of detection of the method (the concentration NAMI-A producing a 
signal-to-noise ratio of 3) was 0.5 µg/ml.   
 
Table 1.   Validation results of the NAMI-A calibration curve samples (n=6). 
Nominal concentration (µg/mL) Measured concentration 
(µg/mL) ± SD 
RSD (%) Accuracy (%) 
100.41 99.8 ± 4.3 4.3 99.4 
200.81 202.5 ±7.6 3.7 100.9 
301.22 306.9 ± 4.8 1.6 101.9 
401.62 401.7 ± 12.5 3.1 100.0 
502.03 497.8 ± 11.0 2.2 99.2 
602.44 597.2 ± 12.1 2.0 99.1 
 
 
Table 2.   Validation results of the NAMI-A precision measurements. 
Nominal concentration 
(µg/mL) 
Within-day precision 
(%) 
Between-day 
precision (%) 
Accuracy (%) 
98.46 2.7 1.4 99.6 
295.37 4.8 4.8 102.1 
492.28 3.4 4.9 98.9 
590.73 2.2 4.0 96.9 
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Stability-indicating capability 
Figure 3 shows the percentage NAMI-A remaining with respect to the initial concentration at 
several time points under the different stress conditions. Table 3 shows the relative retention 
times, maxima of the UV/VIS spectra of the degradation peaks formed under these stress 
conditions, and the extent to which they were formed. 
Clearly, the rate of degradation of NAMI-A is pH-dependent. NAMI-A is most stable in 
acidic solutions and degrades extremely fast in basic solutions, with an undetectable amount 
of NAMI-A remaining in the solution at pH 10 after 15 minutes. NAMI-A in solutions 
exposed to high intensity light, heat, and oxidation degrades slower than in solution at pH 10 
but faster than in solution at pH 7 (Figure 3). Like the acidic solution, the solution in 
hydrogen peroxide has a pH of approximately 3, but degrades more rapidly. Thus, oxidation 
catalyzes the degradation reaction or causes a different type of degradation reaction to occur, 
possibly oxidation of ruthenium (III). If unadjusted in time (as was the case for the solutions 
exposed to light, heat, and oxidation), the pH of all NAMI-A solutions decreases to a value of 
approximately 3.5, indicating the formation of free protons as a result of deprotonation of the 
aqua complexes, leading to formation of ruthenium (III) hydroxides [13, 14].  
 
 
 
Figure 3.  Degradation of NAMI-A under different stress conditions (h = acid; " = neutral  
)= alkaline; f= heat; ! = oxidation;(= light of high intensity). 
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One degradation product (DP 1) is formed under all investigated conditions. It has a relative 
retention time between 1.63 and 1.89 and maxima in its UV/VIS spectrum at 360 and 420 nm. 
It is the main degradation product formed under all conditions, except oxidation and heat. 
Another degradation product (DP 2) appears under multiple conditions, all of acidic pH; it has 
a relative retention time between 1.40 and 1.51 and maxima in its UV/VIS spectrum at 326 
and 374 nm. It can be speculated that DP 1, which is formed under all investigated conditions 
is a hydroxide of NAMI-A. This hydroxide would be formed by substituting one chloride 
ligand by a water molecule, which is then deprotonated, causing the solutions to become 
acidic if the pH is unadjusted, as was the case for the solutions exposed to heat, light, and 
oxidation. In alkaline media, a direct substitution of chloride by hydroxide can be expected. In 
acidic solution, DP 2 also appears, which may be a higher aquated complex, or a DMSO-free 
degradation product. Other degradation products appear to be formed only under influence of 
specific conditions, although exposure to heat and high intensity light show several identical 
degradation products. For other stress conditions, several peaks have very similar UV/VIS 
spectra to DP 2, yet are distinctly separated from it.  
Under most stress conditions, the peak in the chromatogram attributed to NAMI-A (retention 
time approximately 4 minutes) retains the same UV/VIS spectrum during the course of 
degradation, which indicates that no degradation product with different spectroscopic 
properties than NAMI-A co-elutes with it. However, under alkaline conditions, when all 
NAMI-A has degraded (after approximately 15 minutes), a small peak with a different 
UV/VIS spectrum than NAMI-A emerges in the same position (relative retention time 1.00, 
maximum in its UV/VIS spectrum at 350 nm). This peak is most likely a degradation product 
typically formed under alkaline conditions and not an impurity, as it is not observed when all 
NAMI-A in the solutions exposed to light of high intensity or heat has degraded.  
Some variation of relative retention times is observed in the chromatographic analyses (see 
also Table 3). The absolute retention time of NAMI-A lengthened as the column was in use 
for longer periods of time, while the absolute retention time of the degradation products did 
not change to a large extent, decreasing the relative retention time with aging of the column. 
The solutions in buffers (acidic, neutral and alkaline) retain their total peak area at the 
detection wavelength of 358 nm, but not the solutions exposed to light, heat, and oxidation, 
which show a decrease in total peak area in time. In these unbuffered solutions, a general loss 
in UV/VIS absorbance was also noted for completely degraded solutions, a phenomenon 
accompanied by a gradual darkening of the solution, indicating the formation of poly-oxo 
species [13,14].  
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Further studies were conducted to identify degradation products using 2H NMR techniques. 
AAS experiments were performed to determine whether all ruthenium that was applied to the 
column was recovered and to investigate whether ruthenium-containing peaks could be 
discerned that were not visible in the HPLC chromatograms.  
Degradation product profiling 
2H NMR spectroscopy 
2H NMR spectroscopic studies were performed using 25 mM NAMI-A-DMSO-d6 solutions, 
as lower concentrations (such as used during stress testing) did not lead to detectable levels of 
degradation products. Neutral (pH 7.4) and acidic (pH 3.5) solutions were selected as 
degradation media.   
The NMR experiments in combination with UV/VIS analysis led to identification of several 
degradation products of NAMI-A and proposition of a degradation pathway as depicted in 
Figure 4 [13, 14]. The deuterated DMSO group is pivotal in the identification of some 
degradation products and (by the appearance of free DMSO) inferring the presence of others. 
The parent compound gives rise to a pH-independent, single resonance at -15 ppm. At neutral 
conditions, a second peak is identified at -11 ppm, which is likely to correspond to the mono-
hydroxy complex derived from the replacement of one chloride ligand by hydroxide 
(compound B in Figure 4). The resonance of this compound is pH-dependent and, by 
lowering the pH, moves towards lower ppm values, until at pH 3.5 it overlaps the NAMI-A 
parent compound (compound A) at -15 ppm. The pH dependence is probably a result of the 
protonation-deprotonation equilibrium of the hydroxide ligand, which under acidic conditions 
forms a water molecule.  Compounds D, E and F cannot be directly detected using 2H NMR, 
but their presence can be inferred from the quantity of free deuterated DMSO.  
Figure 5A depicts the results obtained for the NMR degradation studies at pH 7.4. It is shown 
that NAMI-A (compound A in Figure 4) is completely degraded within two hours. The mono-
hydroxy species of NAMI-A (compound B in Figure 4), is formed and disappears again, due 
to consecutive degradation. Another compound is detected when almost all NAMI-A has 
disappeared and the mono-hydroxy species is at its maximum concentration. This compound 
is tentatively identified as the di-hydroxy species (compound C in Figure 4). The relative 
concentration of free DMSO increases in time and reaches a plateau after 4 hours, which 
indicates formation of DMSO-free degradation products (compounds D, E and F in figure 4).  
  
                    
Figure 4.  
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Figure 5.  A. NMR degradation study of NAMI-A in solution at pH 7.4 (g= NAMI-A (compound  
A)), " = compound B (mono-hydroxy/aqua species), ’ = not identified with 
certainty, but likely compound C (di-hydroxy/aqua species), f = total DMSO, ( = 
free DMSO). 
B. HPLC degradation study of NAMI-A in solution at pH 7.4  (& = NAMI-A, ! = DP 
1,) = peak with maximum in its UV/VIS spectrum at 350 nm). 
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Figure 6. NMR degradation study of NAMI-A in solution at pH 3.5 (i = NAMI-A and its mono-
aqua / hydroxy species, " = free DMSO, ) = total DMSO). 
 
Figure 6 depicts the results of the NMR study performed at pH 3.5. An increase in free 
DMSO concentration is noted, which indicates formation of DMSO-free degradation 
products. Unfortunately, no quantitative distinction between the parent compound (compound 
A) and its mono-aqua species (compound B) is possible at acidic pH. The mono-aqua species 
appears as a shoulder in the NAMI-A peak, indicating its presence, but making quantification 
impossible. This shoulder appears after approximately 8 hours. As free DMSO is detected 
immediately after dissolution, it can be deduced that at acidic pH, NAMI-A degrades 
primarily by hydrolysis of the DMSO ligand and chlorine substitution occurs only at a low 
rate. This is different from NAMI-A degradation at neutral pH, where chlorine substitution 
appears to play a more prominent role than DMSO hydrolysis.  
Duplication of the NMR experiment with HPLC 
The NMR experiments were duplicated using HPLC analysis in order to identify the peaks 
generated during degradation of NAMI-A in phosphate buffer at pH 3.5 and 7.4. 
Figure 5B depicts the results obtained for the HPLC degradation studies at pH 7.4. The areas 
of the observed peaks in the HPLC chromatogram plotted against time show a similar profile 
as the NMR plot. Immediately after preparation, the solution already contains a degradation 
product at a relative retention time of 1.5 and maxima in its UV/VIS spectrum at 360 and 420 
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nm (DP 1, Table 3). This peak grows in time, then decreases, in the same manner, but at a 
slightly slower rate as found for the mono-hydroxy species in the NMR experiments. This 
might be due to the slightly lower temperature (21°C instead of 25°C) at which this 
experiment was carried out. Based on these results, DP 1 was identified as the mono-hydroxy 
species of NAMI-A (compound B, Figure 4). After 3 hours at pH 7.4, when NAMI-A is 
undetectable, another degradation peak is formed in the HPLC chromatograms with a relative 
retention time of 1.0 and a maximum in its UV/VIS spectrum at 350 nm. This peak may be 
the degradation product which could not be assigned by NMR (tentatively the di-hydroxy 
species of NAMI-A: compound C in Figure 4), or a different degradation product, which is 
formed upon complete degradation of NAMI-A in alkaline solutions. 
The HPLC study performed at pH 3.5 shows the slow formation of the mono-hydroxy species 
of NAMI-A (DP 1, relative retention time 1.5, UV/VIS maxima at 360 and 420 nm). 
Furthermore, a second degradation product (DP 2, Table 3) is formed. It has a relative 
retention time of 1.3 and maxima in its UV/VIS spectrum of 326 and 374 nm and was also 
observed in all solutions at acidic pH during stress testing. NMR analysis showed that at 
acidic pH, NAMI-A degrades mainly by DMSO hydrolysis, thus DP 2 may be any one of the 
DMSO-free degradation products depicted in Figure 4. This is apparently confirmed by the 
fact that when DMSO is added to an acidic solution, DP 2 is formed to a lesser extent. Thus, 
as hydrolysis of the DMSO group is likely prevented by addition of free DMSO, addition of 
DMSO would lead to less formation of the DMSO-free complexes. 
General discussion of NAMI-A degradation 
NAMI-A is a ruthenium(III) [Ru(III)] complex in an octahedral configuration and has rather 
complex chemistry. Ru(III) forms complexes in which the ligands are sensitive to exchange 
reactions. In aqueous solution the first chloride ion in ruthenium hexachloride, [Ru(III)Cl6]3-, 
is exchanged within a few seconds by a water molecule, while the last chloride ion in 
[Ru(III)Cl(H2O)5]2+ to be replaced by a water molecule takes more than one year [16]. In this 
study, UV/VIS and NMR methods were used to obtain relevant insight into the behavior of 
NAMI-A in aqueous solution, especially with respect to its stability. The interpretation of the 
results obtained is of a rather speculative nature. No attention has been paid to the imidazole 
ligand, because neither the HPLC nor the UV/VIS method gives information about this 
ligand, although there are several unidentified peaks in the HPLC chromatograms. It can be 
argued that imidazole (Im), with a pKa of 6.9, will be protonated in solutions of acidic pH, 
resulting in repulsion of like forces between Ru3+ and ImH+, weakening the bond to a large 
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extent. Therefore, it should not be surprising if Im is the most easily exchanged ligand under 
acidic conditions. However, it has been shown by NMR analysis that the imidazole ligand is 
not readily exchanged [14]. It seems likely that DMSO is hydrolyzed in preference to 
imidazole, as an increase in free DMSO is observed in NMR studies. In alkaline and neutral 
medium, the hydroxy-ion is the ligand of choice for exchange and it appears that the chloride 
ligands are preferentially substituted. Further investigation into the degradation mechanism of 
NAMI-A is ongoing. For the moment, the scheme as proposed in Figure 4 remains the most 
logical degradation pathway. 
AAS 
Figure 7 shows the HPLC chromatograms for a solution of NAMI-A in phosphate buffer at 
pH 7.4 immediately after preparation and after 24 hours storage at room temperature in the 
dark and their corresponding AAS ruthenium concentration profiles. Figure 8 shows the 
results for a solution at pH 3.5 immediately after preparation and after 72 hours storage. The 
ruthenium profiles obtained by AAS for both solutions at t=0 and for pH 3.5 at t=72 hours 
match their HPLC chromatograms. The total amount of ruthenium measured in the combined 
fractions was equal to the ruthenium content of the sample taken directly from the solution 
under investigation, indicating that the amount of ruthenium injected into the HPLC is 
completely recovered.  
The solution at pH 7.4 after 24 hours storage shows deviating results. This test solution 
contains approximately 43% of the initial ruthenium concentration. The loss of ruthenium is 
explained by the formation of a black precipitate in this solution. Visual precipitation starts 
after 6 hours of storage at pH 7.4. This precipitate may contain insoluble ruthenium 
hydroxides, oxides, or the poly-oxo species formed upon further degradation (Figure 4). Its 
formation was not observed in the neutral solution during stress testing, as the stress testing 
solution was measured for 2 hours. 
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Figure 7.  A. HPLC chromatogram for NAMI-A at pH 7.4 immediately after preparation (t0). 
  B. AAS ruthenium concentration profiles for NAMI-A at pH 7.4 at t0. 
  C. HPLC chromatogram for NAMI-A at pH 7.4 after 24 hours storage (t24). 
  D. AAS ruthenium concentration profiles for NAMI-A at pH 7.4 at t24. 
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Figure 8.  A. HPLC chromatogram for NAMI-A at pH 3.5 immediately after preparation (t0). 
  B. AAS ruthenium concentration profiles for NAMI-A at pH 3.5 at t0. 
  C. HPLC chromatogram for NAMI-A at pH 3.5 after 72 hours storage (t72). 
  D. AAS ruthenium concentration profiles for NAMI-A at pH 3.5 at t72. 
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Along with loss of ruthenium due to precipitation, it appears that ruthenium is retained on the 
column. The total amount of ruthenium recovered from the collected fractions after injection 
onto the HPLC column contained 21% of the ruthenium present in the test solution at this 
time point. Furthermore, a large ruthenium peak is observed in the AAS ruthenium profile at a 
retention time of 9 minutes, which is observed in the HPLC chromatogram not as a peak, but 
as a deflection from baseline. This deflection, however, has a UV/VIS spectrum with a 
maximum absorption in its UV/VIS spectrum at 318 nm, indicating the presence of a 
ruthenium-containing degradation product that is not fully detected using the HPLC method 
with detection at 358 nm. 
From the AAS experiments, it can be concluded that under normal experimental conditions, 
all ruthenium injected into the HPLC system is recovered and all ruthenium-containing 
compounds form peaks in the chromatogram. However, for severely degraded solutions of 
NAMI-A some ruthenium is retained on the column and not all ruthenium-containing 
compounds are detected with the chromatographic system.  
NAMI-A lyophilized product 
NAMI-A lyophilized product shows an identical chromatogram to NAMI-A drug substance, 
with the main peak exhibiting NAMI-A’s UV/VIS spectrum. The purity of the lyophilized 
product varies slightly with each manufactured batch, but is generally around 97%. The 
presence of one “impurity” is observed: the mono-hydroxy species of NAMI-A (compound B 
in Figure 4). This is probably the result of degradation during the dissolution, filtration, and 
filling steps in the manufacturing process. The lyophilization process, however, does not 
affect the integrity of NAMI-A.  
 
Conclusion 
UV/VIS spectrophotometry and HPLC were used to analytically characterize NAMI-A. The 
HPLC method was validated and found to be linear, accurate, precise and stability indicating. 
Stress testing showed that degradation products were separated from the parent compound. 
One degradation product was identified as the mono-hydroxy product of NAMI-A. AAS 
experiments revealed that generally, all ruthenium that is injected onto the HPLC column is 
recovered and that all ruthenium-containing compounds produce a peak in the chromatogram. 
Upon severe degradation in alkaline solution, loss of NAMI-A and degradation products takes 
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place as a result of precipitation and some ruthenium is retained on the column. However, for 
the pharmaceutical quality control of NAMI-A, a specification will be included to inject 
samples immediately after their preparation, minimizing degradation of the samples and thus 
circumventing detection and retention problems encountered with extremely degraded 
solutions of NAMI-A. Minimization of degradation of the samples in the autosampler vials is 
also achieved by diluting the samples with mobile phase, which has a pH of 2.5. An acidic pH 
has been shown to stabilize NAMI-A in solution.  
NAMI-A lyophilized product shows identical chromatograms and UV/VIS spectra as NAMI-
A drug substance. This stability-indicating HPLC method will be used in future analyses and 
pharmaceutical quality control of NAMI-A drug substance and lyophilized product. 
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Abstract 
NAMI-A is a novel ruthenium complex with selective activity against cancer metastases 
currently in Phase I clinical trials in The Netherlands. The chemical stability of this new agent 
was investigated utilizing a stability-indicating reversed-phase high performance liquid 
chromatographic assay with ultraviolet detection and ultraviolet/visible light 
spectrophotometry. The degradation kinetics of NAMI-A were studied as a function of pH, 
buffer composition, and temperature. Degradation of NAMI-A follows first-order kinetics at 
pH < 6 and zero-order kinetics at pH ≥ 6. A pH-rate profile, employing rate constants 
extrapolated to zero buffer concentration, was constructed, demonstrating that NAMI-A is 
most stable in pH region 3-4. The degradation rate is not significantly affected by specific 
buffer components. Storage temperature strongly influences the degradation rate.  
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Introduction 
NAMI-A (imidazolium trans-tetrachloro(dimethylsulfoxide)imidazoleruthenium(III), H2im 
[trans-RuCl4(DMSO)Him], Figure 1) is a novel ruthenium anticancer agent. Preclinical 
pharmacological studies with NAMI-A showed selective activity against lung metastases of 
murine tumors [1-4] and a relatively low toxicity in mice and dogs [5-7]. Its action seems to 
be independent of the origin (type of primary tumor) and stage of growth of the metastases 
[3,4,8]. NAMI-A possesses no appreciable in vitro tumor cell cytotoxicity [2,5,8,9], although 
an interaction with cell cycle regulation has been observed in a transient accumulation of cells 
in the G2/M phase [5,8,9,10]. Furthermore, NAMI-A increases the capsule thickness around 
the primary tumor and the extracellular matrix around tumor blood vessels, thereby 
preventing tumor cells from invading surrounding tissue and blood vessels [1,9]. More 
recently, NAMI-A was shown to inhibit matrix metalloproteinases and to induce 
antiangiogenic effects [11].  
 
 
 
 
 
 
 
 
 
Figure 1.  Chemical structure of NAMI-A. Molecular weight = 458.18 g/mol. Molecular formula: 
C8H15Cl4N4ORu(III)S. 
 
Based on its promising activity and toxicity profile, NAMI-A is developed as a potential 
anticancer agent and has currently entered Phase I clinical trials. Before a suitable 
pharmaceutical formulation can be developed for a new drug substance, it is important to gain 
insight into the stability of the agent in different types of solutions. This study was initiated 
with the objective to obtain detailed knowledge on the degradation kinetics of NAMI-A in 
aqueous solution, including the effects of several parameters such as pH, buffer composition, 
and temperature on the degradation process.  
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Materials and methods 
Chemicals 
NAMI-A was supplied by SIGEA Srl (Trieste, Italy). Methanol (HPLC grade) was obtained 
from Biosolve Ltd. (Amsterdam, The Netherlands) and distilled water from B. Braun Medical 
(Melsungen, Germany). Trifluoromethanesulfonic acid, sodium acetate trihydrate, acetic acid 
96% (v/v), sodium dihydrogen phosphate dihydrate, disodium tetraborate decahydrate, 
sodium carbonate (anhydrous), sodium citrate monohydrate, hydrochloric acid 37%, sodium 
chloride, perchloric acid (70-72% (w/v)) and sodium hydroxide pellets were purchased from 
Merck (Darmstadt, Germany). Sodium dodecylsulphate was obtained from Fluka Chimica 
GmbH (Buch, Switzerland). All reagents were of analytical grade and used without further 
purification. 
Buffer solutions 
For the kinetic studies the following aqueous buffer solutions were used: pH 1-5, acetate; pH 
6-11, phosphate. Buffers were prepared in concentrations of 0.01, 0.10 and 1.0 M. The pH 
values were measured using a Model 654 pH meter (Metrohm AG, Herisau, Switzerland). 
Kinetic experiments 
Influence of pH and buffer strength 
The degradation reactions were initiated by adding 240 µl of a freshly prepared 50 mg/ml 
stock solution of NAMI-A in distilled water to 11.76 ml buffer solution, resulting in test 
solutions with a NAMI-A concentration of 1.0 mg/ml. The solutions were stored in glass test 
tubes, protected from light. All kinetic studies were conducted at 20-23°C, unless otherwise 
stated. At appropriate time intervals, 500 µl samples were withdrawn from the test solutions, 
diluted 1:1 with mobile phase in an autosampler vial, and injected into the stability-indicating 
HPLC system for analysis. Furthermore, at selected time points, samples were analyzed by 
UV/VIS spectrophotometry. For all solutions, the pH in time was measured and adjusted as 
necessary to keep it constant. All kinetic experiments were performed in duplicate. 
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Influence of temperature 
The effect of temperature on the degradation of NAMI-A was studied at pH 3 (0.1 M acetate 
buffer) and pH 7 (0.1 M phosphate buffer) in the temperature range of 4-37°C. The test 
solutions were prepared as described above, with the use of pre-warmed or -cooled buffer 
solutions. The temperatures of the test solutions were kept constant in a thermostatically 
controlled water bath or refrigerator.  
High Performance Liquid Chromatography (HPLC) 
The HPLC system consisted of a model SP8800 ternary pump (Thermo Separation Products 
(TSP), Fremont, CA, USA), a model 996 photo diode array (PDA) detector (Waters, Milford, 
MA, USA) and a model SP8880 autosampler (TSP). Chromatograms were processed using 
Millenium® software (Waters). Separation was achieved using a µBondapak C18 column 
(Waters), protected with a C8 guard column (Security Guard, Phenomenex, Torrance, CA, 
USA). The mobile phase consisted of 0.50 mM sodium dodecylsulphate in 3% methanol, 
acidified to pH 2.5 using trifluoromethanesulfonic acid (triflic acid). The flow rate was 0.5 
ml/min and the system was operated at ambient temperature. The detection wavelength was 
358 nm and on-line spectral analysis was carried out with the PDA system. The injection 
volume was 20 µl. A run time of 10 minutes was employed for both the standard samples 
(calibration curve and quality control) and of 30 minutes for the samples under investigation. 
Employing this HPLC system, NAMI-A produces a peak with a retention time of 
approximately 4.1 minutes.  
Calibration curves of standard NAMI-A solutions in distilled water were linear (r > 0.98) in 
the concentration range of interest (1-600 µg/ml). 
Ultraviolet/visible light (UV/VIS) spectrophotometry 
UV/VIS spectra were recorded with a Model UV/VIS 918 spectrophotometer (GBC Scientific 
Equipment, Victoria, Australia). Spectra were recorded from 800 to 225 nm. Samples of the 
test solutions were diluted with distilled water to a theoretical concentration of 100 µg/ml 
before measurement.  
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Calculations 
Order of reaction 
The order of reaction was calculated using the graphic method as described by A. Martin [12]. 
Zero, first and second order graphs were drawn for each pH and each buffer concentration by 
plotting time versus NAMI-A concentration, ln NAMI-A concentration, and 1/(NAMI-A 
concentration), respectively. The correlation coefficient of each graph was calculated, and the 
plot with the best linearity described the order of the reaction in the best manner. The 
observed rate constant (kobs) was the slope (multiplied by –1) of the best-fitting graph. Half-
times were determined by entering the appropriate values into the Equations 1 and 2 for zero- 
and first order reactions, respectively: 
 t1/2 = a / (2 x kobs)         (1) 
 t1/2 = ln 2 / kobs         (2) 
where a is the initial NAMI-A concentration (M).   
 
Results and discussion 
Degradation of NAMI-A 
Degradation pathway and general observations 
NAMI-A (Figure 1) consists of a ruthenium atom with six ligands: four chloride ions, one 
DMSO group and one imidazole group. All of these ligands can be replaced by water 
molecules, hydroxide ions, or buffer components, resulting in a wide range of possible 
degradation products. A degradation pathway as depicted in Figure 2 has been proposed for 
NAMI-A [2,13]. The structural elucidation of the various degradation products was based on 
UV/VIS spectrophotometry and NMR spectroscopy. NMR spectroscopy showed that neither 
DMSO nor the imidazole ligand are readily replaced in aqueous solution [2,13], except in 
acidic solutions, where the DMSO group is hydrolyzed as well as the chloride ligands [14,15]. 
The degradation of NAMI-A thus consists of stepwise hydrolysis of the chloride ligands, in 
acidic media accompanied by hydrolysis of the DMSO group, followed by formation of poly-
oxo species. This last step can be visually observed by darkening of the solutions. 
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Figure 3.  Change in UV/VIS spectrum of a solution of 100 µg/mL NAMI-A in distilled water 
in time from t=0 to 96 hours (stored at 20-25°C in the dark). The directions of the 
small arrows indicate an increase or decrease of absorption upon degradation; the 
large arrows indicate the isosbestic points at 274 and 358 nm. 
 
 
 
 
 
Figure 4. Decrease in pH of a 1 mg/ml solution of NAMI-A in distilled water with time. 
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Upon degradation in aqueous buffer solutions, when stored protected from light, the 
UV/VIS spectrum of NAMI-A changes as depicted in Figure 3. Initially, two isosbestic 
points are present, at 274 and 358 nm, suggesting a single transformation in the 
chromophore in the early stages of degradation (substitution of ligands), the duration of 
which is dependent on the pH of the buffer solution. Thereafter, the spectrum began to 
distort the isosbestic points, providing evidence of secondary degradation, which could be 
caused by further substitution of ligands, polymerization, or oxidation or reduction of the 
chromophore Ru(III) . The same changes were observed in all buffered NAMI-A solutions, 
although different time spans were required for these changes in the UV/VIS spectrum. 
If unadjusted in time, the pH of all NAMI-A solutions changed to approximately 3.5 (as 
depicted in Figure 4 for a solution of NAMI-A in water), indicating the formation of 
products with acidic properties (pKa ~ 3.5) and/or protons. As depicted in Figure 2, 
hydrolysis of NAMI-A and subsequent establishment of an equilibrium between the aqua 
and hydroxy products is accompanied by formation of protons, and thus lowering of the 
pH. The kinetic studies were thus performed in buffers. However, even the buffer 
solutions, especially those of alkaline pH and low molarity, needed occasional addition of 
base or acid to keep the pH constant.   
Color changes were observed during the course of degradation. Whereas the color of all 
solutions immediately after preparation was yellow and all UV/VIS spectra at that time 
were identical, the solutions at acidic and neutral pH all darkened and in time turned 
brown, although the time it took for the color change varied (pH 1: 96 hours, pH 7: 4 
hours). The solutions at pH 8-11 turned a lighter yellow color, although these solutions 
were examined for a maximum of 40 minutes. Color changes indicate a change in 
chromophore. Darkening of the solution has been ascribed to formation of poly-oxo or  
–hydroxy species, while loss of color of NAMI-A solutions has been described for 
reduction of the ruthenium atom from Ru(III) to Ru(II) [2,13,15]. 
Degradation kinetics 
Analytical procedures and influence of pH 
Degradation of NAMI-A can be followed using the presented HPLC method, which was 
proven to be stability-indicating, precise and accurate [14]. Figures 5A and 5B show 
typical HPLC chromatograms of a decomposition mixture of NAMI-A at about one half-
life in acidic and neutral media, respectively. Degradation products appear as separate 
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Figure 5.   A.  HPLC chromatogram of partly degraded NAMI-A in 0.1 M acetate solution at 
pH 4 after 48 hours. 
B. HPLC chromatogram of partly degraded NAMI-A in 0.1 M phosphate solution 
at pH 7 after 1.75 hours. 
 
 
peaks and no degradation products co-elute with the NAMI-A peak. In the neutral and 
alkaline reaction mixtures tailing of the NAMI-A peak was observed, as can be observed in 
Figure 5B. UV/VIS analysis of the complete peak, including the tailing portion, showed the 
presence of only NAMI-A. Furthermore, no increase of the tailing area was observed in 
time, as would be expected for overlapping peaks in which one peak was a degradation 
product. It appeared that one or more of the components present in the neutral and alkaline 
buffers caused an interaction between NAMI-A and the column material, but not between 
the degradation products and the column material.  
However, upon injection of the solutions to which sodium chloride had been added, the 
HPLC chromatograms showed two non-separated peaks covering the retention time (tR) 
range of 3.7-5.3 minutes. Both peaks contained NAMI-A, as was determined from their 
UV/VIS spectra, but quantification became impossible by the formation of these two 
peaks. This effect prohibited the investigation of the influence of the ionic strength (µ) on 
the degradation of NAMI-A. These investigations require addition of various amounts of 
salts such as sodium chloride to the buffer solutions. Thus, the separation between NAMI-
A and its degradation products in the HPLC chromatograms justifies use of the HPLC 
method for this kinetic study, but not in sodium chloride-containing solutions. 
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The peak attributed to the mono-hydroxy or -aqua species (compound B in Figure 2) [14], 
with a tR at 6.9 minutes, relative tR 1.7, and maxima in its UV/VIS spectrum at 360 and 420 
nm, is formed in all solutions. It is the only degradation product initially formed at pH 
values ≥ 6 and its formation is pH-dependent. At higher pH values, the rate and extent to 
which it is formed increases. At pH values < 6, more degradation products are formed. The 
degradation product at tR 5.8 minutes (relative tR 1.4, maxima in its UV/VIS spectrum at 
326 and 374 nm) is only formed in solutions at pH <6 and has not yet been positively 
identified, but could be any of the DMSO-free products depicted in Figure 2 [14]. Its 
formation is also pH-dependent, with higher amounts at lower pH values. 
The degradation product at tR 6.1 minutes (relative tR 1.5, maxima in its UV/VIS spectrum 
at 367 and 430 nm) is only formed at pH values <4, appears to a larger extent in more 
acidic solutions, and has not yet been identified. 
Order of reaction 
The degradation of NAMI-A in solutions at pH 1-5 follows (pseudo) first-order kinetics. 
This is indicated by the linearity of the plots (r2 > 0.99) of time versus natural logarithm of 
residual NAMI-A concentration. At pH ≥ 6, however, degradation follows zero-order 
kinetics (r2 for the time versus concentration plots: 0.91 to 0.99).  
The degradation products with a relative tR of 1.4 and 1.5 were only formed at pH < 6 and 
pH < 4, respectively, and were not present in solutions of higher pH. Furthermore, color 
changes in acidic solutions differed from those in alkaline conditions. The observed 
changes indicated a difference in the main NAMI-A degradation mechanism in solutions at 
pH 1-5 and pH ≥ 6, which is in agreement with the calculated difference in order of 
reaction. Table 1 lists observed rate constants and half-lives of the different buffer 
solutions.  
The order determinations could only be performed for the solutions with a pH ≤ 10. The 
solution at pH 11 (and higher) showed immediate and complete degradation upon 
dissolution of NAMI-A and could therefore not be included. 
Influence of pH 
Since the degradation of NAMI-A is strongly pH-dependent, it is important to keep the pH 
constant during the experiments. The kinetic experiments were therefore performed in 
buffer solutions. The overall observed rate constant for the degradation of NAMI-A in  
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buffer solutions of pH 1-5 (following (pseudo) first-order kinetics) is: 
 kobs = k0 + kH[H+] + kOH[OH-] + kbuffer[buffer]    (3)  
where k0 is the (pseudo) first-order rate constant for degradation in water only, and kH and 
kOH are the second order rate constants for proton- and hydroxyl-catalyzed degradation, 
respectively. The term kbuffer[buffer] represents the sum of the second-order rate constants 
for the degradation catalyzed by each of the buffer components multiplied by its 
concentration. To obtain the specific rate constant (k’) at each pH, incorporating only 
proton (H+), hydroxide (OH-) and water (H2O) catalysis, the observed rate constants (kobs) 
were corrected for buffer influence by plotting the kobs against buffer concentration and 
extrapolating to zero buffer concentration. A linear relationship existed at each pH (for all 
pH values) between kobs and the buffer concentration. The obtained k’ is defined by 
Equation 4: 
 k’ = k0 + kH[H+] + kOH[OH-]      (4)  
The calculated values for k’ were used in the construction of the pH-rate profile (Figure 6). 
As the units for k’ were different for the first- and zero-order reactions (pH 1-5 and 6-10, 
respectively), two separate pH-rate profiles were constructed for the different types of 
reaction. Between pH 5 and 6, a combination of first- and zero-order kinetics may prevail. 
A solution at pH 3.5 provides maximal stability for NAMI-A. Neither of the profiles shows 
a slope of ±1, indicating that at 2<pH<3 a combination of solvent and proton catalysis 
takes place and at pH>4, a combination of solvent and hydroxyl catalysis. It was shown 
previously that the rate of the first hydrolytic step during degradation of NAMI-A, leading 
to formation of the mono-aqua or -hydroxy species (compound B in Figure 2), is catalyzed 
by Ru(II) species [2,13,15]. Thus, beside general acid-base and solvent catalysis, catalysis 
such as caused by Ru(II) species, formed by reduction of NAMI-A, additionally could take 
place.     
Figure 6.  pH-rate profile of NAMI-A at 20-23°C. See text for interpretation.  
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Influence of buffers 
Table 1 shows the influence of buffer concentration on the rate of degradation of NAMI-A. 
In general, NAMI-A degradation rates increase with increasing buffer concentration, which 
points to an interaction of NAMI-A with the buffer components. 
To examine whether the type of buffer influenced the rate of degradation, 0.1 M carbonate 
and borate buffers at pH 9, and 0.1M citrate buffer and hydrochloric acid at pH 3 were 
prepared and degradation in these buffers was compared to degradation in 0.1 M phosphate 
and 0.1 M acetate at pH 9 and 3, respectively. No significant influence of the type of buffer 
at either pH was observed on the degradation rate of NAMI-A. 
 
Table 1.  Influence of buffer concentration on kobs and t1/2 of the degradation of NAMI-A. 
pH [buffer] 
(M) 
kobs (s-1) t1/2 (hrs) pH [buffer] 
(M) 
kobs (Ms-1) t1/2 (hrs) 
1 0.01 5.41 x 10-6 35.5 6 0.01 2.77 x 10-8 11.1 
 0.1 5.50 x 10-6 35.0  0.1 2.78 x 10-8 11.1 
 1 5.56 x 10-6 34.7  1 5.55 x 10-8 4.7 
2 0.01 5.56 x 10-6 34.7 7 0.01 1.39 x 10-7 2.3 
 0.1 5.08 x 10-6 37.9  0.1 1.94 x 10-7 1.5 
 1 5.44 x 10-6 35.4  1 1.67 x 10-7 1.5 
3 0.01 3.39 x 10-6 56.8 8 0.01 10.6 x 10-7 0.3 
 0.1 3.94 x 10-6 48.8  0.1 8.61 x 10-7 0.3 
 1 6.19 x 10-6 31.1  1 6.94 x 10-7 0.3 
4 0.01 3.11 x 10-6 61.9 9 0.01 1.64 x 10-6 0.2 
 0.1 3.88 x 10-6 49.5  0.1 1.69 x 10-6 0.1 
 1 5.31 x 10-6 36.3  1 2.58 x 10-6 0.1 
5 0.01 2.88 x 10-6 66.6 10 0.01 30.8 x 10-7 0.1 
 0.1 6.72 x 10-6 28.6  0.1 9.44 x 10-7 0.3 
 1 14.4 x 10-6 13.3     
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Influence of temperature 
The influence of temperature on the degradation of NAMI-A was studied at pH 3 and 7 in 
the temperature range 4-37°C. The Arrhenius relationship between the natural logarithm of 
kobs and the reciprocal of the absolute temperature holds. The activation energy (Ea) at pH 3 
was calculated to be 95.4 kJ/mol and its frequency factor (A) 3.60 x 1011 s-1.   
 
Conclusion 
Degradation of NAMI-A follows (pseudo) first-order kinetics at pH values <6 and zero-
order kinetics at pH values ≥ 6. No specific proton or hydroxyl catalysis was shown. The 
degradation rate and mechanism of NAMI-A are strongly pH-dependent. NAMI-A in 
solution is most stable in the pH region 3-4. Although an influence of buffer concentration 
was observed, no influence of specific buffer components could be determined. 
Temperature strongly influences the degradation rate of NAMI-A. These data, as well as 
those reported by Sava et al. [15], imply that an acidic solvent should be used for NAMI-A 
administration during the clinical trials.  
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Abstract 
NAMI-A is a novel ruthenium complex with selective activity against metastases currently in 
Phase I clinical trials in The Netherlands. The photostability of this new agent in solid state 
and in solution has been investigated utilizing a stability-indicating reversed-phase high 
performance liquid chromatographic (HPLC) assay and ultraviolet/visible (UV/VIS) light 
spectrophotometry. In solid state, NAMI-A proved to be photostable. In solution, however, 
the compound degraded rapidly, in a pH-independent manner in the pH range of 2-5. At 
alkaline pH, the degradation rate was higher than at acidic pH. The type of buffer species had 
little influence. NAMI-A concentration was inversely related to the photostability. Addition 
of photostabilizers (5% DMSO, 2% benzyl alcohol, 0.001% curcumin) marginally increased 
the half-life. NAMI-A´s photostability in solution was influenced to the greatest extent by 
addition of an alcohol, with the least polar solvent system (50% propylene glycol) providing 
the most stable medium. Based on the presented results, it is recommended to store NAMI-A 
solutions in the dark.    
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Introduction 
NAMI-A (imidazolium trans-tetrachloro(dimethylsulfoxide)imidazoleruthenium(III), H2im 
[trans-RuCl4(DMSO)Him], Figure 1 [1]) is a novel ruthenium anticancer agent. Preclinical 
pharmacological and toxicological studies showed selective activity against lung metastases 
of murine tumors [1-4] and low toxicity in mice and dogs [5,6]. Its action seems to be 
independent of the origin (type of primary tumor) and stage of growth of the metastases [4]. 
NAMI-A possesses no direct tumor cell cytotoxicity [3,4,7], although an interaction with cell 
cycle regulation has been observed in a transient accumulation of cells in the G2/M phase 
[3,7,8]. This effect, and the capacity of NAMI-A to inhibit tumor cell matrix 
metalloproteinases, with important anti-angiogenic consequences [9], suggests this compound 
to be active in controlling metastasis growth. Correspondingly, host toxicity was mainly 
related to renal alterations, as expected for a heavy metal-derived compound, although it 
reversed within three weeks from the end of treatment [5].  
 
 
 
 
 
 
 
Figure 1.  Chemical structure of NAMI-A. Molecular weight = 458.18 g/mol. Molecular formula: 
C8H15Cl4N4ORu(III)S. 
 
Based on its promising activity and toxicity profile, NAMI-A is developed as a potential 
anticancer agent and has currently entered Phase I clinical trials. Before a suitable 
pharmaceutical formulation can be developed for a new drug substance, it is important to gain 
insight into its stability. Together with heat, moisture and atmospheric oxygen, light is an 
important external factor in drug stability. Therefore, according to the ICH Guidelines, 
photostability testing should be an integral part of stress testing of new drug substances and 
pharmaceutical products [10]. Information obtained from photostability studies can be used in 
specifying appropriate storage instructions and packaging materials. Previously, it was shown 
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that hydrogen peroxide catalyzes the degradation reaction of NAMI-A in solution or causes a 
different type of degradation reaction to occur, possibly oxidation of ruthenium (III) [11]. 
Another study revealed that temperature affects the degradation of NAMI-A in solution, 
which can be described by the Arrhenius equation [12]. 
This study was initiated with the objective to obtain detailed knowledge on the photostability 
of NAMI-A drug substance in solid state and in aqueous solution. The effects of several 
parameters such as concentration, pH, buffer composition, solvent system, and 
photostabilizers on the degradation rate of NAMI-A in solution were investigated.  
 
Materials and methods 
Chemicals 
NAMI-A was supplied by SIGEA Srl (Trieste, Italy). Sterile Water for Injections was 
purchased from B. Braun Medical (Melsungen, Germany). Methanol (HPLC grade) and 
ethanol 100% were obtained from Biosolve Ltd. (Amsterdam, The Netherlands). 
Trifluoromethanesulfonic acid, sodium acetate trihydrate, acetic acid 96% (v/v), sodium 
dihydrogen phosphate dihydrate, sodium citrate monohydrate, dimethylsulfoxide, perchloric 
acid (70-72% (w/v)), benzyl alcohol, and sodium hydroxide pellets were purchased from 
Merck (Darmstadt, Germany). Sodium dodecylsulphate and quinine hydrochloride dihydrate 
were obtained from Fluka Chemica GmbH (Buch, Switzerland), curcumin from Sigma-
Aldrich (St. Louis, MO, USA), and polypropylene glycol from BUFA BV (Uitgeest, The 
Netherlands). All reagents were of analytical grade and used without further purification. 
Light exposure 
All samples and dark controls (samples placed alongside the exposed samples wrapped in 
aluminum foil) were exposed in triplicate in a Suntest CPS+ equipped with a xenon lamp 
(NXE 1500 B) with a coated quartz dish and window glass filter to allow only light with a 
wavelength of 320-800 nm and a spectral distribution similar to the ID 65 standard, as 
required in the ICH Guideline [10] (all Atlas Material Testing Technology LLC, Chicago, IL, 
USA). Samples were exposed to light at the highest irradiation level of the Suntest apparatus, 
(765 W/m2, after passage of the filters: 68.9 W/m2 at < 400 nm and 170 klux at > 400 nm). 
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The Suntest unit was connected to a SuncoolTM chiller (Atlas). Liquid samples and the 
quinine actinometric solution were exposed in standard 1 cm quartz cells with two frosted 
sides and tight-fitting PTFE caps (4 ml total volume, HELLMA GmbH & Co, Müllheim, 
Germany). Solid samples were exposed in glass petri dishes (∅ 10 cm). The temperature 
during exposure was monitored using a minimum-maximum thermometer (Merck). 
Quinine hydrochloride dihydrate actinometric system 
A 2% (w/v) quinine hydrochloride dihydrate solution served as the actinometric system to 
monitor the intensity of the ultraviolet (UV) radiation around 330 nm [10, 11]. The untoward 
effects of light are generally due to the UV ranges of sunlight acting directly on the 
compound [12]. However, in order to evaluate the changes induced by light exposure under 
normal circumstances, exposure to light with a wavelength of 320-800 nm and a spectral 
distribution similar to the ID 65 standard, as required in the ICH Guidelines [10], was 
employed. The quinine actinometric system was used to monitor the UV energy received by 
the exposed samples, as measured by the change in absorbance at 400 nm (∆A400) between the 
exposed samples and dark controls. The ∆A400 was linear with duration of exposure.  
Christensen et al showed that after light exposure, the quinine actinometric system shows 
dark reactions, which can contribute significantly to the results obtained [13]. Therefore, 
samples (both NAMI-A and quinine) were measured immediately after being taken, thus 
minimizing the chance of distortion of results due to dark reactions taking place upon storage 
of samples.  
High Performance Liquid Chromatography (HPLC) 
The HPLC system consisted of a model SP8800 ternary pump (Thermo Separation Products 
(TSP), Fremont, CA, USA), a model 996 photo diode array (PDA) detector (Waters, Milford, 
MA, USA) and a model SP8880 autosampler (TSP). Chromatograms were processed using 
Millenium® software (Waters). Separation was achieved using a µBondapak C18 column 
(300 mm x 3.9 mm, particle size 10 mm, Waters), protected with a C8 guard column (Security 
Guard, Phenomenex, Torrance, CA, USA). The mobile phase consisted of 0.50 mM sodium 
dodecylsulphate in 3% methanol, acidified to pH 2.5 using trifluoromethanesulfonic acid 
(triflic acid). The flow rate was 0.5 ml/min and the system was operated at ambient 
temperature. The detection wavelength was 358 nm and on-line spectral analysis was carried 
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out with the PDA system. The injection volume was 20 µl. A run time of 10 minutes was 
employed for both the standard samples (calibration curve and quality control) and of 30 
minutes for the samples under investigation. Employing this HPLC system, NAMI-A 
produces a peak with a retention time of approximately 4.1 minutes.  
Calibration curves of standard NAMI-A solutions in distilled water were linear (r>0.98) in the 
concentration range of interest (1-600 µg/ml). Samples were prepared by diluting the solution 
under investigation with sufficient mobile phase to produce 1.00 ml of a solution with a 
theoretical NAMI-A concentration of 500 µg/ml in an autosampler vial. 
Degradation of NAMI-A can be followed using the presented HPLC method, which was 
proven to be stability-indicating, precise and accurate [14]. 
Ultraviolet/visible light (UV/VIS) spectrophotometry 
UV/VIS spectra were recorded with a Model UV/VIS 918 spectrophotometer (GBC Scientific 
Equipment, Victoria, Australia). The absorbance of the quinine actinometric samples was 
measured at 400 nm. For the NAMI-A samples, the absorbance at 390 nm was measured and 
spectra were recorded from 800 to 225 nm. Measurements were performed by diluting the 
solution under investigation to a theoretical concentration of 100 µg/ml with Water for 
Injections.  
Kinetic experiments 
NAMI-A in solid state 
100 mg NAMI-A was spread in a layer of no more than 3 mm thickness, and irradiated for 24 
hours, alongside a dark control and the quinine actinometric system. The quinine actinometric 
system showed a ∆A400 of 0.75 between the dark controls and exposed samples. Before and 
after light exposure, NAMI-A was dissolved in water to a concentration of 1 mg/ml and 
further diluted as appropriate for immediate analysis by HPLC and by UV/VIS 
spectrophotometry. 
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NAMI-A in solution 
Influence of concentration 
The influence of concentration was studied in Water for Injections, at NAMI-A 
concentrations of 1, 10, and 20 mg/ml. Samples of all NAMI-A solutions were taken at 
appropriate time intervals (t= 0, 30 minutes, and 1, 2, 4, and 6 hours) to be able to monitor the 
degradation in a quantitative manner. All other experiments were carried out in 10 mg/ml 
NAMI-A solutions in the appropriate solvent. 
Influence of pH and buffer species 
For both pH and buffer effect studies, buffers at a concentration of 0.15 M were employed. 
pH studies were carried out at pH 7.4 (phosphate buffer), pH 5, pH 3.5 (both acetate buffer), 
and pH 2 (perchloric acid). The effect of buffer species was investigated in citrate and 
phosphate buffers at pH 3.5. 
The pH values of all test solutions in time were measured by a Model 654 pH meter 
(Metrohm AG, Herisau, Switzerland) and adjusted as necessary with perchloric acid or 1 M 
sodium hydroxide. 
Influence of solvent system 
Besides water, four solvent systems were investigated: 50% (v/v) propylene glycol, 50% (v/v) 
ethanol, 0.9% (w/v) NaCl, and 5% (w/v) dextrose. 
Influence of photostabilizers 
The influence of addition of three different photostabilizers was investigated by preparing 
solutions of NAMI-A in 5% (v/v) DMSO, in 2% (v/v) benzyl alcohol, and in 0.001% (w/v) 
curcumin in 50% ethanol. The concentration curcumin was set at 0.001%, as in this 
concentration, curcumin´s UV/VIS spectrum overlapped that of NAMI-A. Curcumin is 
insoluble in water and therefore was dissolved in 100% ethanol in a concentration of 0.002%, 
then diluted 1:1 with a 20 mg/ml solution of NAMI-A in water.  
 Figure 2.  
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Figure 3. Change in UV/VIS spectrum of a solution of 10 mg/ml NAMI-A in distilled water in time 
from t=0 to 24 hours upon light exposure. The directions of the arrows indicate an 
increase or decrease of absorption upon degradation. 
 
Results and discussion 
Degradation pathway and general observations 
A degradation pathway for NAMI-A in solution as depicted in Figure 2 has been proposed 
[1,2,16]. The structural elucidation of the various degradation products was based on UV/VIS 
spectrophotometry and nuclear magnetic resonance (NMR) spectroscopy. Degradation of 
NAMI-A consists of stepwise hydrolysis of the chloride ligands, in acidic media accompanied 
by hydrolysis of the DMSO group, followed by polymerization to poly-oxo or -hydroxy 
species [1, 2, 16]. This degradation mechanism, however, does not take into account specific 
light-catalyzed degradation of NAMI-A.  
Upon photodegradation in water, the UV/VIS spectrum of NAMI-A 10 mg/ml in water 
changed as depicted in Figure 3. Up to 4 hours of exposure, 3 isosbestic points were present, 
at 277, 300, and 365 nm, suggesting a single transformation in the chromophore in the early 
stages of irradiation, although it cannot be excluded that other transformations not involving 
the chromophore take place. After this time, however, the spectrum began to distort the 
isosbestic points, providing evidence of subsequent stages of photodegradation. The loss of 
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isosbestic points was accompanied by a general loss in specific absorbance and darkening of 
the solutions. Similar changes were observed in a solution of NAMI-A in water stored in the 
dark, but these changes occurred at a much lower rate. 
Whereas immediately after dissolution, all NAMI-A solutions were dark yellow, upon 
photolysis, darkening to a brown and subsequently black color took place. Darkening of 
NAMI-A in solution has been ascribed to formation of poly-oxo or –hydroxy species [1,2,15]. 
HPLC analysis revealed that in all solutions one major degradation product was formed upon 
light exposure, which has previously been identified as the mono-hydroxy or –aqua species of 
NAMI-A (compound B in Figure 2) [12]. One other degradation product was also formed in 
all solutions except the solution at pH 7.4 and the solution with 5% DMSO. It has maxima in 
its UV/VIS spectrum at 326 and 374 nm and has not yet been positively identified, although it 
has been observed that it is only formed under acidic conditions and thus may be any one of 
the DMSO-less structures in Figure 2 [14]. At least six other degradation products were 
formed in the different solutions, but all in low amounts (up to 5% of the total peak area). 
Thus, upon photodegradation of NAMI-A, many different products are generated, with 
initially (in the first six hours of light exposure), the mono-hydroxy or -aqua product being 
mainly formed. NAMI-A in solution when stored in the dark degrades in the same manner 
[18], indicating that exposure to high intensity light affects the rate, but not the mechanism, of 
degradation.  
NAMI-A in solid state 
After exposure for 24 hours of NAMI-A drug substance in solid state, no degradation was 
observed in either the exposed samples or the dark controls. This indicates that NAMI-A drug 
substance is photostable under the tested conditions and does not need to be stored protected 
from daylight. 
NAMI-A in solution 
Dark controls 
In general, the degradation of NAMI-A under the influence of light was monitored for six 
hours. During this time period, all dark controls, except for the solution at pH 7.4, showed 
marginal amounts of degradation (2-10%), whereas the exposed samples degraded 
substantially (>80%). The dark control at pH 7.4 degraded completely within 2 hours, 
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whereas the exposed samples at pH 7.4 were completely degraded within 1 hour. Thus, light 
exposure accelerated the rate of degradation substantially.  
Influence of concentration 
Regression analysis (Figure 4) showed that photodegradation of NAMI-A in water follows 
first-order kinetics (r2 ≥ 0.994 for the ln concentration-time plots). The rate of degradation of 
NAMI-A in water is inversely proportional to the NAMI-A concentration. This effect has 
been described previously for several other drugs and has been ascribed to a reduced fraction 
of the sample being exposed to light at higher drug concentrations [16, 17]. 
Influence of pH  
Similar rate constants were found for NAMI-A in water and in the acidic buffers. All buffered 
solutions of NAMI-A showed (pseudo-)first-order degradation kinetics, as indicated by the 
linearity of the ln(concentration)-time plots (r2 > 0.98), except for the solution at pH 7.4, 
which shows zero-order degradation kinetics (r2 = 1 for the concentration-time plot). At pH > 
8 the degradation of NAMI-A was too fast to follow in our experimental design. 
 
Figure 4.   Effect of NAMI-A concentration on the photodegradation in water.  
f  20 mg/ml: y = -0.1649x + 4.5931, r2 = 0.9940 
(  10 mg/ml: y = -0.3746x + 4.6031, r2 = 0.9992  
& 1 mg/ml: y = -1.4354x + 4.5791, r2 = 0.9960 
)  Reference: 10 mg/ml stored in the dark: y = -0.002x + 4.6203, r2 = 0.9950 
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These orders of reaction are identical to those found during storage under dark conditions 
[18]. However, for acidic solutions of NAMI-A stored in the dark, reaction rates are pH-
dependent, with a pH of 3-4 providing the most stable environment [18]. This was not 
observed in the solutions exposed to light: all solutions of acidic pH exhibit similar reaction 
rate constants (Table 1). Only the solution at pH 7.4 degraded at a significantly faster rate 
than the acidic solutions. Thus, the influence of light on the degradation of NAMI-A in 
solution is larger than the influence of pH in acidic solutions. The acidic solutions stored in 
the light show reaction rate constants which are approximately a factor 20 higher than those 
for the solutions stored in the dark. On the other hand, although light enhances the 
degradation rate in alkaline solution by a factor 2 as compared to storage under dark 
conditions, the pH effect is larger than the effect of light under these conditions. 
Influence of buffer species  
Table 1 shows that neither the type nor the concentration of buffers influences the light-
catalyzed degradation of NAMI-A. The small increase in the half-life of NAMI-A in the 
citrate and phosphate buffers (pH 3.5) is most likely a result of the temperature difference.  
Influence of solvent systems  
Although NAMI-A is soluble in water (50 mg/ml), the influence of several cosolvents on its 
photostability in solution was investigated, as the polarity of the solvent could be of influence. 
For example, for minoxidil solutions it has been shown that an increase in solvent polarity 
resulted in a decrease in the rate of photodegradation, with water providing a more 
photostable medium than 25% ethanol and 25% propylene glycol [19]. The influence of the 
same cosolvents was examined on the photostability of NAMI-A, but their proportion was 
increased to 50% in order to enlarge the differences in polarity. Furthermore, as the 
formulated product of NAMI-A will be administered to patients intravenously dissolved in an 
isotonic medium such as normal saline or 5% dextrose, the photostability in these two 
solvents was also examined.    
NAMI-A in the four different solvents showed first-order degradation kinetics, as was 
indicated by the linearity of the ln concentration-time plots (r2 > 0.97). As the pH of all 
solutions was slightly acidic (pH 4-5), this substantiates the previous observation that at 
acidic pH, photodegradation of NAMI-A occurs according to first-order degradation kinetics. 
Figure 5 shows the degradation profiles of NAMI-A in the different solvents. From the results 
in Table 1 and Figure 5, it is obvious that the photostability of NAMI-A depends on the 
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solvent system and the least polar solvent provides the most photostable environment for 
NAMI-A. Normal saline and 5% dextrose showed similar photodegradation rates to those in 
water (taking into account the experimental temperature differences), whereas some degree of 
photostability was provided by 50% ethanol and more by 50% propylene glycol.  
Besides propylene glycol´s low polarity, other factors may also play a role in its 
photoprotective effect on NAMI-A. It raises the viscosity, thus reducing molecular mobility, 
and also lowers the dielectric constant of the medium. Furthermore, the temperature 
difference provides a partial explanation of the decrease in reaction rate constant. All of these 
effects could contribute to the photoprotection of NAMI-A by propylene glycol. 
Photostabilizer effect 
Previously, DMSO has been reported to act as a photoprotective agent for FD & C Red No.3 
(erythrocine, a dye) [20]. Benzoic acid derivatives, such as benzyl alcohol, have been used as 
light absorbers and photoprotective agents [21], while food colorants such as curcumin 
(maximum absorption at 430 nm) protect colored drug substances by spectral overlay [22]. 
Figure 5. Effect of solvent on NAMI-A photodegradation.  
♦ 50% propylene glycol: y = -0.0934x + 4.5637, r2 = 0.9713  
( 50% ethanol:  y = -0.1403x + 4.5459,r2 = 0.9885  
f normal saline: y= -0.2090x + 4.5278, r2 = 0.9742  
) 5% dextrose: y = -0.2282x + 4.5571, r2 = 0.9913 
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 Table 1.  
O
bserved rate constants and half-lives of N
AM
I-A in solution exposed to light of high intensity. 
Effect 
Solvent 
C
0  (m
g/m
l) 
k (sec
-1) 
H
alf-life (hrs) 
T
av (
°C
) 
C
oncentration 
W
ater 
1 
3.99 x 10
-4 
0.5 
27 
 
 
10 
1.04 x 10
-4 
1.9 
27 
 
 
20 
4.58 x 10
-5 
4.2 
30 
pH
 
acetate buffer pH
 2  
10 
9.60 x 10
-5 
2.0 
28 
 
A
cetate buffer pH
 3.5 
10 
1.03 x 10
-4 
1.9 
25 
 
A
cetate buffer pH
 5 
10 
1.00 x 10
-4 
1.9 
25 
 
Phosphate buffer pH
 7.4 
10 
5.58 x 10
-6 M
.sec
-1 
0.6 
25 
B
uffer species 
C
itrate buffer pH
 3.5 
10 
6.32 x 10
-5 
3.0 
21 
 
Phosphate buffer pH
 3.5 
10 
6.32 x 10
-5 
3.0 
21 
Solvent 
50%
 propylene glycol 
10 
2.59 x 10
-5 
7.4 
21 
 
50%
 ethanol 
10 
3.90 x 10
-5 
4.9 
21 
 
0.9%
 N
aC
l 
10 
5.81 x 10
-5 
3.3 
22 
 
5%
 dextrose 
10 
6.34 x 10
-5 
3.0 
22 
Photostabilizer 
5%
 D
M
SO
 
10 
8.10 x 10
-5 
2.4 
30 
 
2%
 benzyl alcohol 
10 
8.03 x 10
-5 
2.4 
26 
 
0.001%
 curcum
in in 50%
 ethanol 
10 
7.83 x 10
-5 
2.5 
26 
C
0  =
 initial N
AM
I-A concentration, T
av  =
 average tem
perature. 
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Addition of 5% DMSO, 2% benzyl alcohol, or 0.001% curcumin resulted in a marginal 
increase in the half-life of NAMI-A upon light exposure. No differences between the 
photoprotectants were observed, although the average temperature during exposure of the 
solution containing 5% DMSO was higher than during exposure of the other two solutions, 
indicating that DMSO might be more effective than benzyl alcohol or curcumin. 
Anti-oxidants, chelating agents 
Many studies have shown photostabilizing effects of anti-oxidants and chelating agents on 
pharmaceutical substances in solution [16, 19, 21, 23]. These studies, however, were not 
executed for NAMI-A, as anti-oxidants by nature are reducing agents and reduce the Ru (III) 
in NAMI-A to Ru (II) [1,2]. Chelating agents bind heavy metals, and thus will bind the 
ruthenium atom of NAMI-A, leading to its decomposition. 
General discussion 
None of the approaches attempted for stabilizing NAMI-A in solution to light exposure 
provided a very large photoprotective effect. Whereas addition of curcumin to a nifedipine 
solution increased the photostability by a factor of 60 [22], the largest effect observed on the 
photostability of NAMI-A was with 50% propylene glycol as solvent, which increased the 
photostability by a factor 3.5. Preparation of a product for intravenous use is preferentially 
performed employing as few excipients as necessary, due to possible intrinsic toxicity or 
activity of the excipient itself or to interactions between the new drug substance and the 
additives, leading to unknown effects on the activity of the new drug substance [25]. 
Previously, it was shown that NAMI-A in solution degrades in compliance with the Arrhenius 
equation [12]. It was, however, not feasible to keep the temperature constant during all 
experiments (Table 1), but the duration of the experiments was relatively short (6 hours), so 
that the temperature could only have a marginal influence.  
Instead of adding excipients to the NAMI-A solutions during manufacture of the 
pharmaceutical product, which might provide a slight degree of photoprotection, based on  
this study, it is preferred to store NAMI-A solutions protected from light. 
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Conclusion 
NAMI-A drug substance in solid state is photostable. In aqueous solution, however, NAMI-A 
degrades rapidly upon light exposure. The degradation rate of samples exposed to light was 
greatly increased as compared to dark controls, indicating light catalysis. However, the 
degradation mechanism had probably not been altered: the same orders of reaction were 
observed and the same degradation products were generated. 
NAMI-A concentration was inversely proportional with photostability. As opposed to 
solutions stored in the dark, lowering the pH did not influence the degradation rate for 
solutions exposed to light. The type of buffer used did not appear to influence the rate of 
degradation upon light exposure. Addition of DMSO, benzyl alcohol, and curcumin as 
photoprotectants showed a minimal photostabilizing effect. Addition of alcohol to the solvent 
system decreased the photodegradation rate slightly. The least polar solvent (50% proylene 
glycol) provided the most photostable medium for NAMI-A in solution, increasing the half-
life by a factor 3.5. 
It is concluded that NAMI-A solutions are photolabile and therefore should be stored 
protected from light. 
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Abstract 
This paper describes the development of a stable pharmaceutical dosage form for NAMI-A, a 
novel antimetastatic ruthenium complex, for Phase I testing. NAMI-A drug substance was 
characterized using several spectrometric and chromatographic techniques. In preformulation 
studies, it was found that NAMI-A in aqueous solution was not stable enough to allow 
sterilization by moist heat. The effect of several excipients on the stability of the formulation 
solution was investigated. None of them provided sufficient stability to allow long-term 
storage of an aqueous solution of NAMI-A. Therefore, a lyophilized product was developed. 
Five different formulations were prepared and subjected to thermogravimetric analysis and 
stability studies at various conditions for one year. Minimal degradation during the 
production process is achieved with a formulation solution of pH 3-4. Of the acids tested, 
only hydrochloric acid (0.1 mM) both stabilized the formulation solution and was compatible 
with the lyophilized product. This product was stable for at least one year when stored at –
20°C, 25°C/60% relative humidity (RH) and 40°C/75% RH, and was also photostable.  
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Introduction 
NAMI-A (imidazolium trans-tetrachloro(dimethylsulfoxide)imidazoleruthenium(III), H2im 
[trans-RuCl4(DMSO)Him], Figure 1 [1] is a novel ruthenium anticancer agent. Preclinical 
pharmacological and toxicological studies showed selective activity against lung metastases 
of murine tumors [1-4] and low toxicity in mice and dogs [5-7]. Its action seems to be 
independent of the origin (type of primary tumor) and stage of growth of the metastases [4,5]. 
NAMI-A possesses no direct tumor cell cytotoxicity [3-5,8], although an interaction with cell 
cycle regulation has been observed with a transient accumulation of cells in the G2/M phase. 
Furthermore, it increases connective tissue disposition around tumor cells and blood vessels, 
reducing intravasation and thus tumor blood supply, but also preventing tumor cells from 
invading surrounding tissue and blood or lymphatic vessels [3,8,9]. Based on the promising 
activity and toxicity profile, NAMI-A was developed as an antimetastatic agent.  
 
Figure 1.  Chemical structure of NAMI-A, molecular weight 458.18 g/mol. 
 
The aim of this study was to develop a stable, parenteral pharmaceutical dosage form for use 
in Phase I clinical trials. The starting dose for these studies was set at a daily times 5 schedule 
of 2.4 mg/m2. However, because up to 400 mg/m2 had been administered to dogs, the dose in 
the Phase I trials was expected to increase substantially. Therefore, a dosage unit content of 
100 mg was considered most appropriate to cover the expected Phase I dosing range. The 
development of a suitable parenteral formulation was performed based on the 
EORTC/CRC/NCI Joint Formulation Working Party guidelines [10].  
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Material and methods 
Chemicals  
NAMI-A drug substance was supplied by SIGEA Srl (Trieste, Italy). NAMI-A lyophilized 
products were manufactured in-house (Department of Pharmacy & Pharmacology, Slotervaart 
Hospital, Amsterdam, The Netherlands). Sterile Water for Injections (WfI, Ecotainer), 0.9% 
(w/v) NaCl (normal saline) and 5% (w/v) dextrose were obtained from B. Braun (Melsungen, 
Germany). Methanol (HPLC grade) was obtained from Biosolve Ltd. (Amsterdam, The 
Netherlands). Trifluoromethanesulfonic acid, citric acid, sodium acetate trihydrate, acetic acid 
96% (v/v), sodium dihydrogen phosphate dihydrate, di-sodium tetraborate decahydrate, 
sodium carbonate (anhydrous), sodium chloride, perchloric acid (70-72% (w/v)), sodium 
hydroxide pellets, quinine monohydrochloride dihydrate, and dimethyl sulfoxide (dried) were 
all purchased from Merck (Darmstadt, Germany). Sodium dodecylsulphate was obtained from 
Fluka Chemica GmbH (Buch, Switzerland), hydroxypropyl-β-cyclodextrin (molar 
substituttion of 0.8) from Sigma-Aldrich (St. Louis, MO, USA), and mannitol from BUFA 
BV (Uitgeest, The Netherlands). All reagents were of analytical grade and used without 
further purification. Excipients and primary packaging used in the manufacture of NAMI-A 
lyophilized product were of European Pharmacopoeia III (Ph.Eur.III) grade. Excipients were 
approved after in-house quality control (based on monographs in the Ph.Eur.). 
1H nuclear magnetic resonance (NMR) spectroscopy 
1H NMR spectra were recorded at room temperature with a Gemini-300 instrument (Varian 
NMR Instruments, Palo Alto, CA, USA). The sample was dissolved in DMSO-d6 (1-2 mg in 
0.65 ml). The central DMSO line at 2.505 ppm was used as the reference line. 
Mass spectrometry (MS) 
Positive and negative electrospray mass spectra were recorded with a Fisons VG Platform II 
(Micromass, Manchester, UK) single quadrupole mass spectrometer. The instrument was 
calibrated with sodium iodide in the range of m/z 100-1000. Nitrogen was used as nebulizer 
gas and as curtain gas, and the cone voltage was 30V.  
Formulation of NAMI-A 
 85
Infrared (IR) spectroscopy 
IR spectra of NAMI-A were recorded with a Model PU 9706 Infrared (IR) spectrophotometer 
(Philips Nederland BV, Eindhoven, The Netherlands) using the potassium bromide (KBr) 
pellet technique. The pellet consisted of 2 mg NAMI-A bulk drug or lyophilized product and 
300 mg potassium bromide. The ratio recording mode was auto-smooth and the scan time 8 
minutes. 
Ultraviolet/visible light (UV/VIS) spectrophotometry 
UV/VIS spectra were recorded with a Model UV/VIS 918 spectrophotometer (GBC Scientific 
Equipment, Victoria, Australia). Spectra were recorded from 800 to 225 nm. Samples were 
prepared by diluting the test solutions of NAMI-A with distilled water to a final concentration 
of 100 µg/ml.  
High Performance Liquid Chromatography (HPLC) 
The HPLC system consisted of a model SP8800 ternary pump (Thermo Separation Products 
(TSP), Fremont, CA, USA), a model 996 photo diode array (PDA) detector (Waters, Milford, 
MA, USA) and a model SP8880 autosampler (TSP). Chromatograms were processed using 
Millennium® software (Waters). Separation was achieved with a µBondapak C18 column 
(Waters), protected with a C8 guard column (Security Guard, Phenomenex, Torrance, CA, 
USA). The mobile phase consisted of 0.50 mM sodium dodecylsulphate in 3% methanol, 
acidified to pH 2.5 with trifluoromethanesulfonic acid (triflic acid). The flow rate was 0.5 
ml/min and the system was operated at ambient temperature. The detection wavelength was 
358 nm and on-line spectral analysis was carried out with the PDA detector. The injection 
volume was 20 µl. A run time of 10 minutes was employed for the standard samples 
(calibration curves and quality controls) and a run time of 30 minutes for the samples under 
investigation. Calibration curves of standard NAMI-A solutions in distilled water were linear 
(r > 0.98) in the concentration range of interest (10-600 µg/ml). In this HPLC system, NAMI-
A produces a peak with a retention time of approximately 4.1 minutes. The method was 
proven to be stability-indicating, precise, and accurate [11]. 
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Melting point 
The melting point of NAMI-A was determined with a Büchi B-540 melting point apparatus 
(Mettler-Toledo GmbH, Greifensee, Switzerland). 
Preformulation studies 
Solubility and stability in water 
The solubility of NAMI-A in water at ambient temperature (21±2ºC) was examined by 
accurately weighing approximately 100 mg NAMI-A in a glass test tube and adding water in 
100 µl increments. After each addition, the solution was shaken for 30 seconds, if not 
dissolved placed in an ultrasonic bath for 15 minutes, and examined visually under polarized 
light for complete dissolution of NAMI-A drug substance. 
The stability of 100 µg/ml solutions of the drug substance in distilled water was determined in 
duplicate at room temperature (21±2°C), elevated temperature (37±2°C) and refrigerated 
temperature (5±3°C), under all conditions protected from light. Aliquots of the solutions 
under examination were extracted periodically, their absorption measured directly at 390 nm 
and quantified in relation to a standard calibration curve (20-120 µg/ml NAMI-A in distilled 
water). The observed rate constants at the various temperatures were calculated from the 
slopes of the ln concentration-time plots (multiplied by –1).   
 pH-rate profile 
A pH-rate profile of NAMI-A in buffered aqueous solution was constructed as described 
previously [12].  
Influence of excipients 
The stability of a 10 mg/ml solution of NAMI-A in a solution containing hydroxypropyl-β-
cyclodextrin in a molar proportion 1:1 and 2:1 was investigated by HPLC. Furthermore, the 
degradation rate of 10 mg/ml NAMI-A at pH 3 and 4 in acetate buffer (1 mM and 0.1 mM, 
respectively), hydrochloric acid (HCl) (1 and 0.1 mM for pH 3 and 4, respectively) or citric 
acid (1.5 and 0.15 mM for pH 3 and 4, respectively), stored at room temperature (21±2°C) in 
the dark, was investigated by HPLC. The effect of addition of 2.5% (w/v) mannitol and/or 5% 
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(v/v) DMSO on the stability of NAMI-A in acidic solution (0.15 mM citric acid and 0.1 mM 
HCl, both pH 4) was investigated at room temperature (21±2°C) in the dark.  
Differential Scanning Calorimetry 
Thermal properties of 5 different formulation solutions of NAMI-A as described under 
“formulation process” were examined by differential scanning calorimetry (DSC). These 
experiments were performed using a Q1000 V 6.2 DSC in T4 mode equipped with a 
refrigerated cooling accessory (RCS) for low temperatures (TA Instruments, New Castle 
(DE), USA). Samples were placed in an aluminum pan, which was subsequently sealed, and 
measured against an empty pan as reference. Temperature scale and heat flux were calibrated 
with indium. Analyses were performed under a nitrogen purge at 50 ml/min. Samples (5-10 
mg) were cooled to -50ºC at a rate of 5°C/min, after which they were heated at a rate of 
2°C/min to -2°C. Subsequently, the samples were cooled again to -50°C and heated to 30°C at 
the same rates. After each cooling and heating step, an isothermal step lasting 5 minutes was 
built in. As a reference, all formulation solutions (without NAMI-A) were subjected to the 
same DSC procedures. 
 
Formulation process 
Based on the results obtained in the preformulation studies, five different formulations of 
NAMI-A were prepared by lyophilization and subjected to quality control and stability 
studies. The formulation solutions consisted of 10 mg/ml NAMI-A in  
A. sterile Water for Injections (WfI) (pH  4.4) 
B.  0.15 mM citric acid  (pH 3.9) 
C.  1.5 mM citric acid (pH 2.8) 
D. 0.1 mM hydrochloric acid (pH 3.8) 
E. 5 mM citric acid in 2.5% (w/v) mannitol (pH 2.8) 
Lyophilization 
NAMI-A lyophilized product was aseptically prepared. Each formulation solution contained 
10 mg/ml NAMI-A and was dissolved with stirring at ambient temperature. After complete 
dissolution, the solution was adjusted to the final volume with the formulation solution and 
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sterile filtered through a 0.22 µm Millipak 40 filter (Millipore, Milford, MA, USA). 
Subsequently, 10 ml aliquots were filled into 30 ml type I glass lyophilization vials 
(Münnerstädter Glaswarenfabrik, Münnerstadt, Germany). Siliconized gray bromobutyl 
rubber stoppers (Type FM 157/1, Helvoet Pharma NV, Alken, Belgium) were positioned on 
each vial. Two vials were equipped with thermocouples and all vials were loaded into a 
Model Lyovac GT 4 freeze-drier (STERIS, Hürth, Germany) pre-chilled to 10°C. The 
products were frozen to -40°C in 1 hour, after which the temperature was increased to -20°C 
in two hours, then decreased to -40°C in 2 hours (annealing step). This temperature was 
maintained for 1.5 hours. After this period, the primary drying phase was started by 
establishing a vacuum of 0.2 mbar in 1 minute and raising the temperature to -20°C in 1 hour. 
This temperature and pressure were maintained for 55 hours. Subsequently, the secondary 
drying phase was started by linearly raising the temperature to 15°C in 5 hours while 
maintaining a chamber pressure of 0.2 mbar. After reaching 15°C, this shelf temperature was 
maintained for 2 hours. Subsequently, the chamber pressure was lowered in one minute to 
0.02 mbar while maintaining the temperature at 15°C. This temperature and pressure were 
maintained for another 5 hours, after which the lyophilization cycle was stopped.  
After completion, the vials were pneumatically closed, and sterile filtered medical grade 
nitrogen was added to lift the vacuum, and the vials were retrieved from the freeze-drier. The 
product was capped with aluminum caps and labeled.  
In-process controls consisted of integrity testing of the filter, weight variation of the filling 
volume, and determination of the NAMI-A concentration and bioburden before and after 
filtration. Furthermore, the shelf, product, and condensor temperatures, as well as the chamber 
pressure were routinely monitored during the lyophilization process. Only clean, sterile, inert 
materials and glassware were used throughout the manufacturing process. All manipulations 
took place in a class 100 (A) down-flow cabinet inside a class 100 (B) clean room (Interflow, 
Wieringerwerf, The Netherlands). Air particle counts in the critical areas and microbiological 
contamination of area and personnel were monitored during the manufacturing process. 
Manufacturing was performed in compliance with the Good Manufacturing Practice (GMP) 
guidelines [13].   
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NAMI-A lyophilized product 
Quality control  
NAMI-A lyophilized products were characterized using the methods described for the drug 
substance as well as by visual inspection of appearance and color and determination of 
reconstitution characteristics (rate of dissolution and pH after reconstitution, presence of 
foreign insoluble matter) and residual moisture content.  
 
Stability of NAMI-A lyophilized product 
Thermogravimetric analysis 
The five lyophilized formulations were subjected to thermogravimetric analysis employing a 
TGA7 Perkin Elmer thermogravimetric analyzer. Duplicate samples of approximately 2 mg 
were heated at 10°C/min from 30 to 200 °C in a nitrogen atmosphere.  
Stability upon storage 
NAMI-A lyophilized products were stored at –20 ± 2°C, 25±2°C/60±5% relative humidity 
(RH), and at 40±2°C/75±5% RH (both elevated temperatures in HEKK 0057 climate 
chambers obtained from Weiss Technik Ltd., Buckinghamshire, UK) for a year and duplicate 
or triplicate samples were taken at different points in time. These samples were visually 
analyzed for appearance and reconstitution characteristics (rate, presence of foreign 
substances, and pH after reconstitution) and were subjected to HPLC analysis to determine 
their content and purity. Furthermore, at the end of the 1-year storage period, the residual 
moisture content was determined for duplicate samples under each storage condition. 
Photostability 
NAMI-A lyophilized products in their primary containers underwent photostability testing in 
a Suntest CPS+ apparatus equipped with a xenon lamp (NXE 1500 B) with a coated quartz 
dish  
and window glass filter to allow only light with a wavelength of 320-800 nm and a spectral  
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distribution similar to the ID 65 standard, as required in the ICH guideline [14] (all Atlas 
Material Testing Technology LLC, Chicago, IL, USA). Samples and dark controls (samples 
placed alongside the exposed samples wrapped in aluminum foil) were exposed in duplicate 
to light at the highest irradiation level (after passage of the filters: 68.9 W/m2 at < 400 nm and 
170 klux at > 400 nm). The Suntest unit was connected to a SuncoolTM chiller (Atlas) and the 
minimum and maximum temperature during exposure were monitored with a minimum-
maximum thermometer (Merck). A 2% (w/v) quinine hydrochloride dihydrate solution served 
as the actinometric system to monitor the intensity of the ultraviolet (UV) radiation around 
330 nm [15] according to the ICH guidelines [14]. The quinine actinometric solution and its 
dark control were exposed in standard 1 cm quartz cells with two frosted sides and tight-
fitting PTFE caps (4 ml total volume, HELLMA GmbH & Co, Müllheim, Germany).  
 
Results and discussion 
Characterization of NAMI-A drug substance 
The results of the characterization of NAMI-A drug substance are shown in Table 1. The 
results are indicative of the structure of NAMI-A. 
 
Preformulation studies 
Solubility and stability in water  
NAMI-A is soluble in water (up to 50 mg/ml). However, when dissolved in water, NAMI-A 
degrades rapidly (t90 approximately 5 hours at + 20-22°C). Degradation follows (pseudo-
)first-order kinetics, as was indicated by the linearity of plots of the natural logarithm of 
NAMI-A concentration versus time (r2 > 0.92). Figure 2, showing the Arrhenius plot for 
NAMI-A in water, demonstrates that for every 10°C rise in temperature, the reaction rate 
constant approximately triples. The pH of an aqueous solution of NAMI-A is approximately 
5. 
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Figure 2.  Arrhenius plot for NAMI-A in water. 
 
 
Figure 3 shows the pH-rate profile of NAMI-A. As was observed and discussed previously 
[12], at acidic pH, degradation of NAMI-A in aqueous solution follows (pseudo-) first-order 
kinetics, whereas at neutral and alkaline pH, zero-order kinetics best describe the degradation 
process. NAMI-A in solution degrades by substitution of its ligands. At neutral and alkaline 
pH, the chloride groups are replaced by water molecules or hydroxide ions, at acidic pH this 
type of degradation is accompanied by hydrolysis of the DMSO ligand [11,12]. NAMI-A 
solutions are most stable between pH 3 and 4, requiring the use of an acidifier for NAMI-A´s 
formulation solution.  
 
 
Figure 3.  A. pH-rate profile of NAMI-A at pH 1-5 ((pseudo-) first-order kinetics). 
  B. pH-rate profile of NAMI-A at pH 6-10 (zero-order kinetics). 
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Influence of excipients 
The effect of several different excipients on the stability of NAMI-A in solution was 
investigated (Table 2). Apart from enhancing the solubility, HP-ß-CD has also been reported 
to increase the aqueous stability of various compounds by preventing interaction between the 
solvent molecules and the drug that is incorporated within the cyclodextrin cavity [16]. 
However, HP-β-CD in either a 1:1 or a 2:1 molar ratio with NAMI-A had a slightly negative 
effect on the degradation rate of NAMI-A in water (Table 2). Therefore, its use was not 
further investigated. 
The addition of three different acidifiers was examined. Citric and acetic acid are commonly 
used to lower the pH of parenteral products [17], whereas hydrochloric acid in theory had the 
additional advantage of containing chloride, which could reduce the rate of hydrolysis of the 
chloride ligands of NAMI-A. The results in Table 2 show that all acidifiers tested stabilized 
NAMI-A in solution, and that the solutions at pH 4 were slightly more stable than the 
solutions at pH 3. This is most likely caused by the concentration of the acidifiers, which is 
higher for the solutions at pH 3. It was shown previously that higher buffer concentrations 
decrease the stability of NAMI-A in solution [12]. Citric acid and hydrochloric acid stabilized 
the solutions to the same extent, but acetate appeared to produce a slightly less stable 
solution. Therefore, further studies were conducted with citric and hydrochloric acid.  
Addition of DMSO to solutions containing citric and hydrochloric acid further stabilized 
NAMI-A, probably by reducing hydrolysis of the DMSO ligand. The optimal concentration 
was 5% (v/v) DMSO, whereas addition of higher amounts did not increase the stability any 
further. Mannitol, a commonly applied bulking agent in lyophilized products, decreased the 
stability of buffered NAMI-A solutions, but addition of 5% DMSO to the solution containing 
mannitol countered its negative effect.  
From the stability results, it was concluded that none of the examined solutions are suitable 
for sterilization by (moist) heat in the primary container, the first choice when manufacturing 
a parenteral product [18,19], or have pharmaceutically acceptable shelf-lives at feasible 
storage conditions. Therefore, it was decided to develop a lyophilized product.  
Table 2.  
Stability of 10 m
g/m
l N
AM
I-A in different solvents w
ith and w
ithout addition of excipients w
hen stored at room
 tem
perature in the dark.  
Solvent 
Excipient 
Stability ratio* 
W
ater 
none (pH
 4.4) 
1.00 
 
H
ydroxypropyl-β-cyclodextrin 1:1 (pH
 4.3) 
0.94 
 
H
ydroxypropyl-β-cyclodextrin 2:1 (pH
 4.3) 
0.91 
A
cetate buffer 
1 m
M
 (pH
 2.9) 
1.06 
 
0.1 m
M
 (pH
 4.0) 
1.12 
C
itric acid 
1.5 m
M
 (pH
 3.2) 
1.19 
 
0.15 m
M
 (pH
 3.9) 
1.25 
 
0.15 m
M
 + 5%
 D
M
SO
 (pH
 4.0) 
1.29 
 
0.15 m
M
 + 2.5%
 m
annitol (pH
 4.2) 
1.03 
 
0.15 m
M
 + 5%
 D
M
SO
 + 2.5%
 m
annitol (pH
 4.0) 
1.27 
H
ydrochloric acid 
1 m
M
 (pH
 3.2) 
1.20 
 
0.1 m
M
 (pH
 3.9) 
1.25 
 
0.1 m
M
 + 5%
 D
M
SO
 (pH
 4.0) 
1.31 
 
0.1 m
M
 + 2.5%
 m
annitol (pH
 4.2) 
1.13 
 
0.1 m
M
 + 5%
 D
M
SO
 + 2.5%
 m
annitol (pH
 4.1) 
1.27 
*stability ratio =
 (Percentage N
AM
I-A rem
aining in solvent under investigation after 48 hours) / (Percentage N
AM
I-A rem
aining in w
ater after 48 hours).
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Five formulation solution compositions (A-E) were investigated, all with a NAMI-A 
concentration of 10 mg/ml. Formulation A contained NAMI-A in only water, as a reference. 
The other formulations were all acidified in order to stabilize the formulation solution during 
the initial steps of the production process (i.e. dissolution, sterile filtration, filling, and 
freezing). Formulation B and C contained different amounts of citric acid to investigate the 
influence of different buffer concentrations on the stability of the final product. Upon 
freezing, citric acid in solution does not lead to a pH shift, and in theory this acid was the 
most suitable acidifier [20]. Hydrochloric acid could sublimate during lyophilization and the 
corresponding increase in pH might induce degradation of NAMI-A. On the other hand, HCl 
has the theoretical advantage of containing chloride ions, providing a more stable 
environment for NAMI-A. Thus, Formulation D was also investigated. Lastly, although 
mannitol slightly decreased the stability of NAMI-A in solution, its addition was investigated, 
because in solid state it might prove to be useful as a bulking agent. In order to attain a pH of 
3 for this solution, however, a concentration of 5 mM citric acid (instead of 1.5 mM) was 
added. The addition of DMSO was not further investigated as lyophilization of a test solution 
of NAMI-A containing 5% DMSO resulted in a product with unacceptable appearance. 
Formulation studies 
Differential Scanning Calorimetry and lyophilization 
Figure 4 shows the DSC thermograms of 10 mg/ml NAMI-A in the five different formulation 
solutions. All formulations show an ice melting endotherm, with extrapolated onsets of 
melting at –1.9°C, -1.7°C, -1.9°C, -1.0°C, and –3.4°C for the NAMI-A solutions in water, 0.1 
mM HCl, 0.15 mM citric acid, 1.5 mM citric acid, and 2.5% mannitol in 5 mM citric acid, 
respectively. Apart from the ice melting endotherm, no other thermal events can be observed 
in any of the solutions, except the one containing mannitol in citric acid (see inset of Figure 
4). This solution shows a glass transition temperature at –31°C, followed by a small 
endotherm and a subsequent crystallization exotherm at -26°C, which disappears upon 
repeating the freezing and heating cycle.  
Figure 4.  
D
SC
 therm
ogram
s of 10 m
g/m
l N
AM
I-A in w
ater (A), 0.15 m
M
 citric acid (B), 1.5 m
M
 citric acid (C
), 0.1 m
M
 hydrochloric acid (D
), and 
5m
M
 citric acid w
ith 2.5%
 (w
/v) m
annitol (E). 
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This behavior has been described previously for mannitol and was found to occur at slightly 
higher (2-3°C) temperatures using similar freezing rates but faster heating rates [21-23]. As 
Her and Nail [22] described, the midpoints of transitions occur at higher temperatures at faster 
heating rates, and the results obtained here confirm these findings. All blank solvents showed 
identical DSC thermograms to the formulation solutions (extrapolated onsets of melting 
within 0.2-1.0°C of the solutions containing NAMI-A), indicating that the freezing and 
heating properties of the formulation solutions are due to the solvents and that addition of 
NAMI-A does not influence these properties. As no thermal events were observed in the DSC 
thermograms of formulations A-D, no special precautions were required in the freeze-drying 
cycle. However, lyophilization of formulation E required the use of an annealing step to 
ensure complete crystallization of mannitol. As degradation of NAMI-A is temperature-
dependent, the shelves of the freeze-drier were pre-chilled to 10°C to prevent degradation 
after the production process as much as possible.  
NAMI-A lyophilized product 
Table 3 shows the results of the quality control performed after manufacture of the five 
batches of lyophilized product. Formulation E had formed a solid cake due to the presence of 
mannitol, whereas for all other formulations, the product was present as spheres inside the 
vials. All formulations immediately reconstituted upon addition of sterile WfI to form a clear, 
dark yellow solution, free from foreign insoluble matter. Formulations A, B, and E had the 
same pH after reconstitution as the formulation solutions before lyophilization. The pH of 
formulation C and D was found to be slightly higher after reconstitution. For formulation D, 
this might be due to some evaporation of HCl upon lyophilization. The residual moisture 
content of all formulations was low, although formulation E contained significantly higher 
amounts than the others, probably due to the presence of mannitol [24]. 
Table 3. 
Q
uality control of N
AM
I-A lyophilized products.  
Test item
 
D
rug substance 
Lot 0200 
Form
ulation A
 
Form
ulation B
 
Form
ulation C
 
Form
ulation D
 
Form
ulation E 
A
ppearance 
O
range-red pow
der
D
ark yellow
 
sphere 
D
ark yellow
 
spheres 
D
ark yellow
 
spheres 
D
ark yellow
 
spheres 
D
ark yellow
 cakes 
pH
 after 
reconstitution 
- 
4.4 
3.9 
3.2 
4.4 
2.8 
Foreign insoluble 
m
atter 
- 
N
one 
N
one 
N
one 
N
one 
N
one 
U
V
/V
IS analysis 
λ
m
ax b: 288, 390, 
452 nm
 
λ
m
ax b: 288, 390, 
452 nm
 
λ
m
ax b: 288, 390, 
452 nm
 
λ
m
ax b: 288, 390, 
452 nm
 
λ
m
ax b: 288, 390, 
452 nm
 
λ
m
ax b: 288, 390, 
452 nm
 
H
PLC
 analysis 
A
. Identity 
B
. C
ontent 
C
. Purity
a 
 A
. tR =4.1 m
in 
B
. – 
C
. 99.6%
 
 A
. tR =4.1 m
in 
B
. 93.2%
 
C
. 99.2%
 
 A
. tR =4.1 m
in 
B
. 94.7%
 
C
. 99.2%
 
 A
. tR =4.1 m
in 
B
. 90.0%
 
C
. 99.4%
 
 A
. tR =4.1 m
in 
B
. 95.8%
 
C
. 99.1%
 
 A
. tR =4.1 m
in 
B
. 94.0%
 
C
. 99.2%
 
R
esidual m
oisture 
content 
- 
<LO
D
c 
<LO
D
c 
0.1%
 
0.2%
 
1.2%
 
Form
ulation A =
 sterile W
ater for Injections, Form
ulation B =
 0.15 m
M
 citric acid, Form
ulation C
 =
 1.5 m
M
 citric acid, Form
ulation D
 =
 0.1 m
M
 
hydrochloric acid, Form
ulation E =
 5 m
M
 citric acid +
 2.5%
 (w
/v) m
annitol. a Purity =
 percentage of the N
AM
I-A peak area w
ith respect to the total peak 
area, b λ
m
ax  = w
avelength of m
axim
um
 absorption, cLO
D
 =
 lim
it of detection.
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Stability of NAMI-A lyophilized product 
Thermogravimetric (TG) analysis 
TG analysis can be used as a screening tool for incompatibilities between components of a 
formulation and for prediction of long-term stability, although isothermal formal stability 
studies are required to confirm indicative results obtained by this method [25]. Figure 5 shows 
the TG profiles of the five formulations of NAMI-A. Formulations A, B, and D do not show 
weight loss up to 150°C and degradation for all three samples starts at 180°C. The behavior of 
these samples is identical to that of NAMI-A drug substance. For formulation C, the onset of 
the first degradation process is about 130°C, whereas for formulation E, there is a small 
weight loss at 80°C, followed by the start of degradation at 140°C. TG-IR analysis of the 
gases evolving from the samples showed that the weight loss at 80°C was due to water 
evaporation (only observed in formulation E, which contained a higher residual moisture 
content than the other formulations), and that the onset of degradation corresponded to the 
emission of hydrochloric acid (HCl) gas. Thus, thermal decomposition of NAMI-A 
lyophilized product involved the release of a chloride ligand with HCl emission. The presence 
of citric acid in a concentration higher than 0.15 mM and/or the presence of mannitol 
apparently decreased the thermal stability of NAMI-A lyophilized substance. It thus appeared 
that formulation C and E could be expected to show a lower stability upon storage than the 
other three formulations.  
 
Figure 5. Thermogravimetric profiles of NAMI-A lyophilized product. 
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Stability upon storage 
All five formulations of NAMI-A were stable when stored at -20°C. Table 4 shows the results 
obtained after one year of storage at 25°C / 60% RH and 40°C / 75% RH. The long-term 
storage condition was defined as 25°C / 60% RH, whereas storage at 40°C / 75% RH was 
considered to be the accelerated condition. Formulation A, B, and D showed no change in 
content and chromatographic purity for either storage condition, while formulation C and E 
slowly degraded. Formulation E proved to be the least stable formulation, with 70% of the 
initial content remaining after 1 year of storage at 40°C/75% RH in the dark. In Formulation 
E, the presence of mannitol (and/or its related higher moisture content) may have added to the 
observed instability. The visual appearance of all formulations remained unchanged at all 
storage conditions, except Formulation E stored at 40°C, which paled in time. These findings 
confirm the expected lower stabilities of Formulations C and E based on TG analysis.  
The results obtained with Formulation C indicate that the presence of citric acid in a 
concentration higher than 0.15 mM destabilized the lyophilized product. Therefore, it was 
decided not to use citric acid as acidifier. Although formulations A and D were equally stable, 
formulation D was chosen as the formulation to be used in the manufacture of NAMI-A 
lyophilized product, because the presence of hydrochloric acid stabilized the formulation 
solution during the production process (t90 approximately 6.3 hours). 
 
Table 4. Percentage NAMI-A remaining with respect to initial content ± standard deviation after 1 
year of storage. 
Storage condition  
Formulation 25°C / 60% RH, dark 40°C / 75% RH, dark 
A 100.2 ± 0.2 99.1 ± 0.9 
B 93.3 ± 6.3 98.5 ± 0.3 
C 86.8 ± 5.6 92.1 ± 0.7 
D 99.3 ± 0.1 96.0 ± 5.2 
E 82.2 ± 8.0 70.6 ± 5.7 
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Photostability 
All five formulations of NAMI-A lyophilized product proved to be stable when exposed in 
their primary container to light of high intensity. No difference was observed between the 
dark controls and the exposed samples. Thus, NAMI-A lyophilized product does not need to 
be stored in the dark. However, in solution NAMI-A is sensitive to light and after 
reconstitution and dilution, it should be protected from light [26]. 
 
Conclusion 
The development of a stable, lyophilized formulation of NAMI-A is presented. The 
formulation solution needs to be acidified in order to stabilize it during the production 
process. Out of the five different formulations of NAMI-A that underwent stability testing, 
the product lyophilized from a formulation solution containing 0.1 mM hydrochloric acid was 
selected for further development. It is photostable and stable for at least one year when stored 
at 25°C/60% RH. TG analysis proved to be predictive of the stability ranking, with the 
product showing weight loss at the lowest temperature also showing the lowest long-term 
stability.    
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Abstract 
NAMI-A is a novel antimetastatic ruthenium complex currently undergoing Phase I clinical 
trials. It is pharmaceutically formulated as a lyophilized product to be reconstituted and 
diluted before infusion. The aim of this study was to determine the reconstitution and dilution 
fluid of choice and to investigate the stability and compatibility of NAMI-A in solution under 
different storage conditions and with several container materials. Furthermore, the hemolytic 
potential and buffer capacity of NAMI-A infusion solution were investigated in vitro.  
Normal saline must be used for reconstitution of NAMI-A, and the reconstituted solution 
must be diluted with normal saline to infusion concentration immediately after dissolution. 
Infusion solutions can be stored for a maximum of 4 hours at room temperature (+20-23°C) or 
24 hours at refrigerated conditions (+2-8°C) before administration to the patient. The infusion 
solutions can be prepared in either glass or PVC containers, although for practical reasons, 
PVC containers are recommended. The infusion solutions are compatible with a PVC infusion 
system consisting of a PVC container, PVC infusion line, and needle. Furthermore, NAMI-A 
infusion solutions have a low buffer capacity and do not cause hemolysis in vitro. Therefore, 
no pain or hemolysis upon infusion of NAMI-A in the clinical setting is expected. 
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Introduction 
NAMI-A (imidazolium trans-tetrachloro(dimethylsulfoxide)imidazoleruthenium(III), H2im 
[trans-RuCl4(DMSO)Him], Figure 1 [1]) is a novel ruthenium anticancer agent. Preclinical 
pharmacological studies with NAMI-A showed selective activity against lung metastases of 
murine tumors [1-4] and low toxicity in mice and dogs [5-7]. Its action seems to be 
independent of the origin (type of primary tumor) and stage of growth of the metastases [4,7]. 
NAMI-A possesses no direct tumor cell cytotoxicity [3,4,7,8], although an interaction with 
cell cycle regulation has been observed in a transient accumulation of cells in the G2/M phase 
[3,8,9]. Furthermore, NAMI-A increases connective tissue disposition around tumor cells and 
blood vessels, reducing intravasation and thus tumor blood supply, but also preventing tumor 
cells from invading surrounding tissue and blood or lymphatic vessels [3,8,9].  
 
 
 
 
 
 
Figure 1.  Chemical structure of NAMI-A. Molecular weight = 458.18 g/mol. Molecular formula: 
C8H15Cl4N4ORu(III)S. 
 
NAMI-A is pharmaceutically formulated as a lyophilized solid for intravenous infusion 
containing 100 mg NAMI-A and 0.036 mg hydrochloric acid (HCl) per dosage unit. Before 
commencement of the clinical trials, we investigated the stability of NAMI-A after 
reconstitution and dilution to infusion concentrations. Compatibility with containers 
composed of glass, low density polyethylene (LD-PE), and polyvinylchloride (PVC) was 
examined in terms of sorption to container material. Furthermore, the hemolytic potential and 
buffer capacity of NAMI-A infusion solutions were investigated in vitro. 
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Materials and methods 
Chemicals 
NAMI-A was supplied by SIGEA Srl (Trieste, Italy). NAMI-A lyophilized product 
containing 100 mg NAMI-A and 0.036 mg hydrochloric acid (HCl) per dosage unit was 
manufactured in-house (Department of Pharmacy & Pharmacology, Slotervaart Hospital, 
Amsterdam, The Netherlands). 5% Dextrose in water (D5W), 0.9% NaCl (normal saline) in 
100 ml glass, LD-PE (Ecoflac), and PVC  (Intraflex) containers, and sterile Water for 
Injections (Ecotainer) were all obtained from B. Braun Medical (Melsungen, Germany). 
Methanol (HPLC grade) was purchased from Biosolve Ltd. (Amsterdam, The Netherlands). 
Trifluoromethanesulfonic acid and hydrochloric acid 37% were obtained from Merck 
(Darmstadt, Germany), sodium dodecylsulphate from Fluka Chimika GmbH (Buch, 
Switzerland). Fresh, citrated blood and plasma ultrafiltrate were purchased from the local 
blood bank (Central Laboratory for Blood transfusion (CLB), Amsterdam, The Netherlands). 
All chemicals were of analytical grade and used without further purification.  
Ultraviolet/visible light (UV/VIS) spectrophotometry 
UV/VIS analysis was used to determine NAMI-A concentrations in solution. Absorptions of 
samples and standard solutions were measured at 390 nm with a Model UV/VIS 918 
spectrophotometer (GBC Scientific Equipment, Victoria, Australia). NAMI-A concentrations 
were calculated on a calibration curve, prepared from a stock solution of 1 mg/ml in water. 
The calibration curve was found to be linear (r > 0.99) in the range of 50-120 µg/ml. The 
method proved to be accurate and precise, as determined on quality control samples at 
concentrations of 80, 100, and 120 µg/ml, prepared from a separate stock solution, as 
measured throughout the analysis.  
Samples of the test solutions were diluted with distilled water to a theoretical concentration of 
100 µg/ml and measured immediately. The quality control samples were stored at refrigerated 
conditions (+2-8°C, dark). Degradation of NAMI-A was monitored by the decrease in 
absorption at 390 nm (Figure 2). As was previously shown [10], none of the degradation 
products show significant absorption at 390 nm. 
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Figure 2.  Change in UV/VIS spectrum of a solution of 100 µg/ml NAMI-A in distilled water in time 
from t=0 to 96 hours (stored at 20-25°C in the dark). The directions of the arrows 
indicate an increase or decrease of absorption upon degradation. 
 
Stability after reconstitution 
NAMI-A lyophilized product for intravenous infusion was reconstituted with 10 ml sterile 
Water for Injections (WfI), normal saline, or D5W in its primary container (30 ml type I glass 
lyophilization vials, Münnerstädter Glaswarenfabrik, Münnerstadt, Germany), resulting in 
solutions with a theoretical NAMI-A concentration of 10.0 mg/ml. The solutions were 
prepared in duplicate and stored at either room temperature (+20-25°C) in the dark, room 
temperature exposed to continuous laboratory light, or refrigerated conditions (+2-8°C, dark). 
Samples were taken periodically and analyzed using UV/VIS spectrophotometry. The pH was 
monitored in time using a Model 654 pH meter (Metrohm AG, Herisau, Switzerland). All 
reconstituted solutions were visually checked for clarity. 
Stability and compatibility after dilution 
NAMI-A lyophilized product was reconstituted and diluted with normal saline to yield 
NAMI-A infusion solutions at concentrations of 0.1 and 1.0 mg/ml in 100 ml glass, LD-PE, 
and PVC containers. The containers were stored at room temperature exposed to light, room 
temperature in the dark, or at refrigerated conditions. All solutions were prepared in triplicate 
and samples were taken immediately after preparation and after 2, 4, 8, 24, and 48 hours of 
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storage and immediately analyzed for NAMI-A by UV/VIS analysis. At these time points, the 
pH of the solutions was also measured. All infusion solutions were visually checked for 
clarity. 
Infusion simulation experiments 
NAMI-A infusion simulation was conducted using an infusion system consisting of 500 ml 
Intraflex containers filled with 500 ml infusion solution at 0.1 or 1 mg/ml in normal saline, 
PVC tubing regularly used for the infusion of cytotoxic agents (1.5 m length, CODAN 
Medizinische Geräte GmbH & Co, Lensahn, Germany) and a needle (Microlance 0.8 x 40 
mm; Becton Dickinson, Franklin Lakes, NJ, USA). Infusion rates were set at 1.0 ml/min for a 
duration of 8 hours. Infusion simulations were performed in triplicate at room temperature, at 
ambient light conditions. Infusion simulation was initiated immediately after preparation of 
the solutions. Samples were taken from the needle outlet 0, 1, 2, 3, 4, 6, and 8 hours after 
initiating the infusion simulation and immediately analyzed for NAMI-A content by UV/VIS 
analysis. The pH was also measured at these time points. The total amount of NAMI-A 
delivered by each infusion system was calculated from the infusion rate and the area under the 
NAMI-A concentration-time curves (AUCs) (equation 1).  
 Total amount of NAMI-A delivered (mg) = AUC (mg/mL.h) x infusion rate (ml/h) (1) 
The AUCs were calculated using the trapezoidal rule.  
Hemolysis  
The potential of NAMI-A infusion solutions at a concentration of 1 mg/ml in normal saline to 
cause hemolysis was examined using both the static and dynamic in vitro test models as 
described by Ward et al. [11] and Krzyzaniak et al. [12-14]. For the static model, 300 µl 
infusion solution was added to 2 ml blood resulting in a formulation:blood ratio of 0.15. The 
solutions were slowly whirl-mixed for 5 seconds and added to 200 ml normal saline to quench 
any hemolytic reaction. For the dynamic model, the infusion solution was infused at a rate of 
1.5 ml/min using a Model 711 syringe pump (IVAC, San Diego, USA) into a tube containing 
blood flowing at a rate of 10 ml/min employing a Model 501 Dz peristaltic pump (Watson 
Marlow, Rotterdam, the Netherlands), which resulted in a formulation:blood ratio of 0.15. 
The contact time with blood was set at 5 seconds by administering the infusion solution 41.5 
cm from the end of the silicone tubing transporting the blood (∅1.6 mm, Watson Marlow). 
The hemolytic reaction was quenched by addition of 167 ml of normal saline to the blood 
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sample. Subsequently, an aliquot of the diluted test solution for each model was centrifuged at 
3000 rpm for 10 minutes. The absorption (A) of the resulting supernatant was measured at 
540 nm with a Model UV/VIS 918 spectrophotometer (GBC Scientific Equipment, Victoria, 
Australia). 
The baseline degree of hemolysis was measured using normal saline at the same 
formulation:blood ratios. The 100% hemolysis level was determined by diluting the blood 
used in both the static and dynamic model with a 100-fold larger volume of distilled water 
instead of normal saline. As a positive control, a mixture of 40/10/50% (v/v/v) propylene 
glycol/ethanol/water (PEW) was used [13]. All experiments were run in triplicate. The 
percentage hemolysis induced by all solutions was calculated using equation 2: 
 % Hemolysis = (Atest solution-Anormal saline)/(A100%-Anormal saline) x 100% (2) 
Buffercapacity 
The volumes of blood simulant to be added to a 1 mg/ml solution of NAMI-A in normal 
saline necessary to reach a physiological pH of 7.40±0.05 were determined by titration of 
50.0 ml of the infusion solution with isotonic phosphate-buffered saline (PBS). PBS was 
prepared using monobasic potassium phosphate (KH2PO4, Merck) and dibasic sodium 
phosphate (Na2HPO4.2H2O, Merck). Titration was performed using a Model 682 
Titroprocessor and a Model 665 Dosimat (both Metrohm, Herisau, Switzerland). For 
comparison, solutions of 0.1 mg/ml cisplatin in normal saline (Platosin®, Pharmachemie BV, 
Haarlem, The Netherlands) and 10 mg/ml and 0.4 mg/ml dacarbazine (Déticène®, Aventis 
Pharma, Frankfurt, Germany), were titrated in the same way. The ratio of the volume of test 
solution to the volume of PBS necessary to reach pH 7.35, expressed as the measured FB-
ratio, was calculated using equation 3 [15]: 
 FB-ratiomeas = [volumeinfusion solution (ml) / volumePBS (ml)] (3) 
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Results and discussion 
Stability in infusion solutions can vary widely with the dilution solution and concentration. 
To assure the quality of the product that is administered to the patient, stability should be 
assessed for commonly applied infusion solutions over the concentration range and under the 
conditions (temperature, light) intended in the clinical setting.  
Initially, the stability after reconstitution was investigated to determine which solution 
provided the most stable environment for NAMI-A. Subsequently, the reconstituted solution 
was diluted 10- and 100- fold and stability and compatibility studies were performed to 
determine the optimal container and storage condition. Lastly, an infusion simulation was 
carried out employing administration parameters intended for use in the clinical setting. The 
results of these studies were used to set specifications for the maximum storage time and 
conditions of the NAMI-A reconstituted and infusion solutions. Additionally, the infusion 
solution was investigated for its buffer capacity and potential to cause hemolysis.  
Stability after reconstitution 
Table 1 shows the stability of NAMI-A after reconstitution with normal saline, D5W, and 
sterile WfI. Solutions in D5W are less stable than in normal saline or sterile WfI at all storage 
conditions. It was previously shown that pH is of great influence on degradation of NAMI-A 
in solution, with maximum stability at pH 3-4 [16]. All solutions, immediately after 
reconstitution, had similar pH values (pH 4.4, 4.2, and 4.5 for WfI, D5W, and normal saline, 
respectively), which all decreased in time to pH 2.5-3.0 after 72 hours. Thus, the pH values of 
the solutions provide no explanation of the differences in stability.  
No differences were found between the solutions stored in the dark and those stored at 
continuous light exposure. Solutions in normal saline still contained >95% of the initial 
NAMI-A concentration after 4 hours at room temperature and 48 hours at refrigerated 
conditions. Based on these results, further studies were conducted using normal saline as 
reconstitution solution and diluent. 
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Stability and compatibility after dilution 
Table 2A and 2B show the results obtained for the stability and compatibility studies of the 
infusion solutions in the three different types of containers at 0.1 mg/ml and 1 mg/ml, 
respectively. At room temperature, the infusion solutions are stable (90-110% of the initial 
concentration remaining) for 4-8 hours, depending on the container and NAMI-A 
concentration. A concentration effect is observed. The reconstituted solutions (10 mg/ml, 
Table 1) are more stable than the infusion solutions (Table 2), and the solutions at 1 mg/ml 
are slightly more stable than the solutions at 0.1 mg/ml. The type of container has no 
significant influence on the stability of the infusion solutions. 
The initial NAMI-A concentrations in the glass and PVC containers were equal to the 
theoretical concentrations of 0.1 and 1.0 mg/ml, but the solution in the LD-PE containers 
showed a NAMI-A concentration that was 5% lower than the theoretical concentrations. This 
indicates that some sorption to the container material may take place, and LD-PE containers 
should not be used for infusion of NAMI-A solutions.  
No large differences in the pH of the solutions in the glass and LD-PE containers was 
observed, but the solutions in the PVC containers showed a significantly lower pH. This was 
a result of the (blank) normal saline solutions in the PVC containers having a pH of 4.5, as 
opposed to the solutions in the glass and LD-PE containers, which had pH values of 6.4 and 
6.1, respectively. For NAMI-A, this low pH is an advantage, as it is most stable in solutions 
with a pH between 3 and 4 [16].  
In conclusion, either glass or PVC containers can be used for the administration of NAMI-A 
infusion solution, but for practical reasons (e.g. breakage of the glass containers), the PVC 
containers are recommended. These containers were thus used for the infusion simulation 
experiments. 
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 Stability of N
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I-A after dilution w
ith norm
al saline to 1 m
g/m
l in glass, LD
-PE or PVC
 containers under different storage conditions. 
 
 
Percentage of initial concentration ± standard deviation 
A
verage pH
 
C
ontainer 
Storage condition 
2 hours 
4 hours 
8 hours 
24 hours 
48 hours 
G
lass 
+20-25°C
, light 
97.4 ± 0.2 
4.9 
95.6 ± 0.8 
4.9 
92.4 ± 1.4 
4.6 
78.2 ± 1.0 
4.3 
63.1 ± 0.9 
3.8 
 
+20-25°C
, dark 
97.9 ± 0.6 
4.9 
95.5 ± 1.4 
4.9 
92.9 ± 1.3 
4.7 
78.4 ± 2.0 
4.3 
62.1 ± 0.8 
3.8 
 
+ 2-8°C
, dark 
99.2 ± 0.5 
4.9 
99.0 ± 0.3 
4.9 
99.9 ± 0.7 
5.0 
97.5 ± 0.8 
5.0 
93.7 ± 2.3 
4.7 
LD
-PE 
+20-25°C
, light 
97.3 ± 0.3 
5.1 
94.2 ± 1.1 
4.9 
89.9 ± 0.1 
4.6 
77.8 ± 0.6 
4.2 
61.0 ± 0.3 
3.9 
 
+20-25°C
, dark 
97.8 ± 1.0 
5.1  
94.3 ± 0.7 
4.9 
89.9 ± 1.5 
4.7 
76.5 ± 0.2 
4.2 
58.7 ± 0.6 
3.9 
 
+ 2-8°C
, dark 
100.7 ± 1.0 
5.2 
99.6 ± 0.9 
5.1 
98.3 ± 2.0 
5.1 
97.8 ± 0.7 
4.9 
94.5 ± 1.5 
4.8 
PV
C
 
+20-25°C
, light 
98.1 ± 0.5 
4.4 
N
/A
 
4.4 
91.1 ± 0.2 
4.3 
78.5 ± 0.5 
4.1 
58.8 ± 0.1 
3.8 
 
+20-25°C
, dark 
97.9 ± 1.0 
4.4 
N
/A
 
4.4 
90.8 ± 1.0 
4.3 
77.1 ± 1.3 
4.1 
56.8 ± 1.0 
3.8 
 
+ 2-8°C
, dark 
99.7 ± 0.4 
4.4 
N
/A
 
4.4 
97.3 ± 0.5 
4.4 
97.4 ± 0.8 
4.4 
94.6 ± 0.7 
4.4 
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Infusion simulation experiments 
In order to set the final administration parameters, infusion simulation experiments were 
performed employing PVC containers with NAMI-A in normal saline, a PVC infusion line 
and needle. Although the intended infusion duration in the clinic is 3 hours, an infusion 
duration of 8 hours was employed to maximize the contact time between the infusion solution 
and infusion system material, to evaluate the stability and compatibility. 
Table 3 shows the results obtained for the infusion simulation experiment. An approximately 
equal rate of degradation was observed as in the smaller containers (Table 2). The amounts of 
NAMI-A delivered from the infusion systems after 8 hours was approximately 92% of the 
nominal amount. The pH of the 0.1 mg/ml solution was 5.0 immediately after preparation and 
4.7 after 8 hours, while the pH of the 1.0 mg/ml solution changed from 4.7 to 4.4 in that 
period of time. The initial concentrations were equal to the nominal concentrations, and any 
loss of NAMI-A was due to degradation, not to immediate sorption to the infusion system 
material. Thus, the PVC infusion system is compatible with NAMI-A infusion solutions.  
 
 
Table 3.  NAMI-A concentration (mg/ml) ± standard deviation of infusion solutions in normal saline 
in 500 ml PVC containers for the infusion simulation study (samples taken from the outlet 
of the infusion system).  
 Nominal NAMI-A concentration  
Time (hrs) 0.1 mg/ml 1.0 mg/ml 
0 0.100 ± 0.002 1.007 ± 0.036 
1 0.100 ± 0.001 1.002 ± 0.018 
2 0.099 ± 0.001 0.994 ± 0.021 
3 0.097 ± 0.002 0.973 ± 0.026 
4 0.095 ± 0.002 0.962 ± 0.024 
6 0.093 ± 0.002 0.920 ± 0.019 
8 0.092 ± 0.002 0.906 ± 0.023 
Total amount of NAMI-A 
released (mg) 
 
46.17 
 
459.69 
(Percentage with respect to 
the nominal NAMI-A dose) 
 
(92.3%) 
 
(91.9%) 
 
Chapter 1.5 
 
 118
Hemolysis 
Hemolysis can cause a wide range of undesirable medical conditions, such as jaundice, 
kernicterus, hemoglobinuria, nephrosis and acute renal failure. Death can occur when 
hemolysis becomes severe. Every effort must therefore be made to minimize the occurrence 
of hemolysis and an evaluation of the ability of a formulation to induce this condition is 
therefore an important component of the development of an intravenous formulation [17].    
NAMI-A infusion solutions are iso-osmotic, but have a pH of 4-5. This low pH might cause 
some disruptions in erythrocyte integrity.  
NAMI-A will be administered at an infusion rate ranging from 0.3 to 4.4 ml/min (assuming a 
dose range of 5-800 mg NAMI-A to be administered in 3 hours, diluted to 50-800 ml with 
normal saline, leading to NAMI-A concentrations of 0.1 and 1.0 mg/ml, respectively). The 
venous blood flow is approximately 40 ml/min (an estimate for the broad range of blood 
flows in the circulatory system [13]), leading to formulation:blood ratio’s of 0.007 to 0.11. In 
order to investigate the worst case, a ratio of 0.15 was used in these studies. Furthermore, 
instead of a contact time of 1 second between the test solution and blood, as described by 
Krzyzaniak et al. to be physiologically realistic for an intravenous bolus injection [12-14], a 
longer contact time of 5 seconds was employed to mimic the continuous exposure of blood to 
the administered agent during prolonged intravenous infusions [15]. 
No hemolysis was detected in the static model, except for the positive control, which showed 
90% hemolysis (data not shown). In the dynamic model also, no hemolysis was observed for 
the NAMI-A solutions, while 40/10/50% PEW caused 10% hemolysis. Based on these results, 
intravenous infusion of NAMI-A solutions is not expected to cause any hemolysis. 
Buffer capacity 
For acidic solutions with a pH < 4, pain upon i.v. bolus injection into isolated vein segments 
of humans has been described [18], which could be an indication of tissue damage [19]. 
Furthermore, i.v. bolus injections at a pH < 2 caused phlebitis [20]. In case of an i.v. infusion, 
vascular irritation or damage is probably more related to the time period that venous tissue is 
exposed to an environment with non-physiological pH. Therefore, the capacity of blood to 
maintain its physiological pH (7.35-7.45) upon i.v. infusion of a solution outside its 
physiological pH ranges is important. This capacity can be expressed as the FB-ratio, the ratio 
of the volume of infusion solution to the volume of blood simulant necessary to reach at least 
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pH 7.35 [15]. The smaller this ratio, the larger the buffer capacity of the pharmaceutical 
formulation and the more blood is required to maintain physiological pH. As applied in the 
hemolysis studies described above, the formulation/blood ratio (Equation 3) is equivalent to 
the ratio of the infusion rate to the blood flow, according to Equation 4: 
 FB-ratiotheor = [infusion rateinfusion solution (ml/min) / blood flow (ml/min)] (4) 
The infusion rate depends on the dose administered, volume of the infusion solution, and 
infusion duration, which are often interrelated. Theoretically, when the FB-ratiomeas is equal to 
or smaller than the FB-ratiotheor intended in clinical practice, and thus the final pH is outside 
the physiological pH range, vascular irritation can be expected as the blood is no longer 
capable of maintaining a physiological pH. In these cases, it is advisable to administer the 
drug over a longer infusion time or via a central vein with high blood flow. Proof of concept 
of this type of in vitro experiment to predict irritation upon infusion was provided by Nuijen 
et al. [15]. 
In this experiment, PBS was selected as blood simulant, because its buffer capacity of 0.036 
is close to that of whole blood (0.0318) [15]. Cisplatin and Déticène® (dacarbazine) solutions 
were used for comparison of the measured and theoretical FB-ratios. Both solutions contain 
acidifiers. Cisplatin does not cause pain, hemolysis, or other negative physical effects upon 
infusion, while Déticène® is known to cause pain at the injection site.  
From Table 4, it can be seen that neither cisplatin nor NAMI-A are expected to cause pH-
induced irritation upon infusion, as their FB-ratiomeas>> FB-ratiotheor. Déticène® shows a FB-
ratiomeas that is approximately equal to or lower than its FB-ratiotheor. Of course it cannot be 
ruled out that NAMI-A infusion will not cause any physical side effects upon infusion that 
may be inherent to the active drug substance [19]. 
 
 Table 4.  
Theoretical and m
easured FB ratio’s of solutions tested for selected anticancer agents and N
AM
I-A infusion solution. 
Form
ulation 
C
om
position 
D
ose
a 
Pre-
adm
inistration 
dilution
b 
(norm
al saline) 
Infusion 
duration
c 
Infusion 
concentration 
tested and initial 
pH
 
FB
-ratio
theor d 
FB
-ratio
m
eas e 
Platosin
® 
C
isplatin 1 m
g/m
l 
Sodium
 chloride 
H
ydrochloric acid 
100 m
g/m
2 
In 2000 m
l 
6-8 hours 
0.1 m
g/m
l, 
pH
 4.4 
0.14-0.11 
50.3 ± 1.3 
D
éticène
®
 
D
acarbazine 10 m
g/m
l
C
itric acid 10 m
g/m
l 
M
annitol 5 m
g/m
l 
(after reconstitution) 
100 m
g/m
2 
B
olus injection: 
undiluted 
Infusion: to 0.4 
m
g/m
l 
B
olus injection: 
5-10 m
in 
Infusion: 15-30 
m
in 
B
olus injection: 
10 m
g/m
l, pH
 
3.5 
Infusion: 0.4 
m
g/m
l, pH
 3.7 
B
olus injection: 
0.09 
Infusion: 0.7 
B
olus injection: 
0.02 
Infusion: 0.8 
N
A
M
I-A
 
N
A
M
I-A
 10 m
g/m
l 
H
ydrochloric acid 
0.0036 m
g/m
l 
(after reconstitution) 
2.4 – 400 
m
g/m
2 f 
In 48-800 m
l 
3 hours 
1.0 m
g/m
l,  
pH
 5.2 
0.007 – 0.11 
20.2 ± 1.4 
a,b,c dose, dilution, and infusion duration based on dose schedules com
m
only applied in clinical practice; d theoretical FB-ratio calculated from
 Equation 4 
(see text), w
ith infusion rate calculated from
 a,b,c and a blood flow
 of 40 m
l/m
in; e m
easured FB-ratio calculated from
 Equation 3 (see text); f expected N
AM
I-A 
dose range in Phase I clinical studies. 
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Conclusions 
NAMI-A lyophilized product for intravenous infusion was subjected to a series of in vitro 
tests to evaluate its stability and suitability for intravenous administration. NAMI-A 
lyophilized product should be reconstituted using normal saline, after which it should be 
immediately diluted to infusion solutions with normal saline. The infusion solution can be 
prepared in glass or PVC containers, although PVC containers are recommended. After 
reconstitution and immediate dilution, NAMI-A infusion solutions are stable (<5% 
degradation) for 4 hours at room temperature or for 24 hours at refrigerated conditions. The 
PVC infusion system, consisting of a PVC container, infusion line and needle was shown to 
be compatible with NAMI-A infusion solutions. 
NAMI-A infusion solutions did not cause hemolysis in vitro and had a low buffer capacity. 
Thus, no serious side effects such as hemolysis or pain upon injection are expected in its 
clinical application. 
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Chapter 2: AP 5280 
Introduction 
The majority of anticancer drugs currently in use is distributed rather uniformly throughout 
the whole body after administration, resulting in systemic toxicity. Drug targeting could 
reduce systemic toxicity by enabling drugs to accumulate selectively in tumor tissue. As a 
result, ideally the local concentration of the drug at the site of action will be high, while its 
concentration in non-target tissue will be below a certain minimal level to prevent side 
effects. Nowadays, many ways to target a drug to its intended site of action have been devised 
(reviewed in [1]). One of the approaches that appears promising in cancer therapy is the 
conjugation of anticancer agents to polymers. 
Macromolecules, such as soluble synthetic and natural polymers, as well as small particles 
and liposomes demonstrate passive tumor accumulation due to the hyperpermeability of the 
angiogenic tumor vasculature in contrast to normal vessels. Poor lymphatic drainage in solid 
tumor tissue can additionally promote retention of macromolecules and therefore this 
phenomenon has been termed the enhanced permeation and retention (EPR) effect [2]. One of 
the synthetic polymers that has been used to bind many anticancer agents is poly-N-(2-
hydroxypropyl) methacrylamide (pHPMA). This polymer was initially developed as a plasma 
expander [3], but proved to show all the characteristics required for a polymer used for 
targeting purposes, as listed in Table 1 and reviewed at length elsewhere [4-8].  
 
 
Table 1. Characteristics of a required of a polymer to be used for targeting.  
Basic requirements for a polymer meant for conjugation 
Biocompatible (nontoxic, non-immunogenic, preferably biodegradable) 
Able to conjugate the drug in sufficient quantities to ensure therapeutic efficacy 
Able to protect the conjugated drug against premature metabolism (or liberation) in transit 
Liberate active drug at site of action and at a rate appropriate to its mechanism of action 
Yield a well-characterized , stable formulation, which can be manufactured reproducibly 
Be amendable to production on a commercial scale, at acceptable cost 
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pHPMA is water-soluble [3] and can be used to increase the water solubility of poorly soluble 
drugs [7]. Antitumor agents have been bound to pHPMA copolymers via peptidyl spacers 
designed to limit drug release in plasma and serum, but to degrade enzymatically by the 
lyosomal proteases, particularly cathepsins B, H, and L. Length and composition of the 
peptidyl spacer was shown in vitro to influence the rate of release [9] and can be modified to 
give the optimal release profile for each pendant drug and the stage of the particular tumor to 
be treated [4]. Injection of pHPMA´s of different molecular weight into rats showed long 
circulation times and molecular-weight dependent uptake and accumulation in tumors [10,11]. 
There are indications that besides their cytotoxic activity, pHPMA-bound drugs have 
immunomobilizing activity [12]. 
Many anticancer agents have been conjugated to pHPMA. To date, five have entered clinical 
trials [8]. Table 2 shows the results obtained thus far in Phase I clinical trials. PNU 166945 
was abandoned because of severe neurotoxicity observed in rodents, but the other pHMPA 
anticancer agents did not show this side effect. Therefore, the polymer itself is not likely to be 
the cause of neurotoxicity. The dose-limiting toxicities of the three Phase I trials that were 
completed to date were comparable to those of the free drug, although fatigue appeared to be 
present to a higher degree in all cases and may be related in some way to pHPMA. Worth 
mentioning is the fact that polymer-conjugated doxorubicin (both as PK1 and PK2) did not 
show any signs of cardiotoxicity, which is a well-known and dose-limiting side effect of free 
doxorubicin.  
The dose of administered drug could be increased substantially compared to administration of 
the free drug in all trials. Doxorubicin, when administered as the free drug, is conventionally 
administered at 50-75 mg/m2, but the recommended doses for Phase II trials were 280 mg/m2 
for PK1 [13] and 120 mg/m2 for PK2 [14]. Camptothecin is not administered as free drug, due 
to its high toxicity and low water-solubility [16], and the highest platinum doses thus far in 
the Phase I trial of AP 5280 are 50-fold higher than those conventionally administered for 
cisplatin [17]. Conjugation of anticancer agents to pHPMA thus appears to be an attractive 
way to decrease systemic toxicity of very effective cytotoxics.  
 
Chapter 2 of this thesis describes the pharmaceutical development of AP 5280. 
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Abstract 
AP 5280 is a novel polymer-conjugated platinum anticancer agent currently in Phase I clinical 
trials. In order to guarantee the quality of AP 5280 drug substance for use in the manufacture 
of a drug product for intravenous human use, an array of tests was utilized for its quality 
control. Proton nuclear magnetic resonance (1H NMR) spectroscopy and infrared (IR) 
spectroscopy were employed for structural identification. The molecular weight (MW) and 
MW distribution, which play a large role in the distribution of AP 5280 in vivo, were 
determined by Size Exclusion Chromatography (SEC). Platinum binding assessment was 
performed using platinum nuclear magnetic resonance (195Pt NMR) spectroscopy. The free 
platinum content and release profile of small platinum species, measured using Flameless 
Atomic Absorption Spectroscopy (F-AAS), were determined as a measure of molecular 
integrity, a very important aspect of its assumed mechanism of action. The total platinum 
content of the copolymer was determined employing flame Atomic Absorption Spectroscopy 
(AAS). The combined results of the analyses performed on AP 5280 drug substance provided 
a meaningful picture of its structure, size, and integrity, and thus an excellent basis for its 
quality control.  
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Introduction 
AP 5280 (poly(N-(2-hydroxypropyl) methacrylamide)-GFLG-Ama=Pt(NH3)2, Figure 1) is a 
novel polymer-conjugated platinum compound, designed for tumor targeting. In this 
copolymer, platinum is attached to poly-N-(2-hydroxypropyl) methacrylamide (pHPMA) via 
a tetrapeptide spacer (glycine-phenylalanine-leucine-glycine, or GFLG), and an 
amidomalonic acid (Ama) chelating agent. Due to the hyperpermeable nature of the 
neovasculature of tumors in combination with their limited lymphatic and/or capillary 
drainage, it is expected that AP 5280 will preferentially accumulate in tumor cells as 
compared to normal tissue. This phenomenon is called the Enhanced Permeation and 
Retention (EPR) effect [1-4]. Subsequently, platinum is released from the polymer 
intratumorally by lysosomal thiol-dependent proteinases, enzymes known to be elevated in 
human tumors [5]. Theoretically, intravenous AP 5280 administration will lead to higher 
intratumoral platinum concentrations and therefore potentially greater efficacy than the 
currently marketed non-polymer platinates cisplatin, carboplatin, and oxaliplatin. Preclinical 
studies show that AP 5280 indeed has a higher therapeutic index than cisplatin and 
carboplatin when administered to mice implanted with several different types of tumor [6]. 
Pharmaceutical quality control of a drug substance is a pivotal step in its use and the 
development of its formulation [7]. The quality of a drug substance has to be ensured in order 
to manufacture a drug product of guaranteed quality. Therefore, great attention should be paid 
to the development of structural and analytical characterization methods of each new drug 
substance. At our laboratory, experience has been gained in the development of assays and the 
formulation of several novel anticancer agents of low molecular weight [8,9,10] as well as of 
(marine-derived) polypeptides [11,12]. Characterization and pharmaceutical development of a 
macromolecule like AP 5280 (20-25 kDa) provided a novel challenge.  
Although pHPMA conjugates of several cytotoxic agents (e.g. doxorubicin [13], paclitaxel 
[14], methotrexate [15], and (9-amino)camptothecin [16,17]) have been developed, their 
complete characterization and quality control have not been published to date. Furthermore, 
no pharmacopoeial methods are available for macromolecules like AP 5280. Therefore, it was 
necessary to develop our own procedures for the pharmaceutical quality control of AP 5280. 
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Figure 1.  Chemical structure of AP 5280 and AP 5279. Molecular weight 24 ± 3 kDa, 
polydispersity index 1.2-2.3 
 
 
This paper describes the development of a series of analytical methods for the quality control 
of AP 5280 drug substance, utilizing several regulatory guidelines [18,19,20] as starting 
points.  
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Materials and methods 
Chemicals 
Access Pharmaceuticals, Inc. (Dallas, Texas, USA) developed and provided the methods to 
determine the free platinum content, release of free platinum, Size Exclusion Chromatography 
(SEC) and interpretation of the 1H NMR spectra, and provided AP 5280 drug substance, AP 
5279 (the O,O-Pt chelate precursor of AP 5280), and pHPMA homopolymer. Phosphate-
buffered saline (PBS) and distilled water were manufactured in-house (Department of 
Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands). Platinum 
atomic absorption standard and lithium perchlorate (LiClO4) were purchased from Sigma-
Aldrich Chemie (Zwijndrecht, The Netherlands). Hydrochloric acid 37% was purchased from 
Merck (Darmstadt, Germany), methanol from Biosolve Ltd. (Amsterdam, The Netherlands), 
and Water for Injections from B.Braun Medical (Melsungen, Germany). All chemicals were 
of analytical grade and used without further purification.  
Proton (1H) and platinum (195Pt) nuclear magnetic resonance (NMR) spectroscopy 
1H and 195Pt NMR spectra were recorded with a Bruker DPX 300 spectrometer with a 5 mm 
multi-nucleus probe. A variable temperature unit was used to maintain the temperature at 293 
K for 1H NMR spectroscopy and at 298 K for 195Pt NMR spectroscopy. The apparatus was 
calibrated using tetramethylsilane (TMS) at δ=0 ppm for 1H NMR spectroscopy and K2PtCl4 
at δ=-1614 ppm for 195Pt NMR as external references. During 1H NMR spectroscopy, the 
water signal was minimized using the presaturation technique. Samples were prepared by 
dissolving 80-100 mg AP 5280 in a total volume of 750 µl water with 5% D2O added for 
locking the signal.  
Infrared (IR) spectroscopy 
IR spectra of AP 5280 were recorded with a Model PU 9706 IR spectrophotometer (Philips 
Nederland B.V., Eindhoven, The Netherlands) using the potassium bromide (KBr) pellet 
technique. The pellet consisted of 2 mg analyte and 300 mg KBr. The ratio recording mode 
was auto-smooth and the scan time 8 minutes. 
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Size Exclusion Chromatography (SEC) 
Chromatographic analyses were performed using a Spectra System P1000 pump, Spectra 
Series AS300 autosampler and RI-150 refractive index detector (all Thermo Separation 
Products (TSP), Fremont, CA, USA). Separation was achieved using a PL aquagel-OH guard 
column (7.5 mm ID x 50 mm, particle size 8µm, Polymer Laboratories, Shropshire, UK), and 
two PL aquagel-OH MIXED columns (7.5 mm ID x 30 cm, particle size 8 µm, Polymer 
Laboratories) in series kept at a temperature of 308 K with a Croco-cil® column oven (TSP). 
The mobile phase consisted of 10 mM LiClO4/methanol 35%/65% (v/v) at a flow of 1.0 
ml/min. The injection volume was 100 µl and the run time 30 minutes. The SEC system was 
calibrated using polyethyleneoxide (PEO) and polyethyleneglycol (PEG) standards (Polymer 
Laboratories) with molecular weights ranging from 1,080 to 219,300 Da. Samples were 
prepared by weighing 2-3 mg of AP 5280 into an autosampler vial and adding 1.0 ml mobile 
phase to dissolve the drug substance by gentle swirling.  
Atomic Absorption Spectroscopy (AAS)  
Total platinum concentrations were measured using a Perkin Elmer 3100 Flame Atomic 
Absorption Spectrometer (Perkin Elmer Inc., Boston, MA, USA). A slit width of 0.7 nm, 
wavelength of 266 nm, and air-acetylene flame were employed. Platinum standards (39.20, 
31.36 and 23.52 mg/l) and quality control samples (35.28, 31.36 and 23.52 mg/l) in 0.4 mg/ml 
pHPMA in 0.11 M hydrochloric acid/methanol 50/50% (v/v) were used for quantification of 
total platinum concentrations. Samples were prepared by dissolution of AP 5280 in 0.11 M 
hydrochloric acid/methanol 50/50% (v/v) to yield a theoretical total platinum concentration of 
approximately 30 mg/l.  
Flameless Atomic Absorption Spectroscopy (F-AAS) 
F-AAS (or graphite furnace AAS) analysis was performed using a SpectrA-A 30/40 Zeeman 
Graphite Furnace Atomic Absorption Spectrometer (Varian, Techtron Pty Ltd, Victoria, 
Australia), consisting of a spectrometer, GTA-75 autosampler and a DS-15 data station 
equipped with the Quality Control Protocol software package (Varian). Absorbances were 
recorded at 265.9 nm, a slit bandwidth of 0.2 nm and a time constant of 0.05 s. Argon was 
used to purge the graphite tube. Analysis of platinum concentrations was carried out as 
previously described [21]. 
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For determination of the free platinum concentration (all platinum species with molecular 
weight < 3 kDa), AP 5280 was dissolved in Water for Injections (WfI) at a concentration of 
2.0 ± 0.1 mg/ml and stored at ambient temperature (+20-25ºC) for one hour. Subsequently, 2 
ml samples were ultrafiltered (45 minutes, 41 x g, Eppendorf 5403 centrifuge) through a 
Centricon YM-3 filter (3 kDa cut-off, Millipore, Milford, MA, USA). The platinum 
concentration in the ultrafiltrate was analyzed in duplicate.  
For determination of the release profile of small platinum species, AP 5280 was dissolved in 
PBS at a concentration of 2.0 ± 0.1 mg/ml and stored at 37°C. After 3 and 24 hours, samples 
were prepared in the same manner as described for the free platinum content determination. 
 
Results and discussion 
In comparison to most other anticancer agents, which are relatively “simple” molecules of low 
molecular weight, AP 5280 is a complex agent. AP 5280 comprises four components: 
pHPMA copolymer, a tetrapeptide spacer, a chelating agent, and a platinum moiety. The 
pHPMA copolymer provides the complex with its molecular weight (a prerequisite for the 
EPR effect [4]) and high aqueous solubility. The tetrapeptide spacer and chelating agent 
connect the platinum moiety to the pHPMA copolymer, and are responsible for binding the 
platinum during systemic transport, but releasing the biologically active platinate 
intratumorally through enzymatic cleavage in the lysosomes of the cells [22]. Finally, the 
structure of the conjugated drug and the way it is bound to the chelator influences interactions 
of the copolymer with the lysosomal enzymes inside the tumor tissue and in this manner 
affects release of the biologically active drug [15, 22].  
For pharmaceutical quality control of an active pharmaceutical ingredient (API), methods to 
structurally characterize it, determine its content and purity, and provide data on any other 
aspect considered important to its biological activity have to be developed. The size of AP 
5280 and its integrity in the blood stream are of extreme importance to its mechanism of 
action, as they can affect both activity and toxicity of the compound. Furthermore, the 
platinum content needs to be determined in order to properly dose the drug. Lastly, the 
analytical methods for the characterization of AP 5280 must be able to distinguish AP 5280 
from related substances (specificity must be proven) [20]. Test methods were developed using 
both an AP 5280 reference substance and two related compounds: AP 5279, and pHPMA  
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homopolymer. AP 5280 is manufactured from a copolymer intermediate consisting of a 90:10 
monomer ratio of HPMA and HPMA substituted with the GFLG linker. The latter is further 
substituted with a terminal amidomalonate chelating group for binding of the 
diammineplatinum(II). The initial (kinetic) product of the platinum addition reaction is the 
O,O-platinum chelate (Figure 1), which is designated AP 5279. Subsequently, this complex is 
rearranged to yield the thermodynamically stable N,O-platinum chelate that is present in AP 
5280. It thus becomes important to confirm that this conversion has essentially progressed to 
completion. 
1H NMR spectroscopy  
1H NMR spectroscopy is probably the most widely used method for structural elucidation of 
any substance containing protons. Table 1 summarizes the results of the characterization of 
AP 5280 reference drug substance using 1H NMR spectroscopy. To test the specificity of this 
technique in the structural identification of AP 5280, AP 5279 and pHPMA homopolymer 
were also analyzed. The 1H NMR spectrum of AP 5279 shows a small extra signal at 5.6 ppm, 
assigned to the methine proton at the 2 position of the malonato moiety, which is not present 
in the 1H NMR spectrum of AP 5280. This is a small but very distinctive difference in the 1H 
NMR spectrum, clearly showing which chelate is present. The pHPMA homopolymer does 
not display the signals at 0.8, 1.6, 4.4, 7.3 and 7.4 ppm, all of which are related to the 
tetrapeptide spacer, which is not present in the pHPMA homopolymer.  
1H NMR spectroscopy thus is a useful analytical method to detect structural changes in AP 
5280. Even the way of coordination of platinum to the chelator (O,O instead of N,O chelate) 
is detected. However, 1H NMR spectroscopy will not detect low levels of many impurities and 
thus is primarily used as an identification method. As each absorbance peak corresponds so 
clearly to a specific proton (group) of the entire molecule, the specification for the 1H NMR 
spectrum of AP 5280 was set to include all of these peaks, without allowing the presence of 
others.  To date, all batches of AP 5280 drug substance received at our laboratory have shown 
identical 1H NMR spectra.  
IR 
The assignments of the IR peaks of AP 5280 drug substance are presented in Table 1. All the 
peaks in the IR spectrum correspond to specific moieties within the molecule.  
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IR analysis of the related substances revealed that for AP 5279 the peak at 1380 cm-1 changes 
to a broad absorption band between 1410-1350 cm-1. The IR spectrum of the pHPMA 
homopolymer shows four extra peaks at 1480, 1450, 1420, and 1372 cm-1 in its IR spectrum. 
Thus, the region between 1350 and 1500 cm-1 should be scrutinized closely during analysis of 
AP 5280, as it is the region that will show small structural changes of the copolymer. These 
changes are small, however, and structural changes are more evident in the 1H NMR spectra. 
SEC 
AP 5280 did not show a distinct ultraviolet/visible light (UV/VIS) spectrum, except for some 
aspecific absorption at 200-230 nm. The lack of a strongly absorbing chromophore precludes 
the use of UV/VIS spectrophotometry and high performance liquid chromatography (HPLC) 
with UV/VIS detection as identity tests. However, AP 5280 in solution was found to display a 
distinct refractive index that was concentration-dependent. Most anticancer agents conjugated 
to pHPMA are analyzed by SEC to determine their molecular weights, usually employing a 
RI detector [13, 15-17]. 
The molecular weight (MW) of copolymers to be administered to humans influences their 
distribution and elimination. Many polymers, including pHPMA, are non-degradable and 
must therefore have a MW lower than the renal excretion threshold, otherwise they would be 
retained in the body. The renal threshold for pHPMA copolymers was determined to be 45 
kDa [23]. 
Synthetic polymers, instead of having a single MW, show a distribution in MW and are 
considered polydisperse. The shape, width, and magnitude of the MW distribution are 
characterized in terms of statistical averages of the distribution: the number-average 
molecular weight Mn, the weight-average molecular weight Mw, and the polydispersity index 
PI. Mn is the average molecular weight per molecule, influencing properties that are affected 
by chain ends, such as colligative properties, refractive index, density and the specific heat 
capacity [24]. Mw is a weighted average for the molecular weight of a molecule and affects 
polymer properties that are influenced by large chains, such as melting point and solution 
viscosity [24]. The width of the distribution, or polydispersity, of a sample is the ratio of the 
Mw to the Mn, Mw / Mn. For a monodisperse or single molecular weight system, the 
polydispersity index (PI) is 1 [24]. 
SEC is an analytical technique used to determine MW distributions based on separation 
according to the differences in hydrodynamic volume (molecular size), not their MW. 
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However, as molecular sizes of copolymers are roughly proportional to their MW, SEC 
provides a rapid and simple means to determine MW averages of copolymers.  
Initially, a SEC system as previously described by Mendichi et al. for the analysis of 
pHPMA-conjugated doxorubicin and paclitaxel [25, 26] was set up, employing columns filled 
with a polystyrene/divinylbenzene matrix at 50°C and 10 mM lithium bromide (to prevent 
molecular aggregation) in dimethylformamide (DMF) as mobile phase. Universal calibration 
was performed using polyethylene oxide (PEO) and polyethylene glycol (PEG) standards, as 
it has been shown that this mode of calibration generally provided more accurate MW values 
than calibration using pHPMA fractions [26]. However, use of this system led to secondary 
interaction of AP 5280 with the gel phase of the column, causing variable distortion of peaks 
and late elution of AP 5280 leading to inaccurately calculated MW values. Different SEC 
systems were thus investigated, resulting in the system as described above. This method has 
produced reproducible and accurate results, with a (negative) reference peak produced by 
lithium perchlorate at a retention time of approximately 21 minutes (Figure 2A). 
AP 5280 shows a normal, mono-modal distribution of MW. A sample chromatogram of AP 
5280 drug substance is shown in Figure 2B. The chromatogram produced by injecting AP 
5279 into the SEC system resulted in an identical SEC chromatogram as produced by 
injection of AP 5280 (Figure 2B). As the MW characteristics of AP 5279 are not different 
from those of AP 5280, it is not surprising that a change in chelator binding is not detected by 
SEC.   
SEC of pHPMA homopolymer produced a chromatogram as depicted in Figure 2C. It shows a 
much broader peak for pHPMA than obtained for AP 5280. As the pHPMA employed in 
these tests did not undergo extensive purification, a wider range of molecular weights is 
present, resulting in a larger polydispersity index (5.5 for pHPMA vs. 1.2-2.3 for AP 5280).  
Figure 2D shows a chromatogram of AP 5280 dissolved in 5% dextrose instead of water. A 
second peak is observed, which is formed by dextrose, as was confirmed by injection of 5% 
dextrose itself. This shows that the SEC method is able to detect the presence of low MW 
compounds as separate peaks. All in all, the presence of related substances and other agents 
with different MW characteristics than AP 5280 will be detected by the SEC system.  
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Figure 2.   A. Sample SEC chromatogram of mobile phase. 
B. Sample SEC chromatogram of AP 5280 drug substance. 
C. Sample SEC chromatogram of pHPMA. 
D. Sample SEC chromatogram of AP 5280 in 5% dextrose. 
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To date, all AP 5280 drug substance batches received at our lab have shown Mw´s in the range 
of 21.8 to 26.5 kDa, Mn´s between 11.8 and 17.0 kDa, and PI´s in the range of 1.54 to 1.89. 
This means that AP 5280 should be easily cleared from the body, as its molecular weight is 
lower than the renal threshold [23], but that accumulation in tumor tissue should take place, 
according to the EPR hypothesis. Specifications were set at 24 ± 3 kDa for the Mw, 14.5 ± 3 
kDa for the Mn, and 1.2-2.3 for the PI.  
195Pt NMR spectroscopy 
195Pt NMR spectroscopy is a technique excellently suited for assessment of platinum binding. 
Because differences in chemical environment of platinum cause resonance shifts, changes in 
platinum binding can be detected. The batches of AP 5280 drug substance obtained thus far 
have shown single signals in the 195Pt NMR spectrum ranging from δ= -2045 to –2053 ppm 
(mean: δ=-2048 ppm, standard deviation: 2.4 ppm).  
AP 5279 produced a 195Pt NMR spectrum with a single signal at δ = - 1725 ppm. The 
combined presence of AP 5280 and AP 5279 led to formation of two signals in the 195Pt NMR 
spectrum, in a ratio according to the relative amount of each chelate present.  
The pHPMA homopolymer was not analyzed by 195Pt NMR spectroscopy, as no platinum is 
present in this molecule. 
Although 195Pt NMR spectroscopy is not a very sensitive method (i.e. the presence of up to 
5% of a differently bound platinum species will not be detected, depending on the measuring 
time), it apparently is a very specific method. Changes in platinum binding will be detected 
by large changes in the peak position, as was illustrated by comparison of the 195Pt NMR 
spectra produced by AP 5280 and AP 5279. The specification for the 195Pt NMR spectrum 
was set at δ = -2048 ± 10 ppm and absence of other signals. 
Total platinum analysis 
For most pHPMA-conjugated anticancer agents, the content of the anticancer agent is 
measured after acid hydrolysis followed by a suitable HPLC or spectroscopic technique [13-
17]. HPLC-UV analysis of AP 5280 after acid hydrolysis employing a previously described 
method for cisplatin analysis [27] showed the presence of several different platinum species, 
making quantification of the total platinum content impossible. Therefore, another approach 
to determine the platinum content was required. AAS is a widely employed method for 
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determination of metal concentrations, and it was investigated for its use in determination of 
the platinum content of AP 5280. 
Initially, a flameless AAS (F-AAS) method was set up to determine the total platinum content 
of AP 5280, but matrix interference limited its use. Therefore, a flame AAS (AAS) method 
was developed to quantitate the total platinum content of AP 5280 drug substance. Again, 
matrix interference at first did not lead to complete recovery of the theoretical amount of total 
platinum (approximately 75%). This problem appeared to originate from the presence of 
pHPMA and was solved by dissolving the standards and samples in identical matrices: 
pHPMA homopolymer was added to the standards in the same concentration as present in AP 
5280 samples. Furthermore, methanol was added to both samples and standards to make the 
solution less viscous, thus facilitating transportation into the flame. Thus, the solvent of both 
samples and standards was prepared to contain 0.4 mg/ml pHPMA (either as homopolymer 
for the standards or as AP 5280 for the samples) in 0.11 M hydrochloric acid/methanol 
50/50% (v/v). This method led to complete recovery of the theoretical total platinum content. 
Each batch of AP 5280 drug substance produced thus far contained 8.0 ± 0.5% (w/w) 
platinum. 
Free platinum content  
Polymer therapeutics offers the opportunity to inactivate the bound cytotoxic drug during 
transport to the tumor and thus reduce its systemic toxicity. In this manner, tumor targeting 
may be improved by the EPR effect. In addition to the platinum bound as the N,O-platinum 
chelate, very small amounts of platinum may remain weakly associated with the AP 5280 
macromolecules during the manufacturing process. These platinum species will readily 
dissociate from AP 5280 in aqueous solution, and this unbound (“free”, low molecular 
weight) platinum may be separated from AP 5280 by passage through a 3 kDa ultrafiltration 
device. It is important to quantitate this characteristic of the drug product and to establish an 
acceptance limit.  
F-AAS was chosen for determination of free platinum, as the free platinum concentrations are 
very low and this method is more sensitive than e.g. AAS. As the samples were ultrafiltered 
before analysis, no matrix interference due to the presence of pHPMA was experienced.    
AP 5280 reference substance was tested for its free platinum content in water at several points 
in time after dissolution, for a duration of 6 days. It was shown that the free platinum content 
did not increase in time. Therefore, water was chosen as the medium in which to determine 
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the free platinum content of each batch of AP 5280 drug substance. Of the lots of AP 5280 
drug substance received thus far, free platinum levels ranged between 0.12 to 0.86% with 
respect to the total platinum content. The acceptance limit was set at 1.0%.  
Release of small platinum species 
Apart from free platinum present in AP 5280 drug substance, some release of small platinum 
species (“liberated platinum”) will take place upon dissolution of AP 5280 in many media due 
to hydrolysis and other exchange mechanisms of platinum with medium components [28]. 
This phenomenon is also likely to take place upon intravenous administration. In order to get 
an indication of the degree of platinum release after intravenous infusion, AP 5280 and related 
compounds were dissolved in PBS (pH 7.4, 37°C). AP 5280 and AP 5279 showed 
characteristic release profiles of liberated platinum, as depicted in Figure 3. Although the free 
platinum contents of AP 5279 and AP 5280 were found to be approximately the same, AP 
5279 showed a release profile with liberated platinum contents being a factor 2-5 higher than 
those of AP 5280. As a reference, platinum release from AP 5280 dissolved in water, the 
medium used for the determination of free platinum, stored at room temperature, was also 
determined. AP 5280 in water does not show any measurable release of platinum. Platinum 
release thus appears to be a process driven by the presence of chloride ions (possibly along 
with other components of the dissolution medium), as was observed previously [27]. The 
liberated platinum contents 3 and 24 hours after dissolution of each different compound 
showed very distinct values and can thus be used as a measure of identity and platinum 
binding stability of AP 5280 drug substance. 
Figure 3. Liberated platinum content of AP 5280 (♦) and AP 5279 (f) in PBS at 37°C and of  
AP 5280 in water at room temperature ()). 
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To date, the batches AP 5280 drug substance produced for clinical trials have shown mean 
liberated platinum contents of 0.88% ± 0.18% of the total platinum content after 3 hours, and 
of 2.70% ± 0.75% after 24 hours of dissolution in PBS (pH 7.4, 37°C). Acceptance limits 
were set at 1.5% of the total platinum content being present as small platinum species 3 hours 
after dissolution and at 3.5% after 24 hours.    
 
Conclusions 
A broad spectrum of analytical techniques was used to characterize AP 5280 drug substance 
and thus gain a meaningful picture of the structure, size, and integrity of this complex 
molecule for quality control purposes. Identification was performed employing 1H NMR and 
IR spectroscopy, and SEC was applied for determination of the molecular weight 
characteristics. The size of AP 5280 is an important aspect in view of its proposed mechanism 
of action. Because the way platinum is bound to the chelator determines how easily it is 
released as a biologically active platinate, platinum binding assessment was performed using 
195Pt NMR spectroscopy. F-AAS was employed to determine the free platinum content and 
the release profile of liberated platinum of AP 5280. This was performed as a measure of the 
integrity of the molecule, which influences the pharmacokinetics of AP 5280.  The assay 
consisted of total platinum content determination by AAS. The identification methods (1H, 
195Pt NMR, IR spectroscopy, and SEC), were tested for their specificity. The presence of 
related substances was detected by these methods. Based on the results obtained in the 
analysis of the first batches of AP 5280 drug substance, specifications were set. Table 2 
summarizes the methods chosen for the quality control of AP 5280 drug substance, the results 
obtained thus far, and the specifications defined on the basis of these results. 
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Abstract 
AP 5280 is a novel polymer-conjugated platinum anticancer agent showing promising in vitro 
and in vivo activity against solid tumors. The aim of this study was to develop a parenteral 
pharmaceutical dosage form for Phase I clinical trials. AP 5280 drug substance was 
characterized using a wide range of analytical techniques and showed excellent solubility in 
water. However, as aqueous solutions of AP 5280 proved to be labile upon sterilization by 
moist heat, it was decided to develop a lyophilized dosage form. Initially, glass vials were 
used as primary packaging, but this led to a high breakage rate, which could be completely 
prevented by the use of CZ-resin vials. Stability studies to date show that the lyophilized 
product in glass vials is stable for at least 12 months when stored at +2-8°C in the dark and 
the lyophilized product in CZ-resin vials is stable for at least 6 months under these conditions. 
Photostability testing revealed photolability of AP 5280 drug substance and lyophilized 
product in both types of primary container, necessitating storage in the dark. The first clinical 
experiences indicate that the proposed formulation is fully applicable for use in the clinical 
setting.   
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Introduction 
AP 5280 (poly(N-(2-hydroxypropyl) methacrylamide)-GFLG-Ama=Pt(NH3)2, molecular 
weight 20-25 kDa, Figure 1) is a novel polymer-conjugated platinum compound, designed for 
tumor targeting. In this copolymer, platinum is attached to a poly-N-(2-hydroxypropyl) 
methacrylamide (pHPMA) backbone via a tetrapeptide spacer (glycine-phenylalanine-
leucine-glycine, or GFLG), and an amidomalonic acid (Ama) chelating agent. Due to the 
hyperpermeable nature of the neovasculature of tumors in combination with their limited 
lymphatic and/or capillary drainage, it is expected that AP 5280 will preferentially 
accumulate at the tumor site, a phenomenon known as the Enhanced Permeation and 
Retention (EPR) effect [1-4]. Subsequently, platinum is released from the polymer 
intratumorally by lysosomal thiol-dependent proteinases, enzymes known to be elevated in 
human tumors [5]. Theoretically, AP 5280 administration will thus lead to higher intratumoral 
platinum concentrations and therefore potentially greater efficacy than the currently marketed 
non-polymer platinates cisplatin, carboplatin, and oxaliplatin. Preclinical studies show that 
AP 5280 has a higher therapeutic index than cisplatin and carboplatin when administered to 
mice implanted with several different types of tumor [6]. On the basis of the promising effects 
seen in preclinical studies, AP 5280 is now further developed as a potential anticancer agent 
against solid tumors. 
 
Figure 1.  Chemical structure of AP 5280. Molecular weight 24 ± 3 kDa, polydispersity index 
1.2-2.3. 
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The discovery of a new drug is of practical significance only if the drug can be formulated 
and presented in a therapeutically acceptable form. The aim of this study was to develop a 
stable, parenteral dosage form for use in Phase I clinical trials. The dosage of AP 5280 is 
expressed in mg platinum (Pt), this being the active component of the compound. The starting 
dose for Phase I clinical studies was set at 90 mg Pt (as AP 5280)/m2 body surface area 
(BSA). Initially, a dosage unit content of 200 mg Pt (as AP 5280) was considered most 
appropriate to cover the expected Phase I dosing range, assuming an average BSA of 1.7 m2 
and a maximum dose level of 10 times the starting dose. The development of a suitable 
parenteral formulation was performed based on the EORTC/CRC/NCI Joint Formulation 
Working Party guidelines [7].  
 
Materials and methods 
Chemicals  
AP 5280 drug substance (containing 8.0 ± 0.5% Pt) was provided by Access Pharmaceuticals, 
Inc (Dallas, Texas, USA). AP 5280 lyophilized product and phosphate-buffered saline (PBS) 
were manufactured in-house (Department of Pharmacy and Pharmacology, Slotervaart 
Hospital, Amsterdam, The Netherlands). Sterile Water for Injections (Ecotainer), 0.9% (w/v) 
NaCl (normal saline), and 5% (w/v) dextrose were obtained from B. Braun (Melsungen, 
Germany). Platinum atomic absorption standard, lithium perchlorate (LiClO4), and Hydranal® 
titrant (2 mg/ml) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Hydrochloric 
acid 37% (w/v), quinine monohydrochloride dihydrate, and methanol were purchased from 
Merck (Darmstadt, Germany), Fluka Chimika GmbH (Buch, Switzerland), and Biosolve Ltd. 
(Amsterdam, The Netherlands), respectively. All chemicals were of analytical grade and used 
without further purification.  
Proton (1H) and platinum (195Pt) nuclear magnetic resonance (NMR) spectroscopy 
1H and 195Pt NMR spectra were recorded with a Bruker DPX 300 spectrometer with a 5 mm 
multi-nucleus probe. A variable temperature unit was used to maintain the temperature at 293 
K for obtaining the 1H NMR spectra and at 298 K for the 195Pt NMR spectra. The apparatus 
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was calibrated using tetramethylsilane at δ=0 ppm (1H NMR) or K2PtCl4 at δ=-1614 ppm 
(195Pt NMR) as external reference. The water signal in the 1H NMR spectra was minimized 
using the presaturation technique. Samples (both drug substance and lyophilized product) 
were prepared by dissolving 80-100 mg in a total volume of 750 µL water with 5% D2O 
added for locking the NMR signal.  
Infrared (IR) spectroscopy 
IR spectra of AP 5280 were recorded with a Model PU 9706 Infrared (IR) spectrophotometer 
(Philips Nederland B.V., Eindhoven, The Netherlands) using the potassium bromide (KBr) 
pellet technique. The pellet consisted of 2 mg AP 5280 bulk drug or lyophilized product and 
300 mg KBr. The ratio recording mode was auto-smooth and the scan time 8 minutes. 
Size Exclusion Chromatography (SEC) 
Chromatographic analyses were performed using a Spectra System P1000 pump, Spectra 
Series AS300 autosampler and RI-150 refractive index detector (all Thermo Separation 
Products (TSP), Fremont, CA, USA). Separation was achieved using a PL aquagel-OH guard 
column (7.5 mm ID x 50 mm, particle size 8µm, Polymer Laboratories, Shropshire, UK), and 
two PL aquagel-OH MIXED columns (7.5 mm ID x 30 cm, particle size 8 µm, Polymer 
Laboratories) in series kept at a temperature of 308 K with a Croco-cil® column oven (TSP). 
The mobile phase consisted of 10 mM LiClO4/methanol 35%/65% (v/v) at a flow of 1.0 
ml/min. The injection volume was 100 µL and the run time 30 minutes. The SEC system was 
calibrated using polyethyleneoxide (PEO) and polyethyleneglycol (PEG) standards (Polymer 
Laboratories) with molecular weights ranging from 1,080 to 219,300 g/mol.  
Samples were prepared by accurately weighing 2-3 mg of AP 5280 drug substance or 
lyophilized product into an autosampler vial and adding 1.00 ml mobile phase to dissolve the 
drug substance by gentle swirling. 
Flame Atomic Absorption Spectrometry (AAS)  
Total platinum concentrations were measured using a Perkin Elmer 3100 Flame Atomic 
Absorption Spectrometer (Perkin Elmer Inc., Boston, MA, USA). A slit width of 0.7 nm, 
wavelength of 266 nm, and air-acetylene flame were employed. Platinum standards (39.20, 
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pHPMA homopolymer in 0.11 M hydrochloric acid/methanol 50/50% (v/v) were used for 
quantification of total platinum concentrations. Samples analyzed for their total platinum 
concentration were diluted with 0.11 M hydrochloric acid/methanol 50/50% (v/v) to yield a 
theoretical total platinum concentration of approximately 30 mg/l.  
Flameless Atomic Absorption Spectrometry (F-AAS) 
F-AAS analysis was performed using a SpectrA-A 30/40 Zeeman Graphite Furnace Atomic 
Absorption Spectrometer (Varian, Techtron Pty Ltd, Victoria, Australia), consisting of a 
spectrometer, GTA-75 autosampler and a DS-15 data station equipped with the Quality 
Control Protocol software package (Varian). Absorbances were recorded at 265.9 nm, a slit 
bandwidth of 0.2 nm and a time constant of 0.05 s. Argon was used to purge the graphite tube. 
Platinum concentrations were measured using a method described previously [8]. 
For determination of the content of small platinum species present in AP 5280 drug substance 
and lyophilized product (“free platinum content”), AP 5280 solutions in Water for Injections 
(WfI) were prepared in triplicate at a concentration of 2.0 ± 0.1 mg/ml. For the drug 
substance, 10 mg AP 5280 was weighed into 5 mL volumetric flasks and dissolved in WfI. 
The lyophilized product was reconstituted with WfI and further diluted using WfI. The 
solutions were stored at ambient temperature (+20-25ºC) for one hour, after which 2 ml 
samples were ultrafiltered (45 minutes, 41 x g, Eppendorf 5403 centrifuge) through a 
Centricon YM-3 filter (3 kDa cut-off, Millipore, Milford, MA, USA). The platinum 
concentration in each ultrafiltrate was analyzed in duplicate.  
Release of small platinum species (“liberated platinum content”) was measured in AP 5280 
solutions at a concentration of 2.0 ± 0.1 mg/ml in PBS. The solutions were prepared in 
triplicate as described for the solutions used for determination of the free platinum content. 
The solutions were stored at 37ºC, and after 3 and 24 hours, 2 ml samples were taken, 
ultrafiltered through Centricon YM-3 filters, and analyzed. Liberated platinum contents were 
also determined in solutions of 125 mg/mL AP 5280 drug substance in normal saline and 5% 
dextrose. These solutions were stored at room temperature (20-25°C) in the dark and samples 
were taken immediately after preparation and after 1, 3, 7, 24, 48 and 96 hours of storage. 
 
31.36 and 23.52 mg/l) and quality control samples (35.28, 31.36 and 23.52 mg/l) in 0.4 mg/ml 
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Solubility of AP 5280 drug substance 
The solubility of AP 5280 in water at ambient temperature (20-25ºC) was examined by 
accurately weighing approximately 100 mg AP 5280 in a glass test tube and adding water in 
100 µL increments. After each addition, the solution was gently stirred and examined visually 
under polarized light for complete dissolution of AP 5280 drug substance.  
Sterilization 
AP 5280 was dissolved in sterile Water for Injection at a concentration of 125 mg/ml. The 
solution was sterilized by moist heat for 15 minutes at 121°C in a Model 6.6.15 autoclave 
(Koninklijke Ad Linden B.V., The Netherlands). 
Differential Scanning Calorimetry 
Transition temperatures and warming characteristics of AP 5280 and pHPMA solutions were 
examined by differential scanning calorimetry (DSC). These experiments were performed 
using a Q1000 V 6.2 DSC in T4 mode equipped with a refrigerated cooling accessory (RCS) 
for low temperatures (TA Instruments, New Castle (DE), USA). Samples were placed in an 
aluminum pan, which was subsequently sealed, and measured against an empty pan as 
reference. Temperature scale and heat flux were calibrated with indium. Analyses were 
performed under a nitrogen purge at 50 ml/min. Samples (125 mg/ml AP 5280 or pHPMA 
homopolymer in water) were cooled to -50ºC at a rate of 5°C/min, after which they were 
heated at a rate of 2°C/min to -2°C. Subsequently, the samples were cooled again to -50°C 
and heated to 30°C at the same rates. After each cooling and heating step, an isothermal step 
lasting 5 minutes was built in. As a reference, water was subjected to the same DSC 
conditions. 
Formulation process 
AP 5280 lyophilized product was aseptically prepared. The formulation solution was prepared 
to contain 10 mg Pt (as AP 5280) /ml in sterile Water for Injections (WfI) and dissolved with 
stirring at ambient temperature, after which it was sterile filtered through a 0.22 µm Millipak 
40 filter (Millipore). Subsequently, the formulation solution was filled into washed and 
sterilized 30 ml type I glass vials (Münnerstädter Glaswarenfabrik GmbH, Münnerstadt,  
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Germany) or 50 ml CZ-resin vials (Daikyo-Seiko, Ltd., Tokyo, Japan). Washed and sterilized 
siliconized gray bromobutyl rubber stoppers (Type FM 157/1, Helvoet Pharma NV, Alken, 
Belgium) were positioned on each vial. The vials were loaded into a Model Lyovac GT 4 
freeze-dryer (STERIS, Hürth, Germany) at ambient temperature and lyophilization was 
performed. After completion of the freeze-drying cycle, the vials were pneumatically closed 
under vacuum and the vials were retrieved from the freeze-dryer. The product was capped 
with aluminum caps (Bico Pharma GmbH, Neuss, Germany) and labeled.  
In-process controls consisted of integrity testing of the filter, weight variation of the filling 
volume, determination of the total platinum concentration and bioburden before and after 
filtration, and monitoring of the product temperature, shelf temperature, chamber pressure, 
and condensor temperature during freeze-drying. Only clean, sterile, inert materials and 
glassware were used throughout the manufacturing process. All manipulations took place in a 
class 100 (A) down-flow cabinet inside a class 100 (B) clean room (Interflow, Wieringerwerf, 
The Netherlands). Air particle counts in the critical areas and microbiological contamination 
of area and personnel were monitored during the manufacturing process. The manufacture 
was performed in compliance with the Good Manufacturing Practice (GMP) guidelines [9].   
Quality control of AP 5280 lyophilized product 
AP 5280 lyophilized product was characterized using the methods also used for the 
characterization of the drug substance as well as by visual inspection of appearance and color 
of the pharmaceutical product, and determination of reconstitution characteristics (rate of 
dissolution and pH after reconstitution, presence of particles) and residual moisture content. 
Furthermore, sterility of the pharmaceutical product was checked by the membrane filtration 
method according to the United States Pharmacopoeia (USP 24), and the presence of bacterial 
endotoxins with the limulus amoebocyte lysate (LAL) test according to the European 
Pharmacopoeia III.  
Residual moisture content 
Residual moisture levels in AP 5280 lyophilized product were determined using the Karl 
Fischer titration method. The content of a vial was quantitatively transferred into the titration 
unit of a Model 658 KF Titrino apparatus (Metrohm, Herisau, Switzerland) with 
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preconditioned methanol, and subsequently titrated using Hydranal Titrant 2.0 mg H2O/ml 
(Sigma-Aldrich). The end-point of the titration was determined bi-amperometrically.  
Stability studies 
Stability of the lyophilized product was examined at the designated long term storage 
condition of + 2-8°C in the dark. After the initial quality control, the samples were tested after 
3, 6, and 12 months of storage. 
Photostability studies 
Photostability of AP 5280 drug substance and final product was determined according to ICH 
guideline Q1B [10]. Samples were exposed to light of high intensity emitted by a Suntest 
CPS+ apparatus with xenon lamp and ID-65 window glass filter allowing passage of light of 
wavelength 320-800 nm, cooled by a SuncoolTM chiller (all Atlas Material Testing 
Technology, Chicago, IL, USA). Samples were exposed to an irradiance level of 68.9 W/m2 
for 24 hours. The following samples were tested: AP 5280 drug substance, spread in a layer 
of no more than 3 mm thickness in a glass petri dish (Ø 10 cm); AP 5280 lyophilized product 
in its primary container (both glass vials and CZ-resin vials); and AP 5280 lyophilized 
product pulverized using a glass rod, taken out of its primary container, and spread in a petri 
dish as described for the drug substance. Dark controls (prepared exactly as the samples, but 
wrapped in aluminum foil, in a manner in which the sample would not come into contact with 
the aluminum, which is known to interact with platinum) were placed alongside all samples to 
evaluate the contribution of thermally induced changes. 1 cm stoppered quartz cells (Hellma 
GmbH&Co., Müllheim, Germany) filled with a 2% (w/v) quinine monohydrochloride 
dihydrate solution (both exposed samples and dark controls) were placed alongside the 
samples to serve as a chemical actinometric system, ensuring that the specified light exposure 
was obtained [10]. 
Table 1.  
O
verview
 of the tests perform
ed, results obtained, and specifications set of AP 5280 drug substance.  
Test m
ethod / item
 
R
esults 
Specification 
1. 
A
ppearance 
 
Light brow
n, flaky substance, free from
 visible signs of 
contam
ination 
Light brow
n, flaky substance, free from
 visible signs of 
contam
ination 
2. 195Pt N
M
R
 spectroscopy 
A
. 
Identity  
B
. 
Purity 
 A
. 
A
 single peak at δ= -2048 ± 2 ppm
  
B
. 
A
bsence of other signals than at δ= -2048 ± 2 ppm
. 
 A
. 
A
 single peak at δ= -2048 ± 10 ppm
  
B
. 
A
bsence of other signals than at δ= -2048 ± 10 ppm
. 
3. 1H
 N
M
R
 spectroscopy 
A
. 
Identity    
 B
. 
Purity 
 A
. 
Peaks are present at 0.8-1.0, 1.1, 1.6, 1.7-2.0, 3.0-3.3, 3.9, 
4.4, 7.3, 7.4, 7.5 and 7.7 ppm
.  
 B
. N
o other accom
panying signals are present. 
 A
. 
Peaks are present at 0.8-1.0, 1.1, 1.6, 1.7-2.0, 3.0-3.3, 3.9, 
4.4, 7.3, 7.4, 7.5 and 7.7 ppm
.  
 B
. N
o other accom
panying signals are present. 
4. F-A
A
S  
A
. 
Free platinum
 content 
 
B
. 
Liberated platinum
 
content 
 A
. 
2.0±0.1 m
g/m
l A
P 5280 in W
fI contains 0.12-0.86%
 free 
Pt (w
ith respect to the total Pt content) at room
 
tem
perature (20-25°C
).  
B
. 
2.0±0.1 m
g/m
l A
P 5280 in PB
S at 37°C
 releases 0.88 ± 
0.18%
 sm
all Pt species after 3 hours and 2.72 ± 0.85%
 
free Pt after 24 hours (w
ith respect to the total Pt content) 
 A
. 
2.0±0.1 m
g/m
l A
P 5280 in W
fI contains ≤1.0%
 free Pt 
(w
ith respect to the total Pt content) at room
 tem
perature 
(20-25°C
).  
B
. 
2.0±0.1 m
g/m
l A
P 5280 in PB
S at 37°C
 releases ≤1.5%
 
sm
all Pt species after 3 hours and ≤3.5%
 free Pt after 24 
hours (w
ith respect to the total Pt content) 
5. A
A
S      
Total platinum
 content 
 8.0 ± 0.5 %
 (w
/w
) 
 8.0 ± 0.5 %
 (w
/w
) 
6. Size-Exclusion  
C
hrom
atography 
A
. 
M
w  
B
. 
M
n  
C
. 
polydispersity index 
D
. 
shape of the peak  
  A
. 
M
w  = 21.8 – 26.5 kD
a 
B
. 
M
n = 11.8 – 17.0 kD
a 
C
. 
PI = 1.5- 1.9 
D
. 
M
ono-m
odal 
  A
. 
M
w  = 24 ± 3 kD
a 
B
. 
M
n = 14.5 ± 4 kD
a 
C
. 
PI = 1.2-2.3 
D
. 
M
ono-m
odal 
7. IR
 spectroscopy  
A
P 5280 exhibits m
ajor absorption bands at approxim
ately 
3700-3100 cm
-1, 2970 cm
-1, 2920 cm
-1, 1630 cm
-1, 1520 cm
-1, 
1380 cm
-1, 1290-1230 cm
-1, 1190 cm
-1, 1140-1050 cm
-1 and 
960-900 cm
-1. 
 
A
P 5280 exhibits m
ajor absorption bands at approxim
ately 
3700-3100 cm
-1, 2970 cm
-1, 2920 cm
-1, 1630 cm
-1, 1520 cm
-1, 
1380 cm
-1, 1290-1230 cm
-1, 1190 cm
-1, 1140-1050 cm
-1 and 
960-900 cm
-1. 
 
M
w  =
 w
eight m
olecular w
eight, M
n  =
 num
ber m
olecular w
eight, PI =
 polydispersity index.
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Results and discussion 
Analytical characterization of AP 5280 drug substance 
A broad spectrum of analytical techniques is used to fully characterize AP 5280 drug 
substance. Table 1 shows the methods chosen and results obtained with multiple batches of 
AP 5280 drug substance. These results were used to define the specifications for the quality 
control of AP 5280 drug substance. Identification was performed employing 1H NMR and IR 
spectroscopy, and SEC for determination of the molecular weight (MW) characteristics. The 
size of AP 5280 is an important aspect of its proposed mechanism of action. Furthermore, in 
order to be efficiently cleared from the body, the MW should be lower than the renal 
threshold, which for pHPMA copolymers was determined to be 45 kDa [11].  
Because the way platinum is bound to the chelator determines how easily it is released as a 
biologically active platinum species, an assessment of the platinum binding was performed 
using 195Pt NMR spectroscopy. F-AAS was employed to determine the free platinum content 
and the release profile of liberated platinum of AP 5280 as a measure of the integrity of the 
molecule, which influences its pharmacokinetics and pharmacodynamics. The assay consisted 
of total platinum content determination by AAS. The combined results of the analyses are 
able to provide a meaningful picture of AP 5280’s structure, size, and integrity.  
Preformulation studies 
Due to the pHPMA copolymer, AP 5280 is a highly water-soluble compound. Its solubility is 
≥ 500 mg/ml. However, beyond a concentration of 125 mg/ml, the solution becomes 
impractically viscous as a consequence of the high polymer concentration. Therefore, the 
concentration AP 5280 for the formulation solution during manufacture was set at 125 mg/ml.  
The stability of AP 5280 in solution was examined in normal saline and 5% dextrose, both 
commonly applied infusion solutions, and in sterile WfI. Using F-AAS analysis of 
ultrafiltered solutions, it was found that during a 4-day storage period at room temperature, 
the liberated platinum content in the normal saline solution steadily increased to 
approximately 3% of the total platinum concentration, as is depicted in Figure 2.  
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Figure 2. Free platinum content of AP 5280 solutions in normal saline and 5% dextrose 
(! = normal saline, " = 5% dextrose). 
 
Upon dissolution in 5% dextrose, small platinum species were released from AP 5280 during 
the first 24 hours, after which a plateau level of approximately 1.5% of the total platinum 
concentration was reached. No significant release of small platinum species was observed for 
the AP 5280 solution in sterile WfI during 4 days of storage (data not shown).  NMR 
spectroscopic analysis of this solution after 4 days showed an identical 1H and 195Pt NMR 
spectrum as immediately after dissolution, confirming that no major structural change had 
taken place during this time.     
Subsequently, stability of the AP 5280 solution in sterile WfI was further examined by 
exposing the solution to a moist heat sterilization cycle. Although the appearance of the 
solution did not change upon sterilization, characteristics of the molecule had altered 
significantly, as is shown in Table 2. Platinum binding had changed, as observed by the shift 
in the 195Pt NMR resonance from –2046 to –2016 ppm, and other structural changes could be 
observed in the appearance of two new peaks in the 1H NMR spectrum. Furthermore, both the 
free and liberated platinum content increased. Lastly, analysis by SEC revealed that although 
the MW profile remained the same, the weight and number molecular weight decreased 
substantially, indicative of breakage of the copolymer chains and/or the peptide chains. The 
polydispersity index increased as compared to the solution before sterilization, providing 
evidence that a broader range of MW’s was present.  
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Table 2.  Quality control results of AP 5280 before and after sterilization by moist heat  
Test item Before sterilization by moist heat After sterilization by moist heat 
Appearance Dark brown solution Dark brown solution 
Foreign insoluble 
matter 
Free from foreign insoluble 
matter 
Free from foreign insoluble 
matter 
195Pt NMR analysis 
1. Identification 
2. Purity 
 
1. δ = -2046 ppm 
2. No other signals are present 
 
1. δ = -2016 ppm 
2. No other signals are present 
1H NMR analysis 
1. Identification 
 
2. Purity 
 
1. Peaks are present at 0.8-1.0, 
1.1, 1.6, 1.7-2.0, 3.0-3.3, 3.9, 
4.4, 7.3, 7.4, 7.5, and 7.7 ppm 
2. No other signals are present 
 
1. Peaks are present at 0.8-1.0, 
1.1, 1.6, 1.7-2.0, 3.0-3.3, 3.9, 
4.4, 7.3, 7.4, 7.5, and 7.7 ppm 
2. Extra peaks at 3.7 and 4.0 
ppm 
F-AAS analysis 
1. Free platinum 
content* 
2. Liberated platinum 
content* 
 
1. 0.2% 
2. 3 hrs: 0.9% 
24 hrs: 3.4% 
 
1. 2.2% 
2. 3 hrs: 3.2% 
24 hrs: 5.4% 
AAS analysis 
Total platinum content 
 
104.8% 
 
104.8% 
SEC 
 
 
 
Mw = 26.7 kDa 
Mn = 12.5 kDa 
PI = 2.14 
Mono-modal 
Mw = 16.4 kDa 
Mn = 6.4 kDa 
PI = 2.55 
Mono-modal 
* with reference to the total platinum content, Mw = weight molecular weight, Mn = number molecular 
weight, PI = polydispersity index. 
 
 
It could be concluded that sterilization by moist heat of AP 5280 in solution leads to a change 
in platinum binding, release of small platinum species and breakage of copolymer and/or 
peptide chains and is thus not an option for production of a parenteral formulation. 
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According to the European Pharmacopoeia III [12] and the ICH Decision Trees for the 
Selection of Sterilisation Methods [13], a parenteral product should preferentially be sterilized 
by terminal sterilization in its primary container. However, this approach clearly caused 
degradation of AP 5280. Solutions in normal saline and 5% dextrose showed some release of 
small platinum species and were not considered to be suitable solvents for long-term storage 
of AP 5280 solutions. Although dissolution of AP 5280 in sterile WfI did not induce changes 
in AP 5280’s structure and integrity for 4 days, the long-term stability of this solution was 
unlikely, as indicated by stress testing. Therefore, in order to produce a stable product with a 
sufficiently long shelf life, it was decided to develop a lyophilized dosage form. 
Differential Scanning Calorimetry 
Figure 3 depicts the DSC thermograms of AP 5280 and pHPMA homopolymer solutions and 
of water. Two thermal events are observed: the glass transitions (T’g) with onsets at –14.7°C 
and –13.2°C (inset Figure 3) for pHPMA and AP 5280, respectively, and an ice melting 
endotherm. The glass transition was identified as such, as it did not disappear upon repetition 
of the cooling and heating cycle and was concentration-dependent. The extrapolated onset 
temperatures of melting of the formulation solution, pHPMA solution, and pure water were –
2.0°C, –2.1°C, and –0.9°C, respectively. From the similarities between the thermograms of 
the pHPMA and formulation solutions, it can be concluded that melting and freezing behavior 
of AP 5280 in aqueous solution is mainly governed by the pHPMA copolymer, this being the 
major component of the molecule.  
Lyophilization of AP 5280 
The product temperature (Tprod) as a function of the shelf temperature (Tshelf) was determined 
empirically for the product in the 30 ml glass vials and in the 50 ml CZ-resin vials (125 
mg/ml AP 5280, 20 and 40 ml fill, respectively) at a chamber pressure (Pc) of 0.15 mbar. 
Each solution was frozen to -40°C in 3 hours, followed by a freeze-hold lasting 5 hours to 
ensure complete freezing of the vial contents. Subsequently, the Pc was reduced to 0.15 mbar, 
after which the Tshelf was raised in steps of 20°C at a rate of 1°C/min to 0°C, followed by 
steps of 10°C at the same heating rate to +30°C. After each rise in Tshelf, the temperature was 
kept constant for a period of three hours, after which the Tprod was determined. The results of 
this experiment are shown in Figure 4. 
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Figure 4.  Product temperature as a function of shelf temperature during lyophilization of  
AP 5280 in glass vials () and CZ-resin vials (). 
 
 
AP 5280 showed a linear increase in Tprod with Tshelf (r2 = 0.99) that was equal for the glass 
vials and the CZ-resin vials. At a Tshelf of +30°C, Tprod was found to be –25°C, which was 
approximately 10°C below the onset of the glass transition temperature and thus considered to 
be a safe drying temperature.     
On the basis of this experiment, lyophilization of the product was performed using a one-step 
freeze-drying cycle. Freezing and a freeze-hold remained as described above, after which the 
Pc was reduced to 0.15 mbar in 1 minute and the Tshelf raised to +30°C in two hours. The 
freeze-drying cycle was stopped when Tprod reached Tshelf (which was approximately 48 hours 
faster for the 20 ml fill in the glass vials than the 40 ml fill in the CZ-resin vials).  
Lyophilization of an aqueous AP 5280 solution resulted in a solid, light brown cake with 
moisture contents less than 2% (Table 3). No meltback of ice and thereby collapse of the 
product, was observed. Quality control of the lyophilized product (Table 3) showed that 
lyophilization does not affect the structural integrity of AP 5280. Only a slight increase in the 
free platinum content was observed with respect to AP 5280 drug substance. 
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Formulation process development 
Based on the findings in the preformulation studies, an aseptic formulation process followed 
by lyophilization was selected as most appropriate for AP 5280. Freeze-drying eliminates 
water from the product, thereby reducing chemical degradation rates and increasing the shelf-
life.  
An aqueous solution at a concentration of 10 mg/ml Pt (corresponding to approximately 125 
mg/ml AP 5280) was selected as the formulation solution. Preparation of a product for 
intravenous use is preferentially performed employing as few excipients as necessary, due to 
possible intrinsic toxicity or activity of the excipient itself or to interactions between the new 
drug substance and the additives, leading to unknown effects on the activity of the new drug 
substance [14]. AP 5280 required no bulking agents, excipients to improve solubility, or 
cryoprotectants in order to manufacture a product of a quality equal to the drug substance. 
The formulation process thus consisted of dissolution of AP 5280 in sterile WfI. A sterile, 
hydrophilic 0.22 µm filter for sterile filtration of the formulation solution (Millipak® 40, 
consisting of modified polyvinylidene fluoride (PVDF) membranes in a polycarbonate 
housing) was found to be compatible with the formulation solution and to comply with 
pharmacopoeial standards. Peroxide cured silicone tubing (Watson Marlow, Cheltenham, 
UK) was chosen for transport of the formulation solution during the filtration and filling 
processes, because it was inert, autoclavable, and met pharmacopoeial specifications with 
respect to extractables. The platinum content of the formulation solution before and after 
filtration was proven to be equal (Pt content before filtration: 8.4 ± 0.2%, Pt content after 
filtration: 8.4 ± 0.3%, n=3), thus no retention of AP 5280 by filters tubing used in the 
manufacturing process took place.  
One major problem was encountered upon manufacture of AP 5280 lyophilized product. 
Initially, the platinum content was set at 200 mg Pt per vial. The batches produced by filling 
20 ml formulation solution into 30 ml glass vials showed a breakage rate ranging from 11 to 
33%. Breakage of vials has been previously described for solutions containing mannitol and 
is usually the result of large fill heights and volumes, high concentrations of the substance to 
be lyophilized, and/or high freezing rates [15, 16]. In view of the expected increase in vial 
content in the course of the clinical study, decrease of the concentration of the AP 5280 
formulation solution was not considered an option. For mannitol solutions, it was found that 
a freezing rate between 0.1 and 1.0°C/min decreased vial breakage as compared to faster and 
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slower freezing rates [15]. As the freezing rate of AP 5280 formulation solution was already 
0.3°C/min, alteration of this rate was not expected to reduce breakage. Therefore, the use of 
larger vials, and thereby reduction of the fill height, was investigated. When 50 ml glass vials 
were employed, no vial breakage was observed. Therefore, breakage of vials was apparently a 
result of the large fill height.  
As the Phase I clinical trials progressed and administered doses of AP 5280 increased, it was 
decided to double the content of AP 5280 per vial, as this would be more convenient for 
preparation of the infusion solutions. However, if the fill height in the 50 ml glass vials was 
increased, similar breakage as experienced for the 20 ml fill volume in the 30 ml glass vials 
could be expected. Therefore, the use of CZ-resin vials was considered, as these are claimed 
to have a considerably higher impact strength compared to glass vials [17]. Preparation of a 
test batch showed that the quality of the lyophilized product was not influenced by the change 
in primary container (Table 3). As transport of CZ-resin vials is more convenient than 
transport of glass vials due to their smaller likelihood of breakage and lower weight (and thus 
reduction of transport costs), the switch to CZ-resin vials was made. Although the CZ-resin 
vials may show ingress of oxygen and may thus be inappropriate for packaging oxygen-
sensitive formulations [18], AP 5280 has not shown any sign of oxygen-sensitivity. 
Furthermore, stability studies were performed to monitor the quality of AP 5280 lyophilized 
product in time and determine if it remained unchanged upon storage.  
Stability studies 
Storage of the lyophilized product 
Table 3 shows the results obtained thus far for the stability studies. To date, AP 5280 
lyophilized product in glass and CZ-resin vials proved to be stable for 12 and 6 months, 
respectively, when stored at 2-8°C, in the dark. No major changes were observed in any of the 
parameters, although the CZ-resin vials show a slight increase in moisture content, but the 
results still conform to specifications. Therefore, refrigerated conditions (2-8°C, dark) were 
chosen as the storage condition of AP 5280 lyophilized product.  
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Photostability 
AP 5280 drug substance and AP 5280 lyophilized product inside and outside its glass and CZ-
resin vials underwent photostability studies. The average temperature during exposure was 
28°C. 
The results obtained for the photostability study are shown in Table 4. Although the free 
platinum content of the exposed sample of AP 5280 drug substance had quadrupled as 
compared to the dark control, the results still conformed to specifications. However, liberated 
platinum content after 24 hours, the weight molecular weight, and the polydispersity index of 
the exposed sample were out of specification. The results obtained for AP 5280 drug 
substance after exposure to light indicated that it is photolabile. Therefore, AP 5280 drug 
substance should be stored protected from light.    
For AP 5280 lyophilized product the product exposed in the glass vials shows a pH after 
reconstitution that is out of specification and the product taken out of its glass primary 
container exposed in a petri dish does not conform to the SEC specifications. The weight 
molecular weight of this product exceeded the upper limit set for this parameter. The SEC 
results indicate that the lyophilized product when removed from the glass primary container 
experienced further polymerization upon exposure to light of high intensity, just like the drug 
substance. The product inside the glass primary container showed no such changes in 
molecular weight parameters and it thus seems that the glass vial provided protection against 
this effect. The product in the glass vials exposed to light of high intensity (both inside and 
out of its glass primary container) showed an increase in the liberated and free platinum 
content when compared to the dark controls, but the results still comply with the 
specifications.  
For the product in the CZ-resin vials, both exposed samples (inside and out of the primary 
container) showed a liberated platinum content after 3 hours that was out of specification. 
Furthermore, the exposed sample in the primary container also had a free platinum content 
that deviated significantly from the dark control. This indicates that AP 5280 lyophilized 
product inside and out of the CZ-resin vials is photolabile. 
In conclusion, AP 5280 lyophilized product, when produced in glass or CZ-resin vials, both 
inside and out of the primary container, is sensitive to photodegradation and should be stored 
in the dark.  
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Stability after reconstitution and dilution to infusion concentrations 
Stability of AP 5280 after reconstitution and dilution to infusion concentrations has been 
described elsewhere [19]. AP 5280 should be reconstituted and diluted to infusion 
concentration with 5% dextrose and administered within 8 hours after preparation to ensure 
that less than 1.0% of the total platinum concentration is present as free platinum.   
 
Conclusions 
Manufacture of a lyophilized product of the investigational polymer-conjugated anticancer 
agent AP 5280 from an aqueous solution has provided the formulation method with the least 
impact on the integrity of AP 5280. Due to breakage of glass vials and in the course of 
upscaling, CZ-resin vials were chosen as the primary container. AP 5280 lyophilized product 
in CZ-resin vials is stable for six months when stored at refrigerated conditions and needs to 
be stored protected from light. AP 5280 is currently in Phase I clinical trials. The first clinical 
data [20] indicate that the proposed formulation is fully applicable in the clinical setting.    
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Abstract 
AP 5280 is a novel polymer-conjugated platinum anticancer agent currently undergoing Phase 
I clinical trials. It is pharmaceutically formulated as a lyophilized product containing 200 mg 
platinum per dosage unit. The aim of this study was to determine the reconstitution and 
dilution fluid of choice and to investigate the stability and compatibility of AP 5280 in 
solution under different storage conditions and with several container materials. Furthermore, 
the hemolytic potential of AP 5280 infusion solution was investigated in vitro. AP 5280 
slowly released small platinum species in all solutions, although this release was enhanced in 
normal saline. Accordingly, 5% dextrose in water (D5W) was selected for reconstitution and 
dilution of AP 5280. Container material (glass or polyvinylchloride (PVC)) did not influence 
the stability of AP 5280 in solution. Storage at refrigerated temperature (+2-8ºC) marginally 
decreased the release rate of liberated platinum. The infusion solutions are compatible with 
the PVC infusion system and do not cause hemolysis in vitro. In conclusion, AP 5280 
lyophilized product should be reconstituted and diluted to infusion concentration with D5W 
and administered within 8 hours after preparation to ensure that less than 1.0% of the total 
platinum concentration is present as liberated platinum.  
Stability and compatibility of AP 5280 
 175
 
Introduction 
AP 5280 (a random copolymer of N-2-hydroxypropyl methacrylamide and the 
methacrylamide of GFLG-ama=Pt(NH3)2, molecular weight 25 ± 3 kDa, Figure 1) is a novel 
copolymer-conjugated platinum compound, designed for tumor targeting. In this copolymer, 
platinum is linked to a N-2-hydroxypropyl methacrylamide (HPMA) backbone via a 
tetrapeptide spacer (glycine-phenylalanine-leucine-glycine, or GFLG), and an amidomalonic 
acid (ama) chelating agent. Due to the hyperpermeable nature of the neovasculature of tumors 
in combination with their limited lymphatic and/or capillary drainage, it is expected that AP 
5280 will preferentially accumulate at the tumor site [1-4]. Subsequently, platinum is released 
from the polymer intratumorally by lysosomal thiol-dependent proteinases, enzymes known to 
be elevated in human tumors [5]. Theoretically, AP 5280 administration will lead to higher 
intratumoral platinum concentrations and therefore potentially greater efficacy than the 
currently marketed non-polymer platinates cisplatin, carboplatin, and oxaliplatin. Preclinical 
studies show that AP 5280 has a higher therapeutic index than cisplatin and carboplatin when 
administered to mice implanted with several different types of tumor [6]. 
 
 
Figure 1.  Chemical structure of AP 5280. Molecular weight 24 ± 3 kDa, polydispersity index 
1.2-2.3. 
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AP 5280 is pharmaceutically formulated as a lyophilized solid for intravenous infusion 
containing 200 mg platinum per dosage unit and has recently entered Phase I clinical trials 
[7]. Before commencement of the clinical trials, we investigated the stability of AP 5280 in 
two commonly used infusion solutions (5% w/v dextrose in water - D5W - or 0.9% w/v 
sodium chloride - normal saline) at various concentrations and storage conditions. Stability 
was measured as the release of small platinum species (“liberated platinum”) from the 
copolymer carrier into the infusion solution, a process that could affect both activity and 
toxicity of the compound in vivo. Compatibility with containers composed of glass and 
polyvinylchloride (PVC) was examined in terms of sorption to container surfaces and release 
of the plasticizer diethylhexylphthalate (DEHP). Subsequently, infusion simulation 
experiments were performed and the hemolytic potential of AP 5280 solutions was 
investigated in vitro. This paper describes the stability and compatibility of AP 5280 in 
solution for clinical application.  
 
Materials and Methods 
Chemicals 
Access Pharmaceuticals, Inc (Dallas, Texas, USA) provided AP 5280 drug substance and 
HPMA homopolymer (poly-HPMA, or pHPMA). AP 5280 lyophilized product containing 
200 mg platinum per dosage unit (2.5 g AP 5280), 5% dextrose in water (D5W) and normal 
saline in glass bottles were manufactured in-house (Department of Pharmacy and 
Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands). D5W in 50 and 500 ml 
PVC containers (Intraflex) was obtained from B. Braun Medical BV (‘s Hertogenbosch, The 
Netherlands). Platinum atomic absorption standard was purchased from Sigma-Aldrich 
Chemie (Zwijndrecht, The Netherlands). Paraplatin® (carboplatin 50 mg/vial) originated from 
Bristol-Myers Squibb BV (Woerden, The Netherlands) and Platosin (cisplatin 1 mg/ml) 
from Pharmachemie (Haarlem, The Netherlands). Fresh, citrated blood and plasma 
ultrafiltrate were purchased from the local blood bank (Central Laboratory for Blood 
transfusion (CLB), Amsterdam, The Netherlands). Hydrochloric acid 37% was purchased 
from Merck (Darmstadt, Germany) and methanol from Biosolve Ltd. (Amsterdam, The 
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Netherlands). All chemicals were of analytical grade and used without further purification. 
Distilled water was used throughout the experiments.  
Total platinum analysis  
Total platinum concentrations were measured using a Perkin Elmer 3100 Flame Atomic 
Absorption Spectrometer (F-AAS) (Perkin Elmer BV, Nieuwerkerk a/d IJssel, The 
Netherlands). A slit width of 0.7 nm, wavelength of 266 nm, and air-acetylene flame were 
employed. Platinum standards (0.0392, 0.03136 and 0.02352 mg/ml) and quality control 
samples (0.03528, 0.03136 and 0.02352 mg/ml) in 0.4 mg/ml pHPMA in 50/50% (v/v) 0.4% 
hydrochloric acid/methanol were used for quantification of total platinum concentrations. 
Samples analyzed for their total platinum concentration were diluted with 50/50% (v/v) 0.4% 
HCl/methanol to yield a theoretical total platinum concentration of approximately 0.03 
mg/ml.  
Liberated platinum analysis 
Liberated platinum concentrations were measured using a SpectrA-A 30/40 Zeeman Graphite 
Furnace Atomic Absorption Spectrometer (AAS) (Varian, Techtron Pty Ltd, Victoria, 
Australia), consisting of a spectrometer, GTA-75 autosampler and a DS-15 data station 
equipped with the Quality Control Protocol software package (Varian). Absorbances were 
recorded at 265.9 nm, a slit bandwidth of 0.2 nm and a time constant of 0.05 s. Argon was 
used to purge the graphite tube. The temperature program of the instrument is shown in Table 
1. Carboplatin calibration curves and cisplatin quality control standards were used to quantify 
the results and validate the analysis [8]. 
Before analysis, samples were ultrafiltered through a Centricon YM-3 filter (3 kDa cut-off; 
Millipore BV, Etten-Leur, The Netherlands). The platinum concentration in each sample was 
analyzed in duplicate and the mean value used for further calculations.  
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Table 1.  Temperature program of the AAS instrument. 
Step no. Temperature (°C) Time (s) Gas flow (L/min) 
1 50 1.0 3.0 
2 85 5.0 3.0 
3 95 30.0 3.0 
4 120 20.0 3.0 
5 250 30.0 3.0 
6 1400 40.0 3.0 
7 1400 20.0 3.0 
8 1400 2.0 0.0 
9 2800 0.7 0.0 
10 2800 2.0 0.0 
11 2800 4.0 3.0 
12 50 13.8 3.0 
 
Chromatography for DEHP determination  
DEHP release from the PVC containers was analyzed using a reversed phase High 
Performance Liquid Chromatography (HPLC) method as previously described [9]. 
Ultrafiltrate samples were injected directly into the system to determine whether any DEHP 
was present. 
195Pt NMR spectroscopy 
195Pt NMR spectra were recorded with a Bruker DPX 300 spectrometer with a 5 mm multi-
nucleus probe. A variable temperature unit was used to maintain the temperature at 298 K. 
The 195Pt NMR spectra were calibrated using K2PtCl4 as an external reference at δ=-1614 
ppm. Samples were measured in solutions containing 5% D2O. Only AP 5280 reconstituted 
solutions contained a platinum concentration high enough to perform 195Pt NMR 
spectroscopic analysis.  
Stability and compatibility 
AP 5280 lyophilized product for intravenous infusion containing 200 mg platinum per dosage 
unit was reconstituted with 14.7 ml D5W or normal saline in its primary container (30 ml 
glass type I lyophilization vials obtained from the Münnerstädter Glaswarenfabrik, 
Münnerstadt, Germany). The resulting solutions had a volume of 16 ml and a theoretical 
platinum content of 12.5 mg/ml and were stored at either room temperature (+20-25°C, 
ambient light) or refrigerated conditions (+2-8°C, dark). Reconstituted solutions were further 
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diluted to yield AP 5280 infusion solutions at concentrations of 0.306, 1.53 and 3.06 mg/ml 
platinum (3.8, 19.1 and 38.3 mg/ml AP 5280, respectively) in D5W or normal saline in 50 ml 
glass containers stored at room temperature. Based upon the initial examinations, D5W was 
selected for further stability and compatibility tests. Infusion solutions in 50 ml PVC 
(Intraflex®) containers were prepared and stored at room temperature or refrigerated 
conditions. All solutions were prepared in triplicate and samples were taken immediately after 
preparation and after 1, 2, 4, 8, 24, 48, 72 and 96 hours of storage and analyzed for total and 
liberated platinum concentrations. DEHP concentrations in samples from the solutions stored 
in Intraflex® containers were determined after 96 hours storage. Furthermore, immediately 
after preparation and after 96 hours storage, 195Pt NMR spectra of the reconstituted solutions 
(12.5 mg/ml platinum) stored at room temperature were recorded. All reconstituted and 
diluted infusion solutions were visually checked for clarity. 
Infusion simulation experiments 
AP 5280 infusion simulations were conducted using an infusion system consisting of a 500 ml 
Intraflex container, PVC tubing regularly used for the infusion of cytotoxic agents (type 
IVAC G52703; IVAC, San Diego, CA, USA) and a needle (Microlance 0.8 x 40 mm; Becton 
Dickinson, Franklin Lakes, NJ, USA). AP 5280 infusion solutions at concentrations of 0.306, 
1.53 and 3.06 mg/ml platinum in D5W were prepared and infusion rates set at 0.35 ml/min for 
a duration of 24 hours. All infusion simulations were performed in triplicate at room 
temperature. Samples were taken from the needle outlet at 0, 1, 2, 4, 8 and 24 hours after 
preparation and analyzed for total and liberated platinum content. The 24-hour samples were 
assayed for the presence of DEHP. The total amount of platinum delivered by each infusion 
system was calculated from the infusion rate and the area under the total platinum 
concentration-time curves (AUCs) (equation 1).  
 Total amount of platinum delivered (mg) = AUC (mg/ml.h) x infusion rate (ml/h) (1) 
The AUCs were calculated using the trapezoidal rule. The same calculations were performed 
to estimate the total amount of liberated platinum delivered by the infusion systems. 
Hemolysis  
The potential of AP 5280 infusion solutions at a concentration of 3.06 mg/ml Platinum in 
D5W to cause hemolysis was examined using both the static and dynamic in vitro test models 
Chapter 2.3 
 180
as described by Ward et al [10] and Krzyzaniak et al. [11-13]. The hemolytic potentials of 
solutions of D5W, 2.5 mg/ml cisplatin in D5W, and 39.2 mg/ml pHPMA in D5W were 
determined for comparison. For the static model, 25, 100 and 250 µL infusion solution was 
added to 500 µL blood, resulting in formulation:blood ratios of 0.05, 0.2 and 0.5, 
respectively. The solutions were slowly whirl-mixed for 5 seconds. For the dynamic model, 
each solution was infused at rates of 0.3 and 1.2 ml/min using a Model 711 syringe pump 
(IVAC, San Diego, USA) into a tube containing blood flowing at a rate of 6 ml/min 
employing a Model 501 Dz peristaltic pump (Watson Marlow, Rotterdam, the Netherlands), 
which resulted in formulation:blood ratios of 0.05 and 0.2, respectively. The contact time with 
blood was set at 5 seconds by administering the infusion solution 25 cm from the end of the 
silicone tubing transporting the blood (∅1.6 mm, Watson Marlow). For both models, the 
hemolytic reaction was quenched by addition of 50 ml normal saline to the blood sample. 
Subsequently, an aliquot of the diluted test solution was centrifuged at 3000 rpm for 10 
minutes. The absorption (A) of the resulting supernatant was measured at 540 nm with a 
Model UV/VIS 918 spectrophotometer (GBC Scientific Equipment, Victoria, Australia). 
The baseline degree of hemolysis was measured using normal saline at the same 
formulation:blood ratios. The 100% hemolysis level was determined by diluting the blood 
used in both the static and dynamic model with 50 ml distilled water instead of normal saline. 
As a positive control, a mixture of 40/10/50% (v/v/v) propylene glycol/ethanol/water (PEW) 
was used [12]. All experiments were run in triplicate. The percentage hemolysis induced by 
all solutions was calculated using equation 2: 
 % Hemolysis = (Atest solution-Anormal saline)/(A100%-Anormal saline) x 100% (2) 
 
Results and discussion 
Before commencement of Phase I clinical trials several pharmaceutical issues of AP 5280 
infusion solutions were investigated to ensure the suitability of the solutions to be 
administered to patients. AP 5280’s proposed starting dose in Phase I clinical studies was 90 
mg platinum/m2, administered in 500 ml as an 1-hour infusion every three weeks. We 
investigated a dose range of 90-900 mg platinum/m2, corresponding to 153 – 1530 mg 
platinum, for a patient with a body surface area of 1.7 m2.  
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All currently marketed platinum drug products have specific requirements with respect to the 
infusion solution employed for reconstitution and dilution, in particular to the presence of 
chloride ions. Furthermore, the storage conditions of the platinum infusion solutions may 
influence the stability. For instance, cisplatin (Platinol) is only chemically stable in solutions 
containing at least 0.2% NaCl; in solutions with a lower chloride concentration, one or both 
of cisplatin’s chloride ions are displaced by water, forming the toxic mono- and diaqua 
species. Furthermore, when stored at refrigerated temperatures, formation of a precipitate 
occurs which is difficult to redissolve, necessitating storage of cisplatin solutions at 15-25°C 
[14-16]. Carboplatin (Paraplatin®) solutions in normal saline, on the other hand, degrade more 
rapidly than solutions in D5W, which are stable for at least 24 hours at room temperature [14-
16]. Contact of oxaliplatin (Eloxatin®) with normal saline results in chemical modifications 
and formation of a precipitate, requiring the use of D5W for reconstitution and dilution  
[17,18]. Carboplatin and oxaliplatin solutions can be stored at either room temperature or 
refrigerated conditions [14,18]. 
For AP 5280, initially small-scale stability and compatibility studies were performed to 
determine the optimal infusion solution, container and storage condition. Subsequently, an 
infusion simulation was carried out employing administration parameters intended for use in 
the clinical setting. 
Release of liberated platinum 
A 3 kDa cut-off value was used to define “small platinum species” and thus the liberated 
platinum content. Figures 2 and 3 depict the percentage platinum released from the polymer 
with time (expressed as the liberated platinum concentration relative to the total platinum 
concentration) for AP 5280 solutions in D5W and normal saline, respectively, when stored at 
room temperature in glass containers. The total platinum concentration in all solutions 
remains constant with time and is in agreement with the theoretical total platinum 
concentration. This indicates that there is no platinum loss due to e.g. sorption to container 
walls.  
The data shown in Figures 2 and 3 indicate that a low concentration of small platinum species 
is present in all investigated AP 5280 solutions. In D5W, the level of liberated platinum shows 
an initial burst, probably due to release of loosely bound platinum resulting from the 
manufacturing process and the presence of small polymer species that successfully pass  
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Figure 2. Release of liberated platinum from AP 5280 in D5W solutions when stored in glass 
containers at room temperature. & = AP 5280 after reconstitution (12.5 mg/ml Pt), ! = 
AP 5280 high concentration infusion solution (3.06 mg/ml Pt), h = AP 5280 medium 
concentration infusion solution (1.53 mg/ml Pt), ) = AP 5280 low concentration infusion 
solution (0.306 mg/ml Pt). 
 
 
 
 
 
 
 
Figure 3. Release of liberated platinum from AP 5280 in normal saline solutions when stored in glass 
containers at room temperature. & = AP 5280 after reconstitution (12.5 mg/ml Pt), ! = 
AP 5280 high concentration infusion solution (3.06 mg/ml Pt), h = AP 5280 medium 
concentration infusion solution (1.53 mg/ml Pt), ) = AP 5280 low concentration infusion 
solution (0.306 mg/ml Pt). 
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through the pores of the filter membrane. After 8-24 hours a plateau of approximately 1.5% 
liberated platinum is reached, which is independent of the AP 5280 concentration. However, 
in normal saline this release process occurs continuously and the liberated platinum 
concentration increases to 3-4% after 96 hours at room temperature (Figure 3). These results 
indicate that release of small platinum species from AP 5280 in solution is enhanced by the 
presence of sodium chloride or one of its components, most likely chloride ions. In normal 
saline solutions, the release process is concentration-dependent, with the lowest AP 5280 
concentration releasing, relatively, the most liberated platinum. This is most likely due to the 
relative abundance of chloride ions with respect to AP 5280 at low concentrations.  
D5W is more suitable as reconstitution and dilution fluid for AP 5280 than normal saline. 
Therefore, further investigations into the stability and compatibility of AP 5280 were 
conducted using D5W.    
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Release of liberated platinum from AP 5280 in D5W solutions when stored in glass 
containers at refrigerated conditions. & = AP 5280 after reconstitution (12.5 mg/ml Pt), 
! = AP 5280 high concentration infusion solution (3.06 mg/ml Pt), h = AP 5280 
medium concentration infusion solution (1.53 mg/ml Pt), ) = AP 5280 low 
concentration infusion solution (0.306 mg/ml Pt). 
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Stability and compatibility 
Figure 4 shows the percentage liberated platinum with respect to total platinum concentration 
of AP 5280 in D5W solutions stored in glass containers at refrigerated conditions. Again, total 
platinum concentrations remain unchanged, while the liberated platinum concentration 
reaches a plateau after 8 hours storage, which is slightly lower (0.2-0.5%) than observed for 
the solutions in D5W stored at room temperature (1.5%, see Figure 2).  
Table 2 shows the total and liberated platinum concentrations of AP 5280 infusion solutions 
in D5W stored in Intraflex PVC containers at both room temperature and refrigerated 
conditions at selected time points. For all solutions a plateau in liberated platinum release is 
reached after 8-24 hours storage, which appears concentration- and marginally storage 
condition-dependent. The highest concentration AP 5280 infusion solution at room 
temperature shows a maximum liberated platinum concentration of about 1.5% and the lowest 
concentration AP 5280 infusion solution at refrigerated condition of about 0.8%. Percentages 
liberated platinum found in Intraflex containers are comparable to the percentages found in 
AP 5280 solutions stored in glass containers. 
Total platinum for all investigated AP 5280 solutions is stable in time and approximately 
equal to the theoretical total platinum concentrations, indicating that no sorption to container 
walls takes place during storage. Any deviation from the theoretical total platinum 
concentrations is a result of the preparation of the solutions and analytical variation. No 
precipitate formation was observed in any of the AP 5280 solutions. The lack of visual 
detection of precipitation is confirmed by the stable total platinum concentrations in time. AP 
5280 is very soluble in water, and hence not likely to precipitate. 
A drawback for the use of PVC administration sets is the possible extraction of plasticizers 
(“leaching”) by the solubilized formulation. Leaching of DEHP, for instance, has been 
described for infusion solutions containing surfactants [19-21]. AP 5280 infusion solutions 
are free from such additives. Nevertheless, as teratogenic and hepatotoxic effects have been 
ascribed to DEHP [22,23], it was deemed important to check for any leaching of DEHP due to 
AP 5280 infusion solutions. No DEHP could be detected in any of the samples (detection 
limit: 0.5 µg DEHP/ml) and clearly AP 5280 infusion solutions do not cause significant 
leaching of DEHP from the PVC (Intraflex) containers. 
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Figure 5.  195Pt NMR spectrum of AP 5280 after reconstitution with D5W after 96 hours storage at 
room temperature. 
 
Figure 5 depicts the 195Pt NMR spectrum of the reconstituted solution in D5W at room 
temperature after 96 hours of storage. The spectra of the same solution immediately after 
preparation and of the AP 5280 reconstituted solutions in normal saline immediately after 
preparation and after 96 hours storage were identical. These results indicate that platinum 
binding characteristics do not change for at least 96 hours. It should be noted, however, that 
the sensitivity of the method is inadequate to detect a small percentage release of liberated 
platinum. This is illustrated by the fact that the solution in normal saline after 96 hours 
storage shows the same 195Pt NMR spectrum as the solution in D5W, while its concentration 
of small platinum species is 4%. The presence of liberated platinum in a concentration as high 
as 4% of the total platinum concentration is not detected by 195Pt NMR spectroscopy. 
The initial experiments show that AP 5280 solutions in D5W are chemically stable for at least 
96 hours. As no difference was observed between the stability of AP 5280 in D5W solutions 
stored in glass or PVC containers, it was decided to employ Intraflex containers for AP 5280 
infusions in the clinic. This choice was made because of the smaller chance of breakage and 
thus exposure of both hospital staff and patients to cytotoxic agents, and convenience of 
handling.  
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Infusion simulation experiments 
In order to set the final administration parameters, infusion simulation experiments were 
performed employing 500 ml Intraflex containers containing AP 5280 in D5W, a PVC 
infusion line (1.5 m length) and a needle. An infusion duration of 24 hours was employed to 
evaluate the liberated platinum release profile in the infusion system. 
Table 3 shows the total and liberated platinum concentrations in time and the total amounts of 
platinum and liberated platinum delivered after 24 hours by each infusion system. Again, all 
three concentrations showed a stable total platinum concentration in time. The total amount of 
platinum delivered was within 90-110% of the theoretical amount for all concentrations 
tested. Deviations from 100% total platinum delivery can be attributed to the preparation of 
the infusion solutions and analytical variation.  
Based on its proposed mode of action, the integrity of AP 5280 upon administration is of 
great importance. Stability of AP 5280 in solution has been evaluated by the extent and rate of 
platinum release (“liberated platinum”) from the polymer. Using the ultrafiltration method to 
separate bound from liberated platinum all platinum species smaller than 3 kDa are gathered 
in the ultrafiltrate. At this moment, identities of the platinum species in the ultrafiltrate are 
unknown as well as their pharmacological effect. Therefore, it is felt that it is important to 
keep the levels of liberated platinum as low as possible in AP 5280 infusion solutions.  
In the 24 hour infusion simulation experiment, approximately 0.6% of the total platinum dose 
was delivered as liberated platinum, regardless of the infusion concentration. For the moment, 
the specification for the liberated platinum concentration has been set at 1.0% of the total 
platinum concentration. In order to keep within safe margins of this specification, AP 5280 
should be reconstituted, diluted and administered within 8 hours. 
No DEHP was detected in any of the 24-hour samples. 
Table 3. 
Total and liberated platinum
 concentrations (m
g/m
l) ± standard deviation of AP 5280 infusion solutions in D
5 W
 in 500 m
l PVC
 containers for 
the infusion sim
ulation study.  
Total platinum
 concentration (m
g/m
l Pt) ± SD
 
Liberated platinum
 concentration (m
g/m
l Pt) ± SD
 
(percentage of total platinum
 concentration) 
Tim
e 
(hrs) 
H
igh 
M
edium
 
Low
 
H
igh 
M
edium
 
Low
 
0 
2.97 ± 0.11 
1.52 ± 0.02 
0.35 ± 0.03 
0.0104 ± 0.0053  
(0.35%
) 
0.0077 ± 0.0017 
(0.51%
) 
0.0021 ± 0.0002 
(0.60%
) 
1 
2.97 ± 0.04 
1.52 ± 0.04 
0.35 ± 0.03 
0.0108 ± 0.0007 
(0.36%
) 
0.0071 ± 0.0001 
(0.47%
) 
0.0013 ± 0.0003 
(0.37%
) 
2 
2.89 ± 0.08 
1.48 ± 0.02 
0.35 ± 0.02 
0.0195 ± 0.0012 
(0.67%
) 
0.0094 ± 0.0036 
(0.64%
) 
0.0015 ± 0.0004 
(0.43%
) 
4 
2.82 ± 0.08 
1.52 ± 0.04 
0.34 ± 0.02 
0.0140 ± 0.0024 
(0.50%
) 
0.0087 ± 0.0028 
(0.57%
) 
0.0016 ± 0.0001 
(0.47%
) 
8 
2.75 ± 0.04 
1.45 ± 0.02 
0.32 ± 0.03 
0.0162 ± 0.0037 
(0.59%
) 
0.0080 ± 0.0021 
(0.55%
) 
0.0019 ± 0.0006 
(0.59%
) 
24 
2.83 ± 0.07 
1.41 ± 0.08 
0.34 ± 0.03 
0.0130 ± 0.0028 
(0.50%
) 
0.0099 ± 0.0049 
(0.70%
) 
0.0029 ± 0.0009 
(0.85%
) 
Total am
ount of  
(liberated) 
platinum
 
delivered 
1413.6 m
g 
(92.4%
) a 
741.6 m
g 
(96.9%
) a 
168.8 m
g 
(110.7%
) a 
7.36 m
g 
(0.52%
) b 
4.38 m
g 
(0.59%
) b 
1.08 m
g 
(0.64%
) b 
H
igh =
 3.06 m
g/m
l Pt, M
edium
 =
 1.53 m
g/m
l Pt, Low
 =
 0.306 m
g/m
l Pt. a Relative am
ount of platinum
 adm
inistered w
ith respect to the theoretical total 
platinum
 dose. b Relative am
ount of liberated platinum
 adm
inistered w
ith respect to total platinum
 dose. 
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Hemolysis 
Hemolysis can cause a wide range of undesirable medical conditions, such as jaundice, 
kernicterus, hemoglobinuria, nephrosis and acute renal failure. Death can occur when 
hemolysis becomes severe. Every effort must therefore be made to minimize the occurrence 
of hemolysis and an evaluation of the ability of a formulation to induce this condition is 
therefore an important component of the development of an intravenous formulation [24].    
AP 5280 infusion solutions are iso-osmotic and of neutral pH and are therefore not expected 
to cause large disruptions in erythrocyte integrity. To date, not many polymers have been 
found to cause hemolysis. In fact, some polymers such as poyvinylpyrrolidone (PVP), dextran 
and hydroxyethylstarch (HES) act in an antihemolytic manner [25]. Other polymers such as 
poly(amidoamines) [26] and polyimides [27] cause little to no hemolysis. However, some 
solid phase poly(methyl methacrylate) formulations were shown to cause hemolysis [28].  As 
AP 5280 is related to poly(methyl methacrylate), it was felt important to test it for its 
hemolytic potential. 
AP 5280 will be administered at an infusion rate of 8.3 ml/min. The venous blood flow is 
approximately 40 ml/min (an estimate for the broad range of blood flows in the circulatory 
system [12]), leading to a formulation:blood (F/B) ratio of 0.2. To evaluate the effect of a 
varying infusion rate, F/B ratio´s of 0.05 and 0.5 were also investigated. Instead of a contact 
time of 1 second between the test solution and blood, as described by Krzyzaniak et al to be 
physiologically realistic for an intravenous bolus injection [11-13], a longer contact time of 5 
seconds was employed to mimic the continuous exposure of blood to the administered agent 
during prolonged intravenous infusions [9]. 
To differentiate between possible hemolytic effects caused by platinum and those caused by 
polymer, solutions of 2.5 mg/ml cisplatin (the maximum solubility of cisplatin) and 39.2 
mg/ml pHPMA (corresponding to a platinum concentration of 3.06 mg/ml in AP 5280) in 
D5W were tested. 
No hemolysis was detected for any of the solutions tested in either the static or dynamic 
model, except for the positive control, which showed increasing degrees of hemolysis with 
increasing F/B ratio´s; up to 88% hemolysis for the F/B ratio of 0.5 in the static model (data 
not shown). Therefore, infusion of AP 5280 solutions is not expected to cause any hemolysis 
upon intravenous administration. 
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Conclusions 
AP 5280 lyophilized product for intravenous infusion was subjected to a series of in vitro 
tests to evaluate its suitability for intravenous administration and for its potential to cause 
hemolysis.  AP 5280 in solution slowly releases liberated platinum, a process enhanced by the 
presence of chloride ions. Therefore, AP 5280 lyophilized product should be reconstituted 
and diluted with D5W. Container material (glass or PVC) does not affect the stability of AP 
5280 in solution. Storage at refrigerated conditions slows down the liberated platinum release 
in AP 5280 solutions. In the infusion simulation experiments, the total amount of liberated 
platinum delivered was low and no DEHP leaching was observed. Finally, no hemolysis was 
shown to occur upon static and dynamic hemolysis tests. In conclusion, AP 5280 should be 
reconstituted and diluted using D5W and either glass or PVC containers can be employed for 
administration of AP 5280 infusion solutions, although for practical reasons PVC containers 
are preferred. Administration should take place within 8 hours after preparation of the 
infusion solutions to ensure that less than 1.0% of the total platinum concentration is present 
as liberated platinum. 
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Summary and concluding remarks 
Cancer is one of the major causes of death in the western world. Current treatment of cancer 
is limited to surgery, radiotherapy, and/or chemotherapy, despite its well-known side effects 
and problems associated with the development of resistance. For most forms of 
(disseminated) cancer, however, no curative therapy is available and the discovery and 
development of novel, active anticancer agents (chemotherapeutics, cytotoxics) is desperately 
needed.  
When a novel anticancer agent is discovered, it is very rarely administered as the pure 
chemical compound itself. It is almost always processed, or formulated, into a well-defined 
pharmaceutical product, which is suitable for the intended use in humans. Anticancer agents 
for experimental use are generally intended for intravenous administration (as injection or 
infusion) to ensure absolute bioavailability, to prevent degradation in the gastrointestinal tract 
(before absorption into the bloodstream), and to be able to adjust or stop administration in 
case of acute toxicity. Consequently, the development of a pharmaceutical formulation of a 
novel anticancer agent is aimed at the development of sterile and stable injectable products.  
Cisplatin, or cis-diamminedichloroplatinum(II) is an anticancer agent that has been in use for 
over 30 years. It contains a platinum atom that is responsible for the anticancer activity. 
Cisplatin is used against many types of cancer and few other anticancer agents have been 
proven as effective as this agent. However, serious side effects, the most prominent of which 
are nefro-, oto- and neurotoxicity and severe nausea and vomiting, limit its clinical use. 
Another major clinical problem is tumor resistance, which can be either intrinsic or acquired. 
The limitations of cisplatin in the clinic have stimulated the search for alternative 
pharmaceutical formulations of cisplatin, alternative complexes containing platinum, and 
compounds containing other heavy metals than platinum, with more acceptable toxicity 
profiles, but retention, and if possible expansion, of efficacy and activity. This has led to the 
development of NAMI-A and AP 5280, amongst others. This thesis is dedicated to the 
development of stable, parenteral pharmaceutical formulations of these two compounds. For 
each agent, initially the development of analytical methods, necessary for the characterization 
and quality control of both the drug substance and the pharmaceutical product, is described. 
For NAMI-A, the degradation in solution and upon exposure to light is investigated in 
separate sections. Subsequently, for both NAMI-A and AP 5280, the development of the 
pharmaceutical formulation and its stability is described. The chapters end with studies that 
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were performed to predict the (bio-)compatibility with infusion systems and blood of the 
formulated product upon clinical application.  
NAMI-A 
Chapter 1 describes the pharmaceutical development of NAMI-A, imidazolium trans-
tetrachloro(dimethylsulfoxide)imidazoleruthenium (III), a ruthenium-based agent that proved 
to be effective against metastases of cancer in animal studies, while showing few side effects. 
Its action appeared independent of the origin (type) of the tumor and the size and extent of the 
metastases. NAMI-A showed no direct influence on the growth of tumor cells, although an 
interaction with the regulation of the cell cycle was found in a transient accumulation of cells 
in the G2/M phase. More important to its mechanism of action appears the fact that NAMI-A 
increases formation of connective tissue around tumor cells and capillaries, which in turn 
decreases the blood supply of tumors. Furthermore, in this manner the tumor cells are 
prevented from entering surrounding tissue and blood and lymphatic vessels, thus spreading 
(metastasizing). To allow clinical evaluation of NAMI-A, an intravenous administration form 
was required.  
Chapter 1.1 describes the development and validation of a high pressure liquid 
chromatography (HPLC) method with ultraviolet (UV) detection for the quality control 
(quantification and purity determination) of NAMI-A drug substance and final product. The 
method proved to be linear, accurate, and precise upon validation. Degradation studies by 
exposure of NAMI-A to extreme conditions, such as acid, base, heat, and oxidation, showed 
that the degradation products and NAMI-A were separated employing this method. 
Comparison of the results obtained with nuclear magnetic resonance (NMR) spectroscopy 
with those obtained using the described HPLC method allowed identification of one 
degradation product, in which one chloride ligand was replaced by a hydroxyl group. 
Furthermore, analysis of the HPLC eluate with atomic absorption spectrometry (AAS) 
showed that under most conditions all ruthenium-containing compounds resulted in a peak in 
the HPLC chromatogram and that all ruthenium that was applied to the column was 
recovered. Only for completely degraded solutions of NAMI-A, some ruthenium was retained 
on the column. The HPLC method complied with all specifications for the quality control of 
NAMI-A drug substance and lyophilized product. 
The degradation kinetics of NAMI-A are described in chapter 1.2. The chemical stability was 
investigated as a function of pH, buffer composition, and temperature. Degradation of NAMI-
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A follows first-order kinetics at pH < 6 and zero-order kinetics at pH  ≥ 6. The pH-rate profile 
showed that NAMI-A in solution is most stable at pH 3-4. The reaction rate was not 
significantly influenced by the composition of the buffers. Temperature was of large influence 
on the rate of degradation of NAMI-A, and degradation could be described with the Arrhenius 
equation. 
In chapter 1.3, the photostability, or the stability upon exposure to light, of NAMI-A is 
described. NAMI-A in its solid state does not degrade under the influence of light. In solution, 
however, the compound degraded rapidly, the rate of which was independent of pH at pH 2-5. 
The degradation rate at higher pH values was higher than under acidic conditions. The 
composition of the buffer had little influence. The photostability was inversely related to 
NAMI-A concentration and addition of photostabilizers was not effective. Addition of an 
alcohol, and thus alteration of the polarity of the solution, influenced the photostability of 
NAMI-A in solution to the greatest extent, with the least polar solvent system (50% propylene 
glycol) providing the most stable medium. Based on the presented results, it was 
recommended to store NAMI-A solutions (including the infusion solutions) in the dark.    
Chapter 1.4 describes the development of a pharmaceutical administration form for NAMI-A.    
Although NAMI-A is soluble in water, it was found that the preparation of a solution of 
NAMI-A as such was not feasible due to its low stability in solution. Addition of excipients 
had little effect on the stability of, although it was found that solutions at acidic pH were most 
stable. Therefore, a lyophilized product was developed. Five different formulations were 
prepared, four of which contained an acid (citric acid or hydrochloric acid) to lower the pH pf 
the formulation solution to pH 3-4 and thus keep degradation during the production process as 
low as possible. Differential scanning calorimetry (DSC) of the formulation solutions aided in 
the development of an optimal freeze-drying cycle. The five lyophilized products were 
subjected to thermogravimetric (TG) analysis and stability studies at -20°C, 25°C / 60% 
relative humidity (RH) en 40°C / 75% RH for one year. Of the acids tested, only hydrochloric 
acid was compatible with the lyophilized product and stabilized the formulation solution 
during the production process. This final product was stable for at least one year when stored 
at all three storage conditions and was also photostable. The final formulation solution was 
chosen to contain a solution of 10 mg/ml NAMI-A in 0.1 mM hydrochloric acid, which led to 
a lyophilized product with 100 mg NAMI-A and 0.036 mg hydrochloric acid per dosage unit. 
Determination of the optimal infusion solution for reconstitution and dilution of NAMI-A 
lyophilized product, as well as the stability and (bio-)compatibility of NAMI-A infusion 
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solutions at different storage conditions and with different infusion materials is described in 
chapter 1.5. Furthermore, the buffer capacity of NAMI-A infusion solutions, a measure for the 
expected venous irritation as a result of the low pH, was investigated in vitro. The potential of 
the infusion solutions to cause hemolysis (destruction of red blood cells) was also 
investigated. Normal saline turned out to be the optimal solution for the reconstitution and 
dilution of NAMI-A. Dilution to infusion concentration should take place immediately after 
reconstitution. Infusion solutions can be stored for a maximum of 4 hours at room temperature 
(+20-23°C) or 24 hours at refrigerated conditions (+2-8°C) before administration to the 
patient. The infusion solutions were compatible with glass and PVC containers, but for 
practical reasons (danger of glass breakage), the use of PVC containers is recommended. It 
was found that NAMI-A infusion solutions have a low buffer capacity, also in comparison 
with marketed intravenous anticancer agents, and no irritation of the capillaries is expected 
upon use in the clinic. Furthermore, on the basis of the hemolysis experiments, NAMI-A is 
not expected to cause destruction of red blood cells. 
AP 5280 
AP 5280, poly(N-(2-hydroxypropyl) methacrylamide)-GFLG-Ama=Pt(NH3)2, is a platinum 
compound that is conjugated to a polymer, designed for tumor targeting. In this copolymer, 
platinum is attached to poly-N-(2-hydroxypropyl) methacrylamide (pHPMA) via a 
tetrapeptide spacer (glycine-phenylalanine-leucine-glycine, or GFLG), and an amidomalonic 
acid (Ama) chelating agent. The new vasculature formed to provide tumors with food and 
oxygen are more permeable than capillaries of normal tissue. Furthermore, tumors have a 
more limited lymphatic and/or capillary drainage than normal tissue. Because of the 
combination of these characteristics, it is expected that AP 5280 will preferentially extravasate 
(pass out of the blood vessels) in tumor tissue and accumulate in tumor cells, a phenomenon 
called the Enhanced Permeation and Retention (EPR) effect. Subsequently, platinum is 
released from the polymer intratumorally by specific enzymes (lysosomal thiol-dependent 
proteinases), which are present in a higher concentration in tumor tissue as compared to 
normal tissue. Subsequently, the free platinum can exert its action (when bound to the 
copolymer, it is inactive). Theoretically, intravenous AP 5280 administration will lead to 
higher intratumoral platinum concentrations and therefore potentially greater efficacy than the 
currently marketed non-polymer platinates cisplatin, carboplatin, and oxaliplatin. Preclinical 
studies show that AP 5280 indeed has a higher therapeutic index than cisplatin and 
carboplatin when administered to tumor-bearing mice. 
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The pharmaceutical quality control of AP 5280 drug substance is presented in chapter 2.1. For 
a large, complex molecule such as AP 5280, a single analytic method did not suffice, but a 
combination of techniques was required to analyze all aspects considered important to its 
mechanism of action. Proton nuclear magnetic resonance (1H NMR) spectroscopy and 
infrared (IR) spectroscopy were employed for structural identification. The molecular weight 
(MW) and MW distribution, which play a large role in the distribution of AP 5280 in the 
body, were determined by size exclusion chromatography (SEC). Platinum binding 
assessment was performed using platinum nuclear magnetic resonance (195Pt NMR) 
spectroscopy. The free platinum content and release profile of platinum, measured using 
flameless atomic absorption spectroscopy (F-AAS), were determined as a measure of 
molecular integrity, a very important aspect of its assumed mechanism of action. The total 
platinum content of the copolymer was determined employing flame AAS. The combined 
results of the analyses performed on AP 5280 drug substance provided a meaningful picture 
of its structure, size, and integrity, and thus an excellent basis for its quality control.  
Chapter 2.2 describes the pharmaceutical formulation of AP 5280. AP 5280 drug substance 
showed excellent solubility in water. However, as aqueous solutions of AP 5280 proved to be 
labile upon sterilization (10 minutes 121°C), it was decided to develop a lyophilized dosage 
form. Initially, glass vials were used as primary packaging, but this led to a high breakage 
rate, which could be completely prevented by the use of CZ-resin vials. Stability studies show 
that the lyophilized product in glass vials is stable for at least 12 months when stored at +2-
8°C in the dark and the lyophilized product in CZ-resin vials is stable for at least 6 months 
under these conditions. Photostability testing revealed degradation of AP 5280 drug substance 
and lyophilized product under the influence of light, necessitating storage in the dark. 
In chapter 2.3, it was determined what the optimal reconstitution and dilution fluid was for AP 
5280, and the stability and compatibility of AP 5280 at different storage conditions was 
examined. Furthermore, the hemolytic potential of the infusion solutions was determined. AP 
5280 slowly releases platinum in all solutions, especially in normal saline. Accordingly, 5% 
dextrose in water was selected for reconstitution and dilution of AP 5280. Container material 
(glass or polyvinylchloride (PVC)) did not influence the stability of AP 5280 in solution. PVC 
was chosen as the infusion material with respect to the possibility of breakage of glass 
containers. Storage at refrigerated temperature (+2-8ºC) marginally decreased the release rate 
of liberated platinum. The infusion solutions were compatible with the PVC infusion system 
and did not cause hemolysis in vitro. Summarizing, AP 5280 lyophilized product should be 
reconstituted and diluted to the intended infusion concentration with 5% dextrose and should 
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be administered within 8 hours after preparation. Under these conditions, the percentage free 
platinum remains below 1.0% of the total platinum concentration. 
Concluding remarks 
The pharmaceutical development of the two novel metal-based anticancer agents NAMI-A 
and AP 5280 is described in this thesis, starting with the development of analytical methods 
for the quality control of drug substance and final product, via the formulation process leading 
to a stable, intravenous administration form, and ending with the stability and compatibility 
studies of the infusion solutions. This research could also serve as the basis for the 
pharmaceutical development of other novel, metal-based anticancer agents. Because many 
metals exchange ligands easily, the compounds will usually not be stable in solution, 
necessitating preparation of a lyophilized product. NAMI-A and AP 5280 are examples of 
this.   
The experiments described in this thesis enabled the clinical evaluation of NAMI-A and AP 
5280. At this time, 23 patients have been treated with NAMI-A and 30 with AP 5280 in the 
clinical Phase I study [Rademaker-Lakhai et al., Proc. Am. Soc. Clin. Oncol. 2001; 21: 107a 
(abstract # 425)]. Subsequent Phase II studies will provide insight into the clinical efficacy of 
these agents.  
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Samenvatting en conclusies 
Kanker is één van de belangrijkste doodsoorzaken in de westerse wereld. De huidige 
behandeling bestaat uit operatief verwijderen van de tumor, bestraling en/of chemotherapie, 
met al zijn bekende bijwerkingen en problemen veroorzaakt door het ontstaan van resistentie. 
Omdat voor veel vormen van de (uitgezaaide) ziekte nog geen curatieve therapie beschikbaar 
is, is de ontdekking en ontwikkeling van nieuwe, werkzame antikanker geneesmiddelen 
(chemotherapeutica, cytostatica) dringend noodzakelijk.  
Als er een nieuw antikanker middel wordt gevonden, wordt het slechts zelden toegediend als 
de pure grondstof. Vrijwel altijd is het noodzakelijk dat de grondstof wordt bewerkt, ofwel 
geformuleerd, tot een goed gedefinieerd farmaceutisch product dat geschikt is voor toediening 
aan de mens. Experimentele antikanker middelen zijn in het algemeen bestemd om 
intraveneus (als injectie of infusie) toegediend te worden. Op deze manier wordt een absolute 
biologische beschikbaarheid verkregen, wordt er voorkomen dat de stof ontleedt in het maag-
darm kanaal (voordat het is opgenomen in de bloedbaan) en kan in geval van acute toxiciteit 
de toediening onmiddelijk worden aangepast of beëindigd. Dientengevolge is de ontwikkeling 
van een farmaceutische formulering van een nieuw antikanker middel veelal gericht op de 
ontwikkeling van steriele en stabiele injecteerbare preparaten.  
Cisplatine, ofwel cis-diamminedichloroplatinum(II), is een antikanker middel dat al langer 
dan 30 jaar in gebruik is. Het bevat een platina atoom, dat verantwoordelijk is voor de 
werking. Cisplatine wordt tegen vele vormen van kanker gebruikt en weinig andere 
cytostatica zijn zo effectief als dit middel. De bijwerkingen, waaronder nier-, oor-, en 
zenuwschade en ernstige misselijkheid en braken, beperken echter het klinische gebruik. 
Bovendien vormt tumorresistentie, die intrinsiek of verworven kan zijn, een ander groot 
klinisch probleem.  
De beperkingen van cisplatine in de kliniek hebben geleid tot een zoektocht naar alternatieve 
farmaceutische formuleringen van cisplatine, alternatieve verbindingen die platina bevatten en  
verbindingen die andere zware metalen dan platina bevatten, in de hoop een middel te vinden 
met meer acceptabele bijwerkingen, maar met dezelfde of verbeterde effectiviteit en activiteit 
als cisplatine. Dit heeft onder andere geleid tot de ontwikkeling van NAMI-A en AP 5280. 
Dit proefschrift is gewijd aan de ontwikkeling van stabiele, parenterale farmaceutische 
toedieningsvormen van deze twee stoffen. Voor elk middel wordt eerst de ontwikkeling van 
analytische methoden beschreven, noodzakelijk voor de karakterisering en kwaliteitscontrole 
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van zowel de grondstof als het farmaceutisch eindproduct. Vervolgens wordt voor NAMI-A 
ingegaan op de ontleding in oplossing en bij blootstelling aan licht. Hierna wordt voor beide 
stoffen de ontwikkeling van de formulering en de stabiliteit hiervan beschreven. De 
hoofdstukken worden afgesloten met studies die zijn uitgevoerd om de (bio-)compatibiliteit  
- de verenigbaarheid met infuussystemen en bloed - van het geformuleerde product bij 
klinische toepassing te kunnen voorspellen. 
 
NAMI-A 
Hoofdstuk 1 beschrijft de farmaceutische ontwikkeling van NAMI-A, imidazolium trans-
tetrachloro(dimethylsulfoxide)imidazoolruthenium(III), een middel dat een ruthenium atoom 
bevat en in dierproeven actief bleek te zijn tegen uitzaaiingen van kanker, terwijl het weinig 
bijwerkingen vertoonde. De werking bleek onafhankelijk van de oorsprong (het type) van de 
tumor en de grootte en uitgebreidheid van de uitzaaiingen. NAMI-A vertoonde geen directe 
invloed op de groei van tumorcellen, alhoewel er wel een interactie met de regulering van de 
celcyclus werd gevonden in een voorbijgaande ophoping van cellen in de G2/M fase. 
Belangrijker voor zijn werking lijkt het feit dat NAMI-A bindweefselvorming rondom 
tumorcellen en bloedvaten bevordert, waardoor de bloedtoevoer van tumoren wordt 
verminderd. Bovendien wordt op deze wijze verhinderd dat tumorcellen de omliggende 
weefsels en bloed- en lymfatische vaten binnendringen en zo verspreid worden (uitzaaien). 
Om de klinische evaluatie van NAMI-A mogelijk te maken was een intraveneuze 
toedieningsvorm van NAMI-A gewenst. 
Hoofdstuk 1.1 beschrijft de ontwikkeling en validatie van een hoge druk vloeistof 
chromatografische (HPLC) methode met ultra-violet (UV) detectie voor de kwaliteitscontrole 
(kwantificering en zuiverheidsbepaling) van NAMI-A grondstof en farmaceutisch 
eindproduct. De beschreven methode bleek bij validatie lineair, nauwkeurig en precies. Door 
ontledingsstudies, waarbij NAMI-A aan extreme omstandigheden zoals zuur, base, verhitting, 
en oxidatie werd blootgesteld bleek dat de ontledingsproducten en NAMI-A met deze 
methode kunnen worden gescheiden. Door het vergelijken van resultaten verkregen met 
nucleaire magnetische resonantie (NMR) spectroscopische experimenten met die verkregen 
met de beschreven HPLC methode kon één degradatieproduct, waarbij een chloride atoom 
was vervangen door een hydroxyl groep, worden geïdentificeerd. Verder werd door de 
analyse van het HPLC eluaat met atomaire absorptie spectrometrie (AAS) aangetoond dat 
onder de meeste omstandigheden alle ruthenium-bevattende verbindingen een piek in het 
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HPLC chromatogram vertoonden en dat alle ruthenium die op de kolom werd gebracht ook 
werd teruggevonden. Alleen van volledig ontlede oplossingen van NAMI-A werd een deel 
van het ruthenium achtergehouden op de kolom. Voor de farmaceutische kwaliteitscontrole 
van NAMI-A grondstof en gevriesdroogd product bleek de ontwikkelde HPLC methode te 
voldoen aan alle eisen. 
De ontledingskinetiek van NAMI-A wordt in hoofdstuk 1.2 beschreven. De chemische 
stabiliteit werd onderzocht als een functie van pH, buffersamenstelling en temperatuur. 
Ontleding van NAMI-A volgt eerste-orde kinetiek bij pH < 6 en nulde-orde kinetiek bij pH ≥ 
6. Het pH profiel liet zien dat NAMI-A in oplossing het meest stabiel is bij een pH van 3-4. 
De ontledingssnelheid werd niet significant beïnvloed door de samenstelling  van de buffers. 
Temperatuur had een grote invloed op de ontledingssnelheid van NAMI-A en ontleding kon 
worden beschreven met de Arrhenius vergelijking. 
In hoofdstuk 1.3 wordt de fotostabiliteit, ofwel de stabiliteit bij blootstelling aan licht, van 
NAMI-A beschreven. In de vaste vorm ontleedde NAMI-A niet onder invloed van licht. In 
oplossing werd echter een snelle ontleding gevonden, die bij pH 2-5 onafhankelijk was van 
pH. De ontledingssnelheid bij hogere pH waarden was hoger dan onder zure condities. De 
samenstelling van de buffer had weinig invloed. De fotostabiliteit was omgekeerd evenredig 
aan de NAMI-A concentratie en toevoeging van fotostabilisatoren was niet effectief. 
Toevoeging van een alcohol, en dus beïnvloeding van de polariteit van het oplosmiddel, had 
de grootste invloed op de fotostabiliteit van NAMI-A in oplossing, waarbij het minst polaire 
oplosmiddel (50% propyleenglycol) tot de grootste stabiliteit leidde. Op basis van de 
resultaten wordt aanbevolen NAMI-A oplossingen (dus ook de infuusoplossingen) in het 
donker te bewaren. 
Hoofdstuk 1.4 beschrijft de ontwikkeling van de farmaceutische toedieningsvorm voor 
NAMI-A. Alhoewel NAMI-A oplosbaar is in water, was de bereiding van een oplossing van 
NAMI-A als zodanig niet haalbaar vanwege de geringe stabiliteit. Toevoeging van 
hulpstoffen bleek weinig invloed te hebben op de stabiliteit, alhoewel er wel gevonden werd 
dat oplossingen met een zure pH het stabielst waren. Hierdoor werd er gekozen voor de 
ontwikkeling van een gevriesdroogd product. Vijf verschillende formuleringen werden bereid, 
waarvan er vier een zuur (citroenzuur of zoutzuur) bevatten om de pH van de 
formuleringsoplossing op 3-4 te brengen en zodoende de ontleding tijdens het productieproces 
minimaal te houden. De oplossingen werden met “differential scanning calorimetry” (DSC) 
onderzocht om een optimale vriesdroogcyclus te ontwikkelen. Op de vijf gevriesdroogde 
producten werd thermogravimetrische (TG) analyse uitgevoerd, evenals stabiliteitsonderzoek 
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bij opslag bij -20°C, 25°C / 60% relatieve luchtvochtigheid (RH) en 40°C / 75% RH 
gedurende een jaar. Van de verschillende zuren bleek alleen zoutzuur verenigbaar met NAMI-
A in het gevriesdroogde product, terwijl het ook de formuleringsoplossing tijdens het 
productieproces stabiliseerde. Dit eindproduct was stabiel bij alle drie de opslagcondities 
gedurende minimaal 1 jaar en was bovendien fotostabiel. Als uiteindelijke 
formuleringsoplossing werd gekozen voor een oplossing van 10 mg/ml NAMI-A in 0.1 mM 
zoutzuur, wat leidde tot een gevriesdroogd product met 100 mg NAMI-A en 0.036 mg 
zoutzuur per doseereenheid.  
De  bepaling van de optimale infuusvloeistof voor de reconstitutie en verdunning van NAMI-
A gevriesdroogd product, alsmede de stabiliteit en (bio-)compatibiliteit van de 
infuusoplossingen onder verschillende opslagcondities en met verschillende infuusmaterialen 
worden beschreven in hoofdstuk 1.5. In deze studie werd bovendien in vitro onderzoek 
uitgevoerd naar de buffercapaciteit van NAMI-A infuusoplossingen, een maat voor de te 
verwachten irritatie aan de bloedvaten door de lage pH. Het eventuele vermogen van de 
infuusoplossingen om hemolyse (afbraak van rode bloedcellen) te veroorzaken werd eveneens 
onderzocht. Fysiologisch zout bleek de optimale oplossing te zijn om NAMI-A gevriesdroogd 
product te reconstitueren en te verdunnen. Na reconstitutie moet de oplossing direct 
doorverdund worden tot de infuusconcentratie. Infuusoplossingen kunnen maximaal 4 uur 
worden bewaard bij kamertemperatuur (+20-23°C) of 24 uur bij koelkasttemperatuur (+2-
8°C) voordat ze worden toegediend aan de patiënt. De infuusoplossingen waren verenigbaar 
met glazen en polyvinylchloride (PVC) infuussystemen, maar om praktische redenen (gevaar 
op breuk bij glas) wordt het gebruik van PVC infuussystemen aanbevolen. Verder werd 
gevonden dat, ook in vergelijking met geregistreerde intraveneuze antikanker middelen, de 
buffercapaciteit van de formulering beperkt is en er geen irritatie aan de bloedvaten te 
verwachten is bij gebruik in de kliniek. Bovendien wordt er op basis van de hemolyse 
experimenten niet verwacht dat NAMI-A bloedafbraak zal veroorzaken. 
 
AP 5280 
AP 5280, poly(N-(2-hydroxypropyl) methacrylamide)-GFLG-Ama=Pt(NH3)2,  is een 
platinaverbinding die gekoppeld is aan een polymeer, ontworpen om deze verbinding 
specifiek naar tumorcellen te sturen, het zogeheten “tumor targeting”. In deze copolymeer is 
platina verbonden aan poly-N-(2-hydroxypropyl) methacrylamide (pHPMA) via een 
tetrapeptide (glycine-fenylalanine-leucine-glycine, ofwel GFLG) en een amidomalonzuur 
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(Ama) chelator. Nieuwe bloedvaten die worden aangelegd om tumoren van voedsel en 
zuurstof te voorzien zijn meer doorlaatbaar dan de bloedvaten van normaal weefsel, waarnaast 
tumoren ook een slechtere lymfatische en capillaire afvoer hebben dan normaal weefsel. Door 
deze eigenschappen wordt er verwacht dat een groot molecuul als AP 5280 bij voorkeur in 
tumorweefsel extravaseert (buiten de bloedvaten treedt) en in de tumorcellen ophoopt, 
hetgeen het “Enhanced Permeation and Retention” (EPR) effect wordt genoemd. In de 
tumorcellen wordt platina losgemaakt van de polymeer door bepaalde enzymen (lysosomale 
thiol-afhankelijke proteinases), waarvan de concentratie in tumorweefsel hoger is dan in 
normaal weefsel. Hierna zal het vrije platina zijn werking uit kunnen oefenen (gebonden aan 
de copolymeer is het inactief). In theorie zal daarom intraveneuze toediening van AP 5280 
leiden tot hogere platina concentraties in tumorcellen en daardoor grotere doeltreffendheid 
dan de huidige geregistreerde niet polymeer-gebonden platinaverbindingen cisplatine, 
carboplatine en oxaliplatine. Preklinische studies hebben aangetoond dat AP 5280 inderdaad 
een hogere therapeutische index heeft dan cisplatine en carboplatine als het toegediend wordt 
aan tumordragende muizen. 
In hoofdstuk 2.1 wordt de farmaceutische kwaliteitscontrole van AP 5280 grondstof 
gepresenteerd. Voor een groot, complex molecuul als AP 5280 kon niet met één 
analysemethode worden volstaan, maar was er een combinatie van technieken nodig om alle 
aspecten die belangrijk werden geacht voor zijn werking te analyseren. Proton nucleaire 
magnetische resonantie (1H NMR) spectroscopie en infra-rood (IR) spectroscopie werden 
gebruikt voor structurele identificatie. Omdat het molecuulgewicht en de spreiding in 
molecuulgewicht een belangrijke rol spelen in de verdeling van AP 5280 in het lichaam, 
werden deze bepaald door middel van “size exclusion chromatography” (SEC). Beoordeling 
van de platina binding werd uitgevoerd met platina nucleaire magnetische resonantie (195Pt 
NMR) spectroscopie. Het vrij platina gehalte en afgifteprofiel van platina, gemeten met 
behulp van vlamloze atomaire absorptie spectroscopie (F-AAS), werden bepaald als maat 
voor de moleculaire integriteit, een belangrijk aspect in het aangenomen 
werkingsmechanisme. Het totaal platina gehalte van het copolymeer werd bepaald met behulp 
van vlam AAS. Het gecombineerde resultaat  van de analyses verschafte een goed beeld van 
de structuur, grootte en integriteit van AP 5280 en dus een uitstekende basis voor de 
kwaliteitscontrole. 
Hoofdstuk 2.2 beschrijft de ontwikkeling van de farmaceutische formulering van AP 5280. 
Alhoewel AP 5280 goed oplosbaar is in water, werd er vastgesteld dat het in waterige 
oplossing ontleedde als de oplossing werd gesteriliseerd (10 minuten bij 121°C). Daarom  
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werd er besloten een gevriesdroogd product te ontwikkelen. Als eerste werden glazen flacons 
gebruikt als primair verpakkingsmateriaal, maar dit leidde tot een hoog breukpercentage, dat 
voorkomen kon worden door het gebruik van CZ-hars flacons. Stabiliteitsstudies toonden aan 
dat het gevriesdroogd product in de glazen flacons stabiel is gedurende tenminste 12 maanden 
bij +2-8°C, in het donker, en dat het gevriesdroogd product in de CZ-hars flacons stabiel is 
gedurende tenminste 6 maanden onder dezelfde condities. Fotostabiliteitsstudies lieten 
afbraak van AP 5280 grondstof en gevriesdroogd product onder invloed van licht zien, 
waardoor het nodig wordt AP 5280 in het donker op te slaan.  
In hoofdstuk 2.3 werd vastgesteld wat de optimale reconstitutie- en verdunningsvloeistof is 
voor AP 5280 en werd de stabiliteit en compatibiliteit onder verschillende bewaarcondities 
bepaald. Bovendien werd onderzocht of de infuusoplossingen hemolyse kunnen veroorzaken. 
In alle oplossingen bleek dat AP 5280 langzaam vrij platina afgeeft, vooral in fysiologisch 
zout. Als gevolg hiervan werd 5% glucose gekozen als infuusvloeistof om AP 5280 te 
reconstitueren en verdunnen. Het materiaal van het infuussysteem (glas of polyvinylchloride 
(PVC)) had geen invloed op de stabiliteit van AP 5280. PVC werd als infuusmateriaal 
gekozen in verband met de mogelijke breuk van glazen infuusmateriaal. Bij opslag in de 
koelkast (+2-8°C) werd een kleine afname van de afgifte van vrij platina gevonden. De 
infuusoplossingen waren verenigbaar met het PVC infuussysteem en veroorzaakten geen 
hemolyse in vitro. Samenvattend blijkt dat AP 5280 gevriesdroogd product dient te worden 
gereconstitueerd en verdund tot de gewenste infuusconcentratie met 5% glucose en dat de 
infuusoplossing binnen 8 uur na bereiding dient  te worden toegediend. Onder deze condities 
blijft het percentage vrij platina minder dan 1.0% van het totaal platina gehalte. 
Conclusies 
Voor de twee nieuwe, metaalbevattende antikanker middelen NAMI-A en AP 5280 wordt in 
dit proefschrift het farmaceutische ontwikkelingstraject beschreven, van de ontwikkeling van 
analysemethoden voor de kwaliteitscontrole van grondstof en eindproduct, via het 
formuleringsproces tot een stabiele,  intraveneuze toedieningsvorm, tot de stabiliteits- en 
compatibliteitsonderzoeken van de infuusoplossingen toe. Het onderzoek zou ook kunnen 
dienen als basis voor de farmaceutische ontwikkeling van andere metaalbevattende nieuwe 
antikanker geneesmiddelen. Doordat veel metalen makkelijk liganden wisselen, zullen deze 
verbindingen zelden stabiel zijn in oplossing en zal er vaak worden gekozen voor de bereiding 
van een gevriesdroogd product. NAMI-A en AP 5280 zijn hier voorbeelden van. 
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De in dit proefschrift beschreven studies hebben het mogelijk gemaakt om NAMI-A en AP 
5280 in de kliniek te onderzoeken. Ondertussen zijn 23 patiënten behandeld met NAMI-A en 
30 met AP 5280 in het klinische fase I onderzoek [Rademaker-Lakhai et al., Proc. Am. Soc. 
Clin. Oncol. 2001; 21: 107a (abstract # 425)]. Vervolg fase II onderzoek zal inzicht geven in de 
klinische effectiviteit van de middelen. 
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